<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Testosterone replacement in men with sexual dysfunction - Lee, H - 2024 | Cochrane Library</title> <meta content="Testosterone replacement in men with sexual dysfunction - Lee, H - 2024 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013071.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Testosterone replacement in men with sexual dysfunction - Lee, H - 2024 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013071.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013071.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Testosterone replacement in men with sexual dysfunction" name="citation_title"/> <meta content="Hunju Lee&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Eu Chang Hwang&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Cheol Kyu Oh" name="citation_author"/> <meta content="Heaundae Paik Hospital, Inje University" name="citation_author_institution"/> <meta content="Solam Lee" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Ho Song Yu" name="citation_author"/> <meta content="Chonnam National University" name="citation_author_institution"/> <meta content="Jung Soo Lim" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Hong Wook Kim" name="citation_author"/> <meta content="Konyang University College of Medicine" name="citation_author_institution"/> <meta content="Thomas Walsh" name="citation_author"/> <meta content="National Cancer Institute" name="citation_author_institution"/> <meta content="Myung Ha Kim" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Jae Hung Jung" name="citation_author"/> <meta content="jungx563@gmail.com" name="citation_author_email"/> <meta content="Philipp Dahm" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD013071.pub2" name="citation_doi"/> <meta content="2024" name="citation_date"/> <meta content="2024/01/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013071.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013071.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013071.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Cardiovascular Diseases; *Erectile Dysfunction [drug therapy]; *Lower Urinary Tract Symptoms [drug therapy]; Prostate; *Prostatic Hyperplasia [complications]; Testosterone [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013071.pub2&amp;doi=10.1002/14651858.CD013071.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="STpJR8yz";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013071\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013071\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ko","th","pt","ms","ja","fa","id","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013071.pub2",title:"Testosterone replacement in men with sexual dysfunction",firstPublishedDate:"Jan 15, 2024 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013071.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013071.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013071.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013071.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013071.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013071.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013071.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013071.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013071.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013071.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5916 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013071.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-sec-0155"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-sec-0063"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-sec-0146"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/appendices#CD013071-sec-0162"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/supinfo/CD013071-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/supinfo/CD013071-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2024 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Testosterone replacement in men with sexual dysfunction</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors should be considered joint first author."><a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information#CD013071-cr-0004">Hunju Lee</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors should be considered joint first author."><a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information#CD013071-cr-0005">Eu Chang Hwang</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information#CD013071-cr-0006">Cheol Kyu Oh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information#CD013071-cr-0007">Solam Lee</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information#CD013071-cr-0008">Ho Song Yu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information#CD013071-cr-0009">Jung Soo Lim</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information#CD013071-cr-0010">Hong Wook Kim</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information#CD013071-cr-0011">Thomas Walsh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information#CD013071-cr-0012">Myung Ha Kim</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information#CD013071-cr-0013"><i class="icon corresponding-author fa fa-envelope"></i>Jae Hung Jung</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information#CD013071-cr-0014">Philipp Dahm</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information/en#CD013071-sec-0167">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 January 2024 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013071.pub2">https://doi.org/10.1002/14651858.CD013071.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013071-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013071-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD013071-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD013071-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013071-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013071-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013071-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013071-abs-0010">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD013071-abs-0008">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013071-abs-0001" lang="en"> <section id="CD013071-sec-0001"> <h3 class="title" id="CD013071-sec-0001">Background</h3> <p>Clinical practice guidelines recommend testosterone replacement therapy (TRT) for men with sexual dysfunction and testosterone deficiency. However, TRT is commonly promoted in men without testosterone deficiency and existing trials often do not clearly report participants' testosterone levels or testosterone‐related symptoms. This review assesses the potential benefits and harms of TRT in men presenting with complaints of sexual dysfunction. </p> </section> <section id="CD013071-sec-0002"> <h3 class="title" id="CD013071-sec-0002">Objectives</h3> <p>To assess the effects of testosterone replacement therapy compared to placebo or other medical treatments in men with sexual dysfunction. </p> </section> <section id="CD013071-sec-0003"> <h3 class="title" id="CD013071-sec-0003">Search methods</h3> <p>We performed a comprehensive search of CENTRAL (the Cochrane Library), MEDLINE, EMBASE, and the trials registries ClinicalTrials.gov and World Health Organization International Clinical Trials Registry Platform, with no restrictions on language of publication or publication status, up to 29 August 2023. </p> </section> <section id="CD013071-sec-0004"> <h3 class="title" id="CD013071-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) in men (40 years or over) with sexual dysfunction. We excluded men with primary or secondary hypogonadism. We compared testosterone or testosterone with phosphodiesterase‐5 inhibitors (PDEI5I) to placebo or PDE5I alone. </p> </section> <section id="CD013071-sec-0005"> <h3 class="title" id="CD013071-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the literature, assessed the risk of bias, extracted data, and rated the certainty of evidence (CoE) according to GRADE using a minimally contextualized approach. We performed statistical analyses using a random‐effects model and interpreted them according to standard Cochrane methodology<i>.</i> Predefined primary outcomes were self‐reported erectile dysfunction assessed by a validated instrument, sexual quality of life assessed by a validated instrument, and cardiovascular mortality. Secondary outcomes were treatment withdrawal due to adverse events, prostate‐related events, and lower urinary tract symptoms (LUTS). We distinguished between short‐term (up to 12 months) and long‐term (&gt; 12 months) outcomes. </p> </section> <section id="CD013071-sec-0006"> <h3 class="title" id="CD013071-sec-0006">Main results</h3> <p>We identified 43 studies with 11,419 randomized participants across three comparisons: testosterone versus placebo, testosterone versus PDE5I, and testosterone with PDE5I versus PDE5I alone. This abstract focuses on the most relevant comparison of testosterone versus placebo. </p> <p><b>Testosterone versus placebo (up to 12 months)</b> </p> <p>Based on a predefined sensitivity analysis of studies at low risk of bias, and an analysis combing data from the similar International Index of Erectile Function (IIEF‐EF) and IIEF‐5 instruments, TRT likely results in little to no difference in erectile function assessed with the IIEF‐EF (mean difference (MD) 2.37, 95% confidence interval (CI) 1.67 to 3.08; I² = 0%; 6 RCTs, 2016 participants; moderate CoE) on a scale from 6 to 30 with larger values reflecting better erectile function. We assumed a minimal clinically important difference (MCID) of greater than or equal to 4. TRT likely results in little to no change in sexual quality of life assessed with the Aging Males' Symptoms scale (MD ‐2.31, 95% CI ‐3.63 to ‐1.00; I² = 0%; 5 RCTs, 1030 participants; moderate CoE) on a scale from 17 to 85 with larger values reflecting worse sexual quality of life. We assumed a MCID of greater than or equal to 10. TRT also likely results in little to no difference in cardiovascular mortality (risk ratio (RR) 0.83, 95% CI 0.21 to 3.26; I² = 0%; 10 RCTs, 3525 participants; moderate CoE). Based on two cardiovascular deaths in the placebo group and an assumed MCID of 3%, this would correspond to no additional deaths per 1000 men (95% CI 1 fewer to 4 more). TRT also likely results in little to no difference in treatment withdrawal due to adverse events, prostate‐related events, or LUTS. </p> <p><b>Testosterone versus placebo (later than 12 months)</b> </p> <p>We are very uncertain about the longer‐term effects of TRT on erectile dysfunction assessed with the IIEF‐EF (MD 4.20, 95% CI ‐2.03 to 10.43; 1 study, 42 participants; very low CoE). We did not find studies reporting on sexual quality of life or cardiovascular mortality. We are very uncertain about the effect of testosterone on treatment withdrawal due to adverse events. We found no studies reporting on prostate‐related events or LUTS. </p> </section> <section id="CD013071-sec-0007"> <h3 class="title" id="CD013071-sec-0007">Authors' conclusions</h3> <p>In the short term, TRT probably has little to no effect on erectile function, sexual quality of life, or cardiovascular mortality compared to a placebo. It likely results in little to no difference in treatment withdrawals due to adverse events, prostate‐related events, or LUTS. In the long term, we are very uncertain about the effects of TRT on erectile function when compared to placebo; we did not find data on its effects on sexual quality of life or cardiovascular mortality. </p> <p>The certainty of evidence ranged from moderate (signaling that we are confident that the reported effect size is likely to be close to the true effect) to very low (indicating that the true effect is likely to be substantially different). The findings of this review should help to inform future guidelines and clinical decision‐making at the point of care. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013071-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013071-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD013071-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD013071-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013071-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013071-abs-0018">Français</a> </li> <li class="section-language"> <a class="" href="full/id#CD013071-abs-0016">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013071-abs-0013">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013071-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013071-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013071-abs-0011">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD013071-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013071-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013071-abs-0002" lang="en"> <h3>Does testosterone work in men who have problems with erections?</h3> <p><b>Background</b> </p> <p>Testosterone is a crucial male hormone. It is commonly used in men with low testosterone levels who experience erection difficulties. However, it is unclear how effective this treatment is and if it has unwanted harmful effects (adverse effects), especially on heart health. </p> <p><b>Key messages</b> </p> <p>In the short term, testosterone replacement therapy has a minimal impact on erectile function, sexual quality of life, and cardiovascular mortality, with few side effects. </p> <p>The long‐term effects of this therapy on erectile function remain uncertain, and data on sexual quality of life and cardiovascular mortality in the long term are lacking. </p> <p>These findings can inform future clinical guidelines and healthcare decisions.</p> <p><b>What did we want to find out?</b> </p> <p>We wanted to know the effects of testosterone replacement therapy on men with erection problems. </p> <p><b>What did we do?</b> </p> <p>We conducted a comprehensive search for studies involving men with low testosterone levels. These studies compared the effects of testosterone with placebo or other medications aimed at improving erections. </p> <p><b>What did we find?</b> </p> <p>We included 43 studies, with 11,419 participants, which compared testosterone with a placebo, but also studies comparing it to phosphodiesterase 5 inhibitors (a group of medications to improve erections). We also found studies where both groups (testosterone and placebo) received phosphodiesterase 5 inhibitors. </p> <p><b>Main results</b> </p> <p>In the short term, testosterone, when compared to a placebo, shows minor changes in erectile function, sexual quality of life, and cardiovascular mortality. </p> <p>When we looked only at studies with robust methods, the results remained consistent: there was little to no effect on erectile function and sexual quality of life. The data suggest that cardiovascular mortality is also unlikely to be significantly impacted. </p> <p>However, in the long term, there is substantial uncertainty regarding the effects of testosterone replacement therapy on erectile dysfunction. Unfortunately, no studies provided information on sexual quality of life or cardiovascular mortality outcomes in the long term. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>The certainty of the evidence is moderate for most of the short‐term outcomes, meaning that we are moderately confident that the result is likely to be close to the true effect. For the long‐term outcomes, we have very limited certainty due to the lack of robust evidence, and further research might alter these conclusions. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The latest information is current as of 29 August 2023.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013071-sec-0155" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013071-sec-0155"></div> <h3 class="title" id="CD013071-sec-0156">Implications for practice</h3> <section id="CD013071-sec-0156"> <p>In the short term, testosterone replacement therapy (TRT) probably has little to no effect on erectile function, sexual quality of life, or cardiovascular mortality compared to placebo. The interpretation of the effects on erectile function is sensitive to the threshold chosen for what constitutes a clinically meaningful difference for men that are being treated. The choice of a lower threshold would result in an interpretation that TRT does have a (small) effect when compared to placebo. There is probably little to no effect on treatment withdrawal due to adverse events, prostate‐related events, or lower urinary tract symptoms (LUTS). While we hypothesized that testosterone levels might be an important effect modifier in men with erectile dysfunction being treated with TRT, we were unable to make this determination due to a lack of data to allow a subgroup analysis. </p> <p>Importantly, we know much less about the long‐term effects of TRT compared to placebo. We are uncertain about the effects on erectile function and found no long‐term data for the outcomes of sexual quality of life or cardiovascular mortality. Given that men are typically treated for years, and that cardiovascular risk factors are common in these men, these limitations should have important implications for patient counseling and monitoring. </p> <p>Given the paucity of data, it is difficult to draw clinical conclusions from our analyses comparing TRT to phosphodiesterase‐5 inhibitors (PDE5I) or TRT as an add‐on to PDEI5I versus PDE5I alone. </p> </section> <h3 class="title" id="CD013071-sec-0157">Implications for research</h3> <section id="CD013071-sec-0157"> <p> <ul id="CD013071-list-0058"> <li> <p>Future studies should better adhere to methodological standards and include all safeguards against bias, which should be clearly reported according to <a href="./references#CD013071-bbs2-0137" title="The CONSORT statement. www.consort-statement.org (accessed prior to 22 September 2017).">CONSORT</a> criteria (<a href="./references#CD013071-bbs2-0198" title="SchulzKF , AltmanDG , MoherD , Group Consort. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology2010;63(8):834-40.">Schulz 2010</a>). </p> </li> <li> <p>A particular issue in this clinical arena is the huge variation in inclusion criteria among studies, for example with regard to age and baseline testosterone level, and their transparent reporting, which is likely to be a major source of heterogeneity. </p> </li> <li> <p>Another specific issue is the length of follow‐up. Future studies should account for the fact that TRT is usually prescribed for many years and therefore plan to follow up participants for an extended period of time. This is particularly important for relatively rare adverse events for which there may be a cumulative risk over time, such as cardiovascular mortality. </p> </li> <li> <p>The interpretation of this review's findings hinges on the presumed minimal clinically important differences (MCIDs). Aside from those applied to outcomes that were measured using validated questionnaires (such as the International Index of Erectile Function (IIEF)), these are inherently subjective. In the future, ongoing research into better ways of arriving at MCIDs will be helpful (<a href="./references#CD013071-bbs2-0182" title="MorganoGP , MbuagbawL , SantessoN , XieF , BrozekJL , SiebertU , et al. Defining decision thresholds for judgments on health benefits and harms using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision (EtD) frameworks: a protocol for a randomised methodological study (GRADE-THRESHOLD). BMJ Open2022;12(3):e053246. [DOI: 10.1136/bmjopen-2021-053246]">Morgano 2022</a>). </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013071-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013071-sec-0008"></div> <div class="table" id="CD013071-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Testosterone compared to placebo in men with sexual dysfunction (short‐term: sensitivity analysis)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> men with sexual dysfunction<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> testosterone<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens?</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo (short‐term)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with testosterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erectile function<br/>Assessed with: sexual domain of AMS<br/>Scale from: 5 (best: no impairment) to 25 (worst: severe impairment)<br/>Follow‐up: range 6 months to 12 months </p> <p>MCID: 3.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>792<br/>(3 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean erectile function ranged from 10.66 to 14.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.15 lower<br/>(1.76 lower to 0.54 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Testosterone likely results in little or no difference in erectile function.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erectile function<br/>Assessed with: IIEF‐EF<br/>Scale from: 6 (worst: severe) to 30 (best: normal)<br/>Follow‐up: range 3 months to 12 months </p> <p>MCID: 5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2016<br/>(6 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean erectile function ranged from 7.8 to 10.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.37 higher<br/>(1.67 higher to 3.08 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual quality of life<br/>Assessed with: overall AMS<br/>Scale from: 17 (best: no impairment) to 85 (worst: severe impairment)<br/>Follow‐up: range 4 months to 12 months </p> <p>MCID: 10</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1030<br/>(5 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual quality of life ranged from 33.59 to 39.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.31 lower<br/>(3.63 lower to 1 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Testosterone likely results in little or no difference in sexual quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual quality of life<br/>Assessed with: overall satisfaction domain of IIEF<br/>Scale from: 1 (worst: severe) to 10 (best: normal)<br/>Follow‐up: range 12 weeks to 30 weeks </p> <p>MCID: 1.25</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>786<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual quality of life was 5.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.56 higher<br/>(0.11 lower to 1.23 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality<br/>Follow‐up: range 3 months to 12 months </p> <p>MCID: absolute risk difference of 3%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3525<br/>(10 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.21 to 3.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Testosterone likely results in little or no difference in cardiovascular mortality.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/>(1 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment withdrawal due to adverse events<br/>Follow‐up: range 3 months to 12 months </p> <p>MCID: absolute risk difference of 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2966<br/>(12 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/>(0.56 to 1.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Testosterone likely results in little or no difference in treatment withdrawal due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 fewer per 1000<br/>(16 fewer to 7 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostate‐related events:<br/>Follow‐up: range 3 months to 12 months </p> <p>MCID: absolute risk difference of 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3439<br/>(10 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.65<br/>(1.08 to 2.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Testosterone likely results in little or no difference in prostate‐related events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 more per 1000<br/>(2 more to 29 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower urinary tract symptoms<br/>Assessed with: IPSS<br/>Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/>Follow‐up: range 3 months to 12 months </p> <p>MCID: 3</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1488<br/>(6 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1,6,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean lower urinary tract symptoms ranged from 5.7 to 10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.37<br/>(1.39 lower to 0.64 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone likely results in little or no difference in lower urinary tract symptoms.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>AMS:</b> Aging Males' Symptoms score; <b>CI:</b> confidence interval; <b>IIEF:</b> International Index of Erectile Function; <b>IPSS:</b> International Prostate Symptom Score; <b>MCID:</b> minimal clinically important difference<i>;</i><b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for indirectness: differences in population (group with mixed age under 40 years old and/or baseline serum testosterone level over 12 nmol/L). </p> <p><sup>2</sup>Minimal clinically important difference: 25% improvement (greater than 3.5 points) from baseline (testosterone: 14.21; placebo: 14.53). </p> <p><sup>3</sup>Minimal clinically important difference: comes from <a href="./references#CD013071-bbs2-0196" title="RosenRC , AllenKR , NiX , AraujoAB . Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. European Urology2011;60(5):1010-6.">Rosen 2011</a>. </p> <p><sup>4</sup>Minimal clinically important difference: 25% improvement (greater than 10.0 points) from baseline (testosterone: 41.88; placebo: 42.74). </p> <p><sup>5</sup>Minimal clinically important difference: 25% improvement (greater than 1.25 points) from baseline (testosterone: 5.35; placebo: 5.28). </p> <p><sup>6</sup>Not downgraded further for inconsistency: moderate heterogeneity, but not clinically important. </p> <p><sup>7</sup>Minimal clinically important difference: comes from <a href="./references#CD013071-bbs2-0131" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker-CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?Journal of Urology1995;154(5):1770-4.">Barry 1995</a>. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013071-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Testosterone compared to placebo in men with sexual dysfunction (long‐term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> men with sexual dysfunction<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> testosterone<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens?</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with testosterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erectile function<br/>Assessed with IIEF‐EF<br/>Scale from: 1 (worst: severe) to 30 (best: normal)<br/>Follow‐up: 13 months </p> <p>MCID: 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean erectile function was 10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.2 higher<br/>(2.03 lower to 10.43 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are very uncertain about the effect of testosterone on erectile function.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment withdrawal due to adverse events<br/>Follow‐up: range 13 months to 24 months </p> <p>MCID: absolute risk difference of 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>122<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/>(0.58 to 1.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are very uncertain about the effect of testosterone on treatment withdrawal due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 more per 1000<br/>(133 fewer to 273 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostate‐related events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower urinary tract symptoms</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>IIEF‐EF:</b> International Index of Erectile Function‐Erectile Function; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear or high risk of selection, attrition, and/or reporting bias. </p> <p><sup>2</sup>Downgraded by one level for indirectness: difference in population (inclusion criterion of baseline serum testosterone level below 15 nmol/L in the included study (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>) was higher than that of the diagnostic criteria of late‐onset hypogonadism). </p> <p><sup>3</sup>Downgraded by two levels for imprecision: insufficient information size and/or wide confidence interval crosses the assumed threshold of clinically important difference. </p> <p><sup>4</sup>Minimal clinically important difference: comes from <a href="./references#CD013071-bbs2-0196" title="RosenRC , AllenKR , NiX , AraujoAB . Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. European Urology2011;60(5):1010-6.">Rosen 2011</a>. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013071-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Testosterone compared to PDE5I in men with sexual dysfunction (short‐term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> men with sexual dysfunction<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> testosterone<br/><b>Comparison:</b> PDE5I </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens?</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PDE5I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with testosterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erectile function<br/>Assessed with IIEF‐5<br/>Scale from: 1 (worst: severe) to 25 (best: normal)<br/>Follow‐up: 6 weeks </p> <p>MCID: 5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean erectile function was 18.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.4 lower<br/>(5.47 lower to 1.33 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are very uncertain about the effect of testosterone on erectile function.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual quality of life<br/>Assessed with AMS<br/>Scale from: 17 (best: no impairment) to 85 (worst: severe impairment)<br/>Follow‐up: 6 weeks </p> <p>MCID: 9.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2,3,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual quality of life was 36.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.82 lower<br/>(6.85 lower to 0.79 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are very uncertain about the effect of testosterone on sexual quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostate‐related events<br/>Follow‐up: 6 weeks </p> <p>MCID: absolute risk difference of 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>64<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable <sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are very uncertain about the effect of testosterone on prostate‐related events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower urinary tract symptoms</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>AMS:</b> Aging Males' Symptoms score; <b>CI:</b> confidence interval; <b>IIEF:</b> International Index of Erectile Function; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>PDE5I:</b> phosphodiesterase 5 inhibitor; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear or high risk of selection, performance, detection, and reporting bias. </p> <p><sup>2</sup>Not downgraded further for indirectness: while the included study did not clearly define the age of the study population, the mean age was over 45 years old. </p> <p><sup>3</sup>Downgraded by two levels for imprecision: insufficient information size or confidence interval crosses the assumed threshold of clinically important difference. </p> <p><sup>4</sup>Minimal clinically important difference: comes from <a href="./references#CD013071-bbs2-0205" title="SpalivieroM , StromKH , GuX , ArakiM , CulkinDJ , WongC . Does Greenlight HPS laser photoselective vaporization prostatectomy affect sexual function?Journal of Endourology2010;24(12):2051-7.">Spaliviero 2010</a>. </p> <p><sup>5</sup>Minimal clinically important difference: 25% improvement (greater than 9.5 points) from baseline (testosterone: 38.83; PDE5I: 37.06). </p> <p><sup>6</sup>No events in either group. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013071-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Testosterone as an add‐on to PDE5I compared to PDE5I alone in men with sexual dysfunction (short‐term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> men with sexual dysfunction<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> testosterone as an add‐on to PDE5I vs PDE5I alone<br/><b>Comparison:</b> PDE5I </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens?</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PDE5I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with testosterone + PDE5I</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erectile function (conversion to IIEF‐EF)<br/>Assessed with IIEF‐EF<br/>Scale from: 1 (worst: severe) to 30 (best: normal)<br/>Follow‐up: range 6 weeks to 16 weeks </p> <p>MCID: 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1,2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean erectile function ranged from 14.05 to 20.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.79 higher<br/>(1.25 higher to 4.33 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone as an add‐on to PDEI5I may result in little or no difference in erectile function. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual quality of life assessed with overall satisfaction domain of IIEF<br/>Scale from: 1 (worst: severe) to 10 (best: normal)<br/>Follow‐up: range 14 weeks to 16 weeks </p> <p>MCID: 1.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>282<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>3,5,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual quality of life ranged from 6.10 to 6.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.34 higher<br/>(0.76 lower to 1.45 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone as an add‐on to PDEI5I may result in little or no difference in sexual quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment withdrawal due to adverse events<br/>Follow‐up: range 12 weeks to 16 weeks </p> <p>MCID: absolute risk difference of 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>388<br/>(3 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1,3,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.26<br/>(0.32 to 4.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Testosterone as an add‐on to PDEI5I may result in little to no difference in treatment withdrawal due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 more per 1000<br/>(28 fewer to 163 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostate‐related events</p> <p>Follow‐up: range 6 weeks to 16 weeks</p> <p>MCID: absolute risk difference of 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>373<br/>(3 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>8,9,10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.83<br/>(0.84 to 55.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population <sup>11</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are very uncertain about the effect of testosterone as an add‐on to PDEI5I on prostate‐related events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower urinary tract symptoms</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>IIEF‐EF:</b> International Index of Erectile Function‐Erectile Function; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>PDE5I:</b> phosphodiesterase 5 inhibitor; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear or high risk of selection, performance, detection, and/or reporting bias among the included studies. </p> <p><sup>2</sup>Not downgraded further for indirectness: while the included studies (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>, <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>) did not clearly define the age of the study population, the mean age was over 45 years old. </p> <p><sup>3</sup>Downgraded by one level for imprecision: confidence interval crosses the assumed threshold of clinically important difference. </p> <p><sup>4</sup>Minimal clinically important difference: comes from <a href="./references#CD013071-bbs2-0196" title="RosenRC , AllenKR , NiX , AraujoAB . Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. European Urology2011;60(5):1010-6.">Rosen 2011</a>. </p> <p><sup>5</sup>Downgraded by one level for inconsistency: substantial heterogeneity. </p> <p><sup>6</sup>Minimal clinically important difference: 25% improvement (greater than 1.2 points) from the baseline (testosterone + PDE5I: 4.30; PDE5I: 4.94). </p> <p><sup>7</sup>Not downgraded further for indirectness: while the study includes men aged over 18 years old (<a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>), the mean age was over 45 years old. </p> <p><sup>8</sup>Not downgraded further for study limitations: while one study was rated unclear or high risk of bias overall (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>), there was no event (no effect on overall effect estimate). </p> <p><sup>9</sup>Downgraded by one level for indirectness: surrogate outcome used (participants with high prostate‐specific antigen over 4 ng/mL). </p> <p><sup>10</sup>Downgraded by two levels for imprecision: insufficient information size or wide confidence interval crosses the assumed threshold of clinically important difference. </p> <p><sup>11</sup>No event in control group. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013071-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013071-sec-0009"></div> <section id="CD013071-sec-0010"> <h3 class="title" id="CD013071-sec-0010">Description of the condition</h3> <p>Sexual dysfunction refers to a wide range of issues that interfere with an individual's ability to experience satisfaction or pleasure during sexual activity. Sexual dysfunction can affect either men or women and occur at any stage of the sexual response cycle, which includes desire, arousal, plateau, orgasm, and resolution (<a href="./references#CD013071-bbs2-0179" title="McCabeMP , SharlipID , AtallaE , BalonR , FisherAD , LaumannE , et al. Definitions of sexual dysfunctions in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. Journal of Sexual Medicine2016;13(2):135-43.">McCabe 2016a</a>). While there are few epidemiologic studies addressing the incidence and prevalence of sexual dysfunction in men, the overall prevalence of sexual dysfunction ranges up to 46% of the general population (<a href="./references#CD013071-bbs2-0180" title="McCabeMP , SharlipID , LewisR , AtallaE , BalonR , FisherAD , et al. Incidence and prevalence of sexual dysfunction in women and men: a consensus statement from the fourth international consultation on sexual medicine 2015. Journal of Sexual Medicine2016;13(2):144-52.">McCabe 2016b</a>). Studies demonstrate that most sexual dysfunctions increase with age. For example, the overall prevalence of erectile dysfunction was 19.2% in men aged 30 to 80 years, with a steep age‐related increase from 2.3% to 53.4% (<a href="./references#CD013071-bbs2-0133" title="BraunM , WassmerG , KlotzT , ReifenrathB , MathersM , EngelmannU . Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. International Journal of Impotence Research2000;12(6):305-11.">Braun 2000</a>; <a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0183" title="MulhallJP , TrostLW , BranniganRE , KurtzEG , RedmonJB , ChilesKA , et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology2018;200(2):423-32. [DOI: 10.1016/j.juro.2018.03.115]">Mulhall 2018</a>). While the social burden of sexual dysfunction has not been studied well, the total economic burden of erectile dysfunction was estimated at GBP 53 million annually according to a report from the United Kingdom (<a href="./references#CD013071-bbs2-0130" title="BalonR . Burden of Sexual Dysfunction. Journal of Sex &amp; Marital Therapy2017;43(1):49-55.">Balon 2017</a>). In addition, sexual dysfunction can cause significant psychological distress such as anxiety, depression, lack of sexual confidence, poor self‐esteem, impaired quality of life, and interpersonal difficulties (<a href="./references#CD013071-bbs2-0178" title="McCabeM , AlthofSE , AssalianP , Chevret-MeassonM , LeiblumSR , SimonelliC , et al. Psychological and interpersonal dimensions of sexual function and dysfunction. Journal of Sexual Medicine2010;7:327-36.">McCabe 2010</a>). </p> <p>The current guidelines classify sexual dysfunction into four main categories in men: erectile dysfunction, premature ejaculation, ejaculatory disorders, and low sexual desire (<a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>). Erectile dysfunction, the most prevalent complaint in men with sexual dysfunction, is defined as the inability of a man to achieve and maintain an erection of sufficient strength for satisfactory sexual activity. Ejaculatory dysfunction includes premature ejaculation, delayed ejaculation, anejaculation or anorgasmia, and retrograde ejaculation. Low sexual desire is defined as the persistent or recurrent deficiency (or absence) of sexual or erotic thoughts or fantasies and desire for sexual activity (<a href="./references#CD013071-bbs2-0134" title="BurnettAL , NehraA , BreauRH , CulkinDJ , FaradayMM , HakimLS , et al. Erectile dysfunction: AUA guideline. Journal of Urology2018;200(3):633-41.">Burnett 2018</a>; <a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0202" title="ShindelAW , AlthofSE , CarrierS , ChouR , McMahonCG , MulhallJP , et al. Disorders of ejaculation: an AUA/SMSNA guideline. Journal of Urology2022;207(3):504-12.">Shindel 2022</a>). Sexual function in men is complex and multifactorial, with significant overlap. </p> <section id="CD013071-sec-0011"> <h4 class="title">Diagnosis</h4> <p>The first step in evaluating men presenting with sexual complaints is obtaining a detailed sexual, medical, and psychosocial history. Subsequently, a physical examination focused on the genitourinary, endocrine, vascular, and neurological systems should be conducted to identify possible contributing factors (e.g. pelvic or perineal trauma) or comorbid conditions (e.g. anatomic problems, penile curvature) (<a href="./references#CD013071-bbs2-0134" title="BurnettAL , NehraA , BreauRH , CulkinDJ , FaradayMM , HakimLS , et al. Erectile dysfunction: AUA guideline. Journal of Urology2018;200(3):633-41.">Burnett 2018</a>; <a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0159" title="HatzimouratidisK , SaloniaA , AdaikanG , BuvatJ , CarrierS , El-MeliegyA , . Pharmacotherapy for erectile dysfunction: recommendations from the fourth international consultation for sexual medicine (ICSM 2015). Journal of Sexual Medicine2016;13(4):465-88.">Hatzimouratidis 2016</a>; <a href="./references#CD013071-bbs2-0202" title="ShindelAW , AlthofSE , CarrierS , ChouR , McMahonCG , MulhallJP , et al. Disorders of ejaculation: an AUA/SMSNA guideline. Journal of Urology2022;207(3):504-12.">Shindel 2022</a>). Additionally, laboratory testing of glucose‐lipid profile and hormonal tests, including testosterone and/or gonadotrophin, which regulates testosterone production, should be performed. Further laboratory tests may be considered in selected patients with specific signs and associated symptoms (e.g. prostate‐specific antigen (PSA)). Specific diagnostic tests, such as nocturnal penile tumescence and rigidity tests, intracavernous injection tests, dynamic duplex ultrasound of the penis, and arteriography, may be necessary to differentiate the type of erectile dysfunction or for medico‐legal reasons (<a href="./references#CD013071-bbs2-0134" title="BurnettAL , NehraA , BreauRH , CulkinDJ , FaradayMM , HakimLS , et al. Erectile dysfunction: AUA guideline. Journal of Urology2018;200(3):633-41.">Burnett 2018</a>; <a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0202" title="ShindelAW , AlthofSE , CarrierS , ChouR , McMahonCG , MulhallJP , et al. Disorders of ejaculation: an AUA/SMSNA guideline. Journal of Urology2022;207(3):504-12.">Shindel 2022</a>). </p> </section> <section id="CD013071-sec-0012"> <h4 class="title">Treatment</h4> <p>Treatment of sexual dysfunction in men depends on the underlying cause and type of dysfunction. Firstly, lifestyle modifications, such as a healthy diet and regular exercise, can play a significant role in managing sexual dysfunction, in particular erectile dysfunction that may be associated with modifiable or reversible risk factors. Oral pharmacotherapy has been commonly used as the first‐line treatment for the treatment of sexual dysfunction (<a href="./references#CD013071-bbs2-0134" title="BurnettAL , NehraA , BreauRH , CulkinDJ , FaradayMM , HakimLS , et al. Erectile dysfunction: AUA guideline. Journal of Urology2018;200(3):633-41.">Burnett 2018</a>; <a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0157" title="GuptaBP , MuradMH , CliftonMM , ProkopL , NehraA , KopeckySL . The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Archives of Internal Medicine2011;171(20):1797-803.">Gupta 2011</a>). Phosphodiesterase type 5 inhibitors (PDE5Is), which regulate intra‐cellular signaling cyclic guanosine monophosphate pathways of cavernous smooth muscle, are the most popular oral pharmacological agent for erectile dysfunction. A variety of PDE5Is have been approved and are the most commonly used for treatment of erectile dysfunction (<a href="./references#CD013071-bbs2-0134" title="BurnettAL , NehraA , BreauRH , CulkinDJ , FaradayMM , HakimLS , et al. Erectile dysfunction: AUA guideline. Journal of Urology2018;200(3):633-41.">Burnett 2018</a>; <a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0159" title="HatzimouratidisK , SaloniaA , AdaikanG , BuvatJ , CarrierS , El-MeliegyA , . Pharmacotherapy for erectile dysfunction: recommendations from the fourth international consultation for sexual medicine (ICSM 2015). Journal of Sexual Medicine2016;13(4):465-88.">Hatzimouratidis 2016</a>). Selective serotonin reuptake inhibitors, PDE5Is, and pregabalin (a new generation of gabapentinoid) have been found to help premature ejaculation. Sympathomimetics can be used for delayed or retrograde ejaculation. However, the evidence is still lacking (<a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0202" title="ShindelAW , AlthofSE , CarrierS , ChouR , McMahonCG , MulhallJP , et al. Disorders of ejaculation: an AUA/SMSNA guideline. Journal of Urology2022;207(3):504-12.">Shindel 2022</a>). Sexual concerns are the main symptoms of men with testosterone deficiency. The published literature also suggests a beneficial effect of testosterone replacement therapy (TRT) on several aspects of sexual life, including intercourse frequency, orgasm, and overall satisfaction. In addition, TRT combined with PDE5I may be more effective than monotherapy with testosterone or PDE5I (<a href="./references#CD013071-bbs2-0134" title="BurnettAL , NehraA , BreauRH , CulkinDJ , FaradayMM , HakimLS , et al. Erectile dysfunction: AUA guideline. Journal of Urology2018;200(3):633-41.">Burnett 2018</a>; <a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0173" title="KheraM , AdaikanG , BuvatJ , CarrierS , El-MeliegyA , HatzimouratidisK , et al. Diagnosis and treatment of testosterone deficiency: recommendations from the Fourth International Consultation on Sexual Medicine (ICSM 2015). Journal of Sexual Medicine2016;13(12):1787-804.">Khera 2016a</a>; <a href="./references#CD013071-bbs2-0176" title="LunenfeldB , MskhalayaG , KalinchenkoS , TishovaY . Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. Aging Male2013;16(4):143-50.">Lunenfeld 2013</a>; <a href="./references#CD013071-bbs2-0183" title="MulhallJP , TrostLW , BranniganRE , KurtzEG , RedmonJB , ChilesKA , et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology2018;200(2):423-32. [DOI: 10.1016/j.juro.2018.03.115]">Mulhall 2018</a>; <a href="./references#CD013071-bbs2-0212" title="WangC , NieschlagE , SwerdloffR , BehreHM , HellstromWJ , GoorenLJ , et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. International Journal of Impotence Research2009;21(1):1-8.">Wang 2009</a>). For men with low sexual desire, a meta‐analysis showed the favorable effect of testosterone therapy on sexual motivation and also the presence of sexual thoughts (<a href="./references#CD013071-bbs2-0170" title="IsidoriAM , GiannettaE , GianfrilliD , GrecoEA , BonifacioV , AversaA , et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clinical Endocrinology2005;63(4):381-94.">Isidori 2005</a>). There are also various alternative therapies using devices (e.g. vacuum erection devices) and surgical treatments (e.g. implantation of a penile prosthesis) that have been used in specific conditions or based on patient's preference (<a href="./references#CD013071-bbs2-0134" title="BurnettAL , NehraA , BreauRH , CulkinDJ , FaradayMM , HakimLS , et al. Erectile dysfunction: AUA guideline. Journal of Urology2018;200(3):633-41.">Burnett 2018</a>; <a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0202" title="ShindelAW , AlthofSE , CarrierS , ChouR , McMahonCG , MulhallJP , et al. Disorders of ejaculation: an AUA/SMSNA guideline. Journal of Urology2022;207(3):504-12.">Shindel 2022</a>). </p> </section> </section> <section id="CD013071-sec-0013"> <h3 class="title" id="CD013071-sec-0013">Description of the intervention</h3> <p>Testosterone is a well known hormone that is involved in the regulation of all steps of the male sexual response including sexual thoughts, motivations, and erection (<a href="./references#CD013071-bbs2-0139" title="CoronaG , IsidoriAM , AversaA , BurnettAL , MaggiM . Endocrinologic control of men's sexual desire and arousal/erection. Journal of Sexual Medicine2016;13(3):317-37.">Corona 2016</a>). Previous studies have reported that sexual symptoms, particularly impairment of sexual desire, erectile dysfunction, and decreased frequency of morning erections, were associated with age‐dependent decline of testosterone (<a href="./references#CD013071-bbs2-0214" title="WuFC , TajarA , BeynonJM , PyeSR , SilmanAJ , FinnJD , O'NeillTW , et al. Identification of late-onset hypogonadism in middle-aged and elderly men. New England Journal of Medicine2010;363(2):123-35.">Wu 2010</a>). Similar findings were reported in patients consulting for sexual dysfunctions (<a href="./references#CD013071-bbs2-0192" title="RastrelliG , CoronaG , TarocchiM , MannucciE , MaggiM . How to define hypogonadism? Results from a population of men consulting for sexual dysfunction. Journal of Endocrinological Investigation2016;39(4):473-84.">Rastrelli 2016</a>). In addition, testosterone plays a crucial role in regulating penile function induced by several enzymatic activities (e.g. nitric oxide). Based on this role in sexual dysfunction, the clinical practice guidelines recommend testosterone for men with sexual dysfunction (i.e. erectile dysfunction and low sexual desire) and testosterone deficiency, defined as &lt; 12 nmol/L (which corresponds to &lt; 350 ng/L) (<a href="./references#CD013071-bbs2-0134" title="BurnettAL , NehraA , BreauRH , CulkinDJ , FaradayMM , HakimLS , et al. Erectile dysfunction: AUA guideline. Journal of Urology2018;200(3):633-41.">Burnett 2018</a>; <a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0173" title="KheraM , AdaikanG , BuvatJ , CarrierS , El-MeliegyA , HatzimouratidisK , et al. Diagnosis and treatment of testosterone deficiency: recommendations from the Fourth International Consultation on Sexual Medicine (ICSM 2015). Journal of Sexual Medicine2016;13(12):1787-804.">Khera 2016a</a>; <a href="./references#CD013071-bbs2-0176" title="LunenfeldB , MskhalayaG , KalinchenkoS , TishovaY . Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. Aging Male2013;16(4):143-50.">Lunenfeld 2013</a>; <a href="./references#CD013071-bbs2-0183" title="MulhallJP , TrostLW , BranniganRE , KurtzEG , RedmonJB , ChilesKA , et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology2018;200(2):423-32. [DOI: 10.1016/j.juro.2018.03.115]">Mulhall 2018</a>; <a href="./references#CD013071-bbs2-0212" title="WangC , NieschlagE , SwerdloffR , BehreHM , HellstromWJ , GoorenLJ , et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. International Journal of Impotence Research2009;21(1):1-8.">Wang 2009</a>). </p> <p>Testosterone has been available for more than 70 years, and the number of new testosterone preparations has increased dramatically over the last two decades (<a href="./references#CD013071-bbs2-0185" title="NieschlagE , NieschlagS . Testosterone deficiency: a historical perspective. Asian Journal of Andrology2014;16(2):161-8.">Nieschlag 2014</a>). Recent US data showed that 2.2 million men were prescribed testosterone in 2013 compared to 1.2 million in 2010 (<a href="./references#CD013071-bbs2-0184" title='NguyenCP , HirschMS , MoenyD , KaulS , MohamoudM , JoffeHV . Testosterone and "age-related hypogonadism" - FDA concerns. New England Journal of Medicine2015;373(8):689-91.'>Nguyen 2015</a>). Estimated expenditure for testosterone prescription for older American men on Medicare rose from USD 108 million in 2007 to USD 402 million in 2016 (<a href="./references#CD013071-bbs2-0181" title="MordenNE , WoloshinS , BrooksCG , SchwartzLM . Trends in testosterone prescribing for age-related hypogonadism in men with and without heart disease. JAMA Internal Medicine2019;179(3):446-8. [DOI: 10.1001/jamainternmed.2018.6505]">Morden 2019</a>). Aggressive marketing strategies by pharmaceutical companies may explain the remarkable increase in testosterone use, even in the absence of an appropriate diagnosis (<a href="./references#CD013071-bbs2-0173" title="KheraM , AdaikanG , BuvatJ , CarrierS , El-MeliegyA , HatzimouratidisK , et al. Diagnosis and treatment of testosterone deficiency: recommendations from the Fourth International Consultation on Sexual Medicine (ICSM 2015). Journal of Sexual Medicine2016;13(12):1787-804.">Khera 2016a</a>; <a href="./references#CD013071-bbs2-0176" title="LunenfeldB , MskhalayaG , KalinchenkoS , TishovaY . Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. Aging Male2013;16(4):143-50.">Lunenfeld 2013</a>; <a href="./references#CD013071-bbs2-0183" title="MulhallJP , TrostLW , BranniganRE , KurtzEG , RedmonJB , ChilesKA , et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology2018;200(2):423-32. [DOI: 10.1016/j.juro.2018.03.115]">Mulhall 2018</a>; <a href="./references#CD013071-bbs2-0212" title="WangC , NieschlagE , SwerdloffR , BehreHM , HellstromWJ , GoorenLJ , et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. International Journal of Impotence Research2009;21(1):1-8.">Wang 2009</a>). </p> <p>Currently, available TRT options include intramuscular injections, transdermal, subcutaneous pellets, oral, and buccal formulations (<a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0153" title="GiagulliVA , TriggianiV , CoronaG , CarboneD , LicchelliB , TafaroE , et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations. Current Pharmaceutical Design2011;17(15):1500-11.">Giagulli 2011</a>; <a href="./references#CD013071-bbs2-0204" title="ShoskesJJ , WilsonMK , SpinnerML . Pharmacology of testosterone replacement therapy preparations. Translational Andrology and Urology2016;5(6):834-43.">Shoskes 2016</a>). </p> <p> <ul id="CD013071-list-0001"> <li> <p>Intramuscular injections are the longest available therapy option. While relatively inexpensive, frequent testosterone administration is required to maintain therapeutic levels at two‐ to three‐week intervals owing to their short half‐life. Recently, longer‐acting testosterone injections have become available with improved compliance compared with shorter‐acting testosterone injections. </p> </li> <li> <p>Transdermal formulations (such as gels, creams, and solutions) maintain stable physiological testosterone levels and require daily application. However, there are concerns regarding local adverse events such as skin irritation and rash. </p> </li> <li> <p>Subdermal administration (subcutaneous pellet implantation) provides sustained normal testosterone levels for three to four months, but implantation is invasive, requiring surgical intervention. </p> </li> <li> <p>Other therapies (oral tablets and buccal patches) are also available. These formulations are convenient for daily use but have disadvantages owing to frequent fluctuations in plasma testosterone levels. </p> </li> </ul> </p> <p>TRT can be initiated with approved formulations based on patient preference, predicted adverse effects, cost, and insurance coverage (<a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0204" title="ShoskesJJ , WilsonMK , SpinnerML . Pharmacology of testosterone replacement therapy preparations. Translational Andrology and Urology2016;5(6):834-43.">Shoskes 2016</a>). </p> <section id="CD013071-sec-0014"> <h4 class="title">Adverse effects of the intervention</h4> <p>The most critical concerns about testosterone administration relate to cardiovascular risks in older men with age‐related decline in testosterone levels (<a href="./references#CD013071-bbs2-0209" title="US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. www.fda.gov/Drugs/DrugSafety/ucm436259.htm (accessed prior to 28 October 2022).">US Food and Drug Administration</a>). Two observational studies that examined the risk of cardiovascular events associated with TRT found an increased risk of cardiovascular harm (<a href="./references#CD013071-bbs2-0149" title="FinkleWD , GreenlandS , RidgewayGK , AdamsJL , FrascoMA , CookMB , et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLOS One2014;9(1):e85805.">Finkle 2014</a>; <a href="./references#CD013071-bbs2-0210" title="VigenR , O'DonnellCI , BaronAE , GrunwaldGK , MaddoxTM , BradleySM , et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA2013;310(17):1829-36.">Vigen 2013</a>). Similarly, a recent meta‐analysis of 27 randomized controlled trials reported that testosterone therapy was associated with an increased risk of adverse cardiovascular events (odds ratio 1.5, 95% confidence interval 1.1 to 2.1) (<a href="./references#CD013071-bbs2-0215" title="XuL , FreemanG , CowlingBJ , SchoolingCM . Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Medicine2013;11:108.">Xu 2013</a>). As a result, the <a href="./references#CD013071-bbs2-0209" title="US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. www.fda.gov/Drugs/DrugSafety/ucm436259.htm (accessed prior to 28 October 2022).">US Food and Drug Administration</a> (FDA) has warned that TRT increases cardiovascular risk and has cautioned that prescription testosterone products are approved only for men with low testosterone levels caused by certain medical conditions (<a href="./references#CD013071-bbs2-0209" title="US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. www.fda.gov/Drugs/DrugSafety/ucm436259.htm (accessed prior to 28 October 2022).">US Food and Drug Administration</a>). </p> <p>Additional adverse events associated with TRT are polycythemia and an increase in prostate‐related events. Although the effect of TRT on the risk of venous thromboembolism related to polycythemia remains poorly understood, several studies support the thrombogenic potential of TRT (<a href="./references#CD013071-bbs2-0177" title="MartinezC , SuissaS , RietbrockS , KatholingA , FreedmanB , CohenAT , et al. Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ2016;355:i5968.">Martinez 2016</a>). Another potential risk of TRT is an increased incidence of prostate‐related events (i.e. the combined incidence of prostate biopsy, prostate enlargement, elevated prostate‐specific antigen (PSA), and prostate cancer) (<a href="./references#CD013071-bbs2-0135" title="CalofOM , SinghAB , LeeML , KennyAM , UrbanRJ , TenoverJL , et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2005;60(11):1451-7.">Calof 2005</a>). There are concerns that TRT may increase prostate cancer risk, but it is unclear whether there is, in fact, a causal relation (<a href="./references#CD013071-bbs2-0142" title="CowardRM , SimhanJ , Carson CC 3rd. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU International2009;103(9):1179-83.">Coward 2009</a>; <a href="./references#CD013071-bbs2-0201" title="ShabsighR , CrawfordED , NehraA , SlawinKM . Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. International Journal of Impotence Research2009;21(1):9-23.">Shabsigh 2009</a>; <a href="./references#CD013071-bbs2-0211" title="WalshTJ , ShoresMM , KrakauerCA , ForsbergCW , FoxAE , MooreKP , et al. Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels. PLOS One2018;13(6):e0199194.">Walsh 2018</a>). </p> <p>In addition, exogenous testosterone also produces dose‐dependent depression of gonadotropin (follicle‐stimulating hormone (FSH) and luteinizing hormone (LH)) release either by direct action on the pituitary gland or by suppression of the hypothalamic gonadotropin‐releasing hormone (GnRH) release. Reduced gonadotropin secretion decreases intratesticular and peripheral testosterone levels, which can cause adverse effects such as testicular atrophy, oligospermia, azoospermia, and other sperm abnormalities (<a href="./references#CD013071-bbs2-0150" title="FronczakCM , KimED , BarqawiAB . The insults of illicit drug use on male fertility. Journal of Andrology2012;33(4):515-28.">Fronczak 2012</a>). In addition, a lack of libido, erectile dysfunction, or even gynecomastia may also be observed (<a href="./references#CD013071-bbs2-0186" title="NieschlagE , VoronaE . Mechanisms in endocrinology: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. European Journal of Endocrinology2015;173(2):R47-58.">Nieschlag 2015</a>). </p> </section> </section> <section id="CD013071-sec-0015"> <h3 class="title" id="CD013071-sec-0015">How the intervention might work</h3> <p>Testosterone is secreted primarily by the testes and, to a lesser extent, by the adrenal glands. It exerts its action through binding to and activation of the androgen receptor in most organ systems, including the central and peripheral nervous system, musculoskeletal system, reproductive system, and cardiovascular system (<a href="./references#CD013071-bbs2-0138" title="CoronaG , RastrelliG , FortiG , MaggiM . Update in testosterone therapy for men. Journal of Sexual Medicine2011;8(3):639-54; quiz 655.">Corona 2011</a>). </p> <p>Testosterone plays a critical role in developing the male reproductive organs, such as the testes and prostate, and promotes secondary sexual characteristics during puberty (<a href="./references#CD013071-bbs2-0151" title="GannonJR , WalshTJ . Testosterone and sexual function. Urologic Clinics of North America2016;43(2):217-22.">Gannon 2016</a>; <a href="./references#CD013071-bbs2-0188" title="OhlanderSJ , LindgrenMC , LipshultzLI . Testosterone and male infertility. Urologic Clinics of North America2016;43(2):195-202.">Ohlander 2016</a>). In addition, testosterone modulates male sexual desire, spontaneous sexual thoughts, motivation, attentiveness to erotic stimuli, and sexual activity including regulation of penile erection (<a href="./references#CD013071-bbs2-0151" title="GannonJR , WalshTJ . Testosterone and sexual function. Urologic Clinics of North America2016;43(2):217-22.">Gannon 2016</a>). It also stimulates muscle protein synthesis and may increase bone mineral density by a direct effect or by an indirect action requiring conversion to estradiol (<a href="./references#CD013071-bbs2-0132" title="BorstSE , YarrowJF . Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men. American Journal of Physiology. Endocrinology and Metabolism.2015;308(12):E1035-42.">Borst 2015</a>). Finally, testosterone is thought to exert a variety of beneficial effects on blood vessels and the heart through improving lipid profiles, insulin sensitivity, and exercise tolerance (<a href="./references#CD013071-bbs2-0174" title="KlonerRA , Carson C 3rd, DobsA , KopeckyS , Mohler ER 3rd. Testosterone and cardiovascular disease. Journal of the American College of Cardiology2016;67(5):545-57.">Kloner 2016</a>). </p> </section> <section id="CD013071-sec-0016"> <h3 class="title" id="CD013071-sec-0016">Why it is important to do this review</h3> <p>Since exogenous testosterone administration, known as TRT, became available for the Klinefelter and the Kallmann syndrome (<a href="./references#CD013071-bbs2-0185" title="NieschlagE , NieschlagS . Testosterone deficiency: a historical perspective. Asian Journal of Andrology2014;16(2):161-8.">Nieschlag 2014</a>; <a href="./references#CD013071-bbs2-0217" title="ZitzmannM , NieschlagE . Hormone substitution in male hypogonadism. Molecular and Cellular Endocrinology2000;161(1-2):73-88.">Zitzmann 2000</a>), the FDA has approved testosterone products for men who have low testosterone levels associated with certain medical conditions, such as failure of the testicles to produce testosterone because of genetic problems or exposure to chemotherapy (primary hypogonadism), or problems with the pituitary gland or hypothalamus that control the production of testosterone by the testis (secondary hypogonadism) (<a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0173" title="KheraM , AdaikanG , BuvatJ , CarrierS , El-MeliegyA , HatzimouratidisK , et al. Diagnosis and treatment of testosterone deficiency: recommendations from the Fourth International Consultation on Sexual Medicine (ICSM 2015). Journal of Sexual Medicine2016;13(12):1787-804.">Khera 2016a</a>; <a href="./references#CD013071-bbs2-0176" title="LunenfeldB , MskhalayaG , KalinchenkoS , TishovaY . Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. Aging Male2013;16(4):143-50.">Lunenfeld 2013</a>; <a href="./references#CD013071-bbs2-0183" title="MulhallJP , TrostLW , BranniganRE , KurtzEG , RedmonJB , ChilesKA , et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology2018;200(2):423-32. [DOI: 10.1016/j.juro.2018.03.115]">Mulhall 2018</a>; <a href="./references#CD013071-bbs2-0212" title="WangC , NieschlagE , SwerdloffR , BehreHM , HellstromWJ , GoorenLJ , et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. International Journal of Impotence Research2009;21(1):1-8.">Wang 2009</a>). However, current guidelines by major professional societies in andrology and endocrinology recommend TRT in the treatment of erectile dysfunction and problems with libido arising from low testosterone levels in aging men without other medical causes of low testosterone (<a href="./references#CD013071-bbs2-0134" title="BurnettAL , NehraA , BreauRH , CulkinDJ , FaradayMM , HakimLS , et al. Erectile dysfunction: AUA guideline. Journal of Urology2018;200(3):633-41.">Burnett 2018</a>; <a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0173" title="KheraM , AdaikanG , BuvatJ , CarrierS , El-MeliegyA , HatzimouratidisK , et al. Diagnosis and treatment of testosterone deficiency: recommendations from the Fourth International Consultation on Sexual Medicine (ICSM 2015). Journal of Sexual Medicine2016;13(12):1787-804.">Khera 2016a</a>; <a href="./references#CD013071-bbs2-0176" title="LunenfeldB , MskhalayaG , KalinchenkoS , TishovaY . Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. Aging Male2013;16(4):143-50.">Lunenfeld 2013</a>; <a href="./references#CD013071-bbs2-0183" title="MulhallJP , TrostLW , BranniganRE , KurtzEG , RedmonJB , ChilesKA , et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology2018;200(2):423-32. [DOI: 10.1016/j.juro.2018.03.115]">Mulhall 2018</a>; <a href="./references#CD013071-bbs2-0212" title="WangC , NieschlagE , SwerdloffR , BehreHM , HellstromWJ , GoorenLJ , et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. International Journal of Impotence Research2009;21(1):1-8.">Wang 2009</a>). In addition, there are existing systematic reviews for TRT; however, they have focused on TRT effects in the broader population, regardless of the presence or absence of testosterone‐related symptoms. </p> <p>While current guidelines recommend TRT only in men with testosterone deficiency based on a consistent body of evidence (<a href="./references#CD013071-bbs2-0134" title="BurnettAL , NehraA , BreauRH , CulkinDJ , FaradayMM , HakimLS , et al. Erectile dysfunction: AUA guideline. Journal of Urology2018;200(3):633-41.">Burnett 2018</a>; <a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0173" title="KheraM , AdaikanG , BuvatJ , CarrierS , El-MeliegyA , HatzimouratidisK , et al. Diagnosis and treatment of testosterone deficiency: recommendations from the Fourth International Consultation on Sexual Medicine (ICSM 2015). Journal of Sexual Medicine2016;13(12):1787-804.">Khera 2016a</a>; <a href="./references#CD013071-bbs2-0176" title="LunenfeldB , MskhalayaG , KalinchenkoS , TishovaY . Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. Aging Male2013;16(4):143-50.">Lunenfeld 2013</a>; <a href="./references#CD013071-bbs2-0183" title="MulhallJP , TrostLW , BranniganRE , KurtzEG , RedmonJB , ChilesKA , et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology2018;200(2):423-32. [DOI: 10.1016/j.juro.2018.03.115]">Mulhall 2018</a>; <a href="./references#CD013071-bbs2-0212" title="WangC , NieschlagE , SwerdloffR , BehreHM , HellstromWJ , GoorenLJ , et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. International Journal of Impotence Research2009;21(1):1-8.">Wang 2009</a>), there are concerns about widespread use of testosterone for eugonadal men based on both global and US data, which reflect an overall increase in the prescribing of TRT, possibly as self‐medication in response to advertising (<a href="./references#CD013071-bbs2-0171" title="JasujaGK , BhasinS , RoseAJ . Patterns of testosterone prescription overuse. Current Opinion in Endocrinology, Diabetes and Obesity2017;24(3):240-5.">Jasuja 2017</a>). </p> <p>Therefore, in this review, we have focused on men with sexual dysfunction (i.e. testosterone‐related symptoms) regardless of serum testosterone level, to determine the role of TRT in the population without certain medical conditions. </p> <p>More importantly, no systematic reviews so far have used the same rigorous methodology as a Cochrane review, which includes the GRADE approach for rating the certainty of evidence (<a href="./references#CD013071-bbs2-0156" title="GuoC , GuW , LiuM , PengBO , YaoX , YangB , et al. Efficacy and safety of testosterone replacement therapy in men with hypogonadism: a meta-analysis study of placebo-controlled trials. Experimental Therapeutic Medicine2016;11(3):853-63.">Guo 2016</a>; <a href="./references#CD013071-bbs2-0208" title="TsertsvadzeA , FinkHA , YazdiF , MacDonaldR , BellaAJ , AnsariMT , et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Annals of Internal Medicine2009;151(9):650-61.">Tsertsvadze 2009</a>). Given this question's controversial and important nature, we have conducted a methodologically rigorous assessment of the benefits and harms of TRT in men with sexual dysfunction. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013071-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013071-sec-0017"></div> <p>To assess the effects of testosterone replacement therapy compared to placebo or other medical treatments in men with sexual dysfunction. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013071-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013071-sec-0018"></div> <section id="CD013071-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013071-sec-0020"> <h4 class="title">Types of studies</h4> <p>As randomized controlled trials (RCTs) are considered to provide the strongest measure of whether an intervention has an effect, we planned to include parallel‐group RCTs, cluster‐RCTs, and cross‐over RCTs. </p> </section> <section id="CD013071-sec-0021"> <h4 class="title">Types of participants</h4> <p>We included adult men (aged 40 years and over) with sexual dysfunction. The age limitation is based on observations from the Massachusetts Male Aging Study, which noted that the prevalence of complete erectile dysfunction triples from 5% to 15% between 40 and 70 years (<a href="./references#CD013071-bbs2-0148" title="FeldmanHA , GoldsteinI , HatzichristouDG , KraneRJ , McKinlayJB . Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. Journal of Urology1994;151(1):54-61.">Feldman 1994</a>). </p> <p>We excluded men who had hematocrit &gt; 55%, known prostate cancer, androgen‐dependent carcinoma of the male mammary gland, past or existing liver tumors, other significant medical (e.g. angina) or psychological conditions (e.g. schizophrenia), taken medications known to interfere with testosterone metabolism, hypersensitivity to the active substance of the study medication, clinically diagnosed sleep apnea or testosterone treatment within the previous six months. We excluded men with primary or secondary hypogonadism (e.g. Klinefelter syndrome or hypogonadotropic hypogonadism). Additionally, we excluded ill or fragile older men who were not appropriate for the pharmacotherapy of sexual dysfunction. </p> <section id="CD013071-sec-0022"> <h5 class="title">Diagnostic criteria for sexual dysfunction</h5> <p>We defined sexual dysfunction as acquired symptoms of decreased libido (or desire to engage in sexual activity) and/or erectile dysfunction, referring to the inability to attain or maintain an erection sufficient to permit satisfactory sexual performance (<a href="./references#CD013071-bbs2-0173" title="KheraM , AdaikanG , BuvatJ , CarrierS , El-MeliegyA , HatzimouratidisK , et al. Diagnosis and treatment of testosterone deficiency: recommendations from the Fourth International Consultation on Sexual Medicine (ICSM 2015). Journal of Sexual Medicine2016;13(12):1787-804.">Khera 2016a</a>; <a href="./references#CD013071-bbs2-0176" title="LunenfeldB , MskhalayaG , KalinchenkoS , TishovaY . Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. Aging Male2013;16(4):143-50.">Lunenfeld 2013</a>; <a href="./references#CD013071-bbs2-0212" title="WangC , NieschlagE , SwerdloffR , BehreHM , HellstromWJ , GoorenLJ , et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. International Journal of Impotence Research2009;21(1):1-8.">Wang 2009</a>). We included trials that used validated questionnaires related to sexual dysfunction, such as Aging Males' Symptoms (AMS) or the International Index of Erectile Function (IIEF), to establish the diagnosis of sexual dysfunction (<a href="./references#CD013071-bbs2-0160" title="HeinemannLAJ , ZimmermannT , VermeulenA , ThielC , HummelW . A new ‘aging males’ symptoms' rating scale. Aging Male1999;2(2):105-14.">Heinemann 1999</a>; <a href="./references#CD013071-bbs2-0195" title="RosenRC , RileyA , WagnerG , OsterlohIH , KirkpatrickJ , MishraA . The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology1997;49(6):822-30.">Rosen 1997</a>). </p> <p> <ul id="CD013071-list-0002"> <li> <p>AMS: three dimensions (psychological, somatic, and sexual subscale), consisting of 17 items rated on a scale of severity from one to five points. The total score ranges from 17 to 85, with higher scores indicating severe symptoms consistent with testosterone deficiency (&lt; 26 points: no significant symptoms; 27 to 36 points: mild symptoms; 37 to 49 points: moderate symptoms; &gt; 50 points: severe symptoms) (<a href="./references#CD013071-bbs2-0160" title="HeinemannLAJ , ZimmermannT , VermeulenA , ThielC , HummelW . A new ‘aging males’ symptoms' rating scale. Aging Male1999;2(2):105-14.">Heinemann 1999</a>). </p> </li> <li> <p>IIEF: 15 items (IIEF‐15), which are divided into five domains: erectile function (six items), orgasmic function (two items), sexual desire (two items), intercourse satisfaction (three items), and overall satisfaction (two items). Each question is scored on a scale from 0 to 5, with a maximum possible score for each subdomain as follows: erectile function (30 points), orgasmic function (10 points), sexual desire (10 points), intercourse satisfaction (15 points), and overall satisfaction (10 points). Based on the erectile function domain of IIEF, erectile dysfunction (ED) can be classified into five categories (6 to 10 points: severe; 11 to 16 points: moderate; 17 to 21 points: mild to moderate; 22 to 25 points: mild; 26 to 30 points: no ED) (<a href="./references#CD013071-bbs2-0136" title="CappelleriJC , RosenRC , SmithMD , MishraA , OsterlohIH . Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology1999;54(2):346-51.">Cappelleri 1999</a>). </p> </li> <li> <p>IIEF‐5: a shortened five‐item version of the IIEF, scored on a scale from 5 to 25, with lower scores indicating severe ED (5 to 7 points: severe; 8 to 11 points: moderate; 12 to 16 points: mild to moderate; 17 to 21 points: mild; 22 to 25 points: no ED) (<a href="./references#CD013071-bbs2-0195" title="RosenRC , RileyA , WagnerG , OsterlohIH , KirkpatrickJ , MishraA . The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology1997;49(6):822-30.">Rosen 1997</a>). </p> </li> </ul> </p> </section> </section> <section id="CD013071-sec-0023"> <h4 class="title">Types of interventions</h4> <p>We planned to investigate the following comparisons of intervention versus control/comparator.</p> <section id="CD013071-sec-0024"> <h5 class="title">Intervention</h5> <p> <ul id="CD013071-list-0003"> <li> <p>Testosterone, regardless of formulation</p> </li> <li> <p>Testosterone as an add‐on to phosphodiesterase 5 inhibitors (PDE5I)</p> </li> </ul> </p> </section> <section id="CD013071-sec-0025"> <h5 class="title">Comparator</h5> <p> <ul id="CD013071-list-0004"> <li> <p>Placebo compared with testosterone or testosterone as an add‐on to PDE5I</p> </li> <li> <p>PDE5I compared with testosterone or testosterone as an add‐on to PDE5I</p> </li> </ul> </p> <p>We chose the most commonly used pharmacological agent, PDE5I, as a comparator. In addition, we compared testosterone monotherapy or combination therapy with PDE5I to placebo or PDE5I monotherapy. </p> <p>Concomitant interventions had to be the same in both the intervention and comparator groups to establish fair comparisons. </p> </section> <section id="CD013071-sec-0026"> <h5 class="title">Minimum duration of intervention and follow‐up</h5> <p>We defined a clinically meaningful minimal duration of the intervention and follow‐up as one month (four weeks). </p> </section> <section id="CD013071-sec-0027"> <h5 class="title">Summary of specific exclusion criteria</h5> <p>We excluded trials in men with the following.</p> <p> <ul id="CD013071-list-0005"> <li> <p>Primary hypogonadism, such as disorders of the testicles</p> </li> <li> <p>Secondary hypogonadism, such as disorders of the pituitary gland or brain that cause hypogonadism </p> </li> <li> <p>Disorders that cause hormonal disturbances, such as Cushing disease or syndrome</p> </li> <li> <p>Relative or absolute contraindications of TRT such as hematocrit &gt; 55%, known prostate cancer or PSA levels greater than 4 ng/mL, and untreated sleep apnea </p> </li> </ul> </p> </section> </section> <section id="CD013071-sec-0028"> <h4 class="title">Types of outcome measures</h4> <p>We did not exclude a trial if it failed to report one or several of our primary or secondary outcome measures. If a trial reported none of our primary or secondary outcomes, we provided some basic information in the results section and additional tables. </p> <p>We investigated the following outcomes using the methods and time points specified below. </p> <section id="CD013071-sec-0029"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013071-list-0006"> <li> <p>Erectile function</p> </li> <li> <p>Sexual quality of life</p> </li> <li> <p>Cardiovascular mortality</p> </li> </ul> </p> </section> <section id="CD013071-sec-0030"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013071-list-0007"> <li> <p>Treatment withdrawal due to adverse events</p> </li> <li> <p>Prostate‐related events</p> </li> <li> <p>Lower urinary tract symptoms</p> </li> </ul> </p> <section id="CD013071-sec-0031"> <h6 class="title">Method of outcome measurement</h6> <p>We considered clinically important differences for the review outcomes to rate the certainty of the evidence for imprecision in the summary of findings tables (<a href="./references#CD013071-bbs2-0172" title="JohnstonBC , ThorlundK , SchunemannHJ , XieF , MuradMH , MontoriVM , et al. Improving the interpretation of quality of life evidence in meta-analyses: the application of minimal important difference units. Health and Quality of Life Outcomes2010;8:116.">Johnston 2010</a>). We used minimal clinically important differences (MCIDs) for participant‐reported outcomes and clinically relevant absolute or relative effect measures for dichotomous outcomes to define the clinically important differences based on a minimally contextualized GRADE approach (<a href="./references#CD013071-bbs2-0216" title="ZengL , Brignardello-PetersenR , HultcrantzM , MustafaRA , MuradMH , IorioA , et al. GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. Journal of Clinical Epidemiology2022;150:216-24.">Zeng 2022</a>). </p> <section id="CD013071-sec-0032"> <p><b>Erectile function</b></p> <p> <ul id="CD013071-list-0008"> <li> <p>Evaluated by validated questionnaires, such as the sexual domain of AMS, erectile function domain of IIEF or IIEF‐5. </p> </li> <li> <p>We considered the MCID in the erectile function domain score of IIEF to be four (<a href="./references#CD013071-bbs2-0196" title="RosenRC , AllenKR , NiX , AraujoAB . Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. European Urology2011;60(5):1010-6.">Rosen 2011</a>). We also considered an improvement of IIEF‐5 to be over five points as a MCID (<a href="./references#CD013071-bbs2-0205" title="SpalivieroM , StromKH , GuX , ArakiM , CulkinDJ , WongC . Does Greenlight HPS laser photoselective vaporization prostatectomy affect sexual function?Journal of Endourology2010;24(12):2051-7.">Spaliviero 2010</a>). There is no established threshold in the sexual domain of AMS. We used a MCID of 25% improvement from the baseline in AMS (<a href="./references#CD013071-bbs2-0158" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology2011;64:1283-93.">Guyatt 2011</a>). </p> </li> </ul> </p> </section> <section id="CD013071-sec-0033"> <p><b>Sexual quality of life</b></p> <p> <ul id="CD013071-list-0009"> <li> <p>Evaluated by validated questionnaires, such as a total score of AMS and the overall satisfaction domain of IIEF. </p> </li> <li> <p>There is no reported threshold for the total score of AMS and the overall satisfaction domain of IIEF. We used a MCID of 25% improvement from the baseline to assess sexual quality of life (<a href="./references#CD013071-bbs2-0158" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology2011;64:1283-93.">Guyatt 2011</a>). </p> </li> </ul> </p> </section> <section id="CD013071-sec-0034"> <p><b>Cardiovascular mortality</b></p> <p> <ul id="CD013071-list-0010"> <li> <p>Such as mortality related to myocardial infarction, heart failure, constrictive pericarditis, stroke, and any type of embolism or thrombosis after participants were randomized to intervention/comparator groups (<a href="./references#CD013071-bbs2-0048" title="BasariaS , CovielloAD , TravisonTG , StorerTW , FarwellWR , JetteAM , et al. Adverse events associated with testosterone administration. New England Journal of Medicine2010;363(2):109-22. [DOI: 10.1056/NEJMoa1000485]">Basaria 2010</a>). </p> </li> <li> <p>We considered a MCID to be an absolute risk difference of at least 3%.</p> </li> </ul> </p> </section> <section id="CD013071-sec-0035"> <p><b>Treatment withdrawal due to adverse events</b></p> <p> <ul id="CD013071-list-0011"> <li> <p>Defined as treatment discontinuation due to adverse events at any time after participants were randomized to intervention/comparator groups. </p> </li> <li> <p>We considered a MCID to be an absolute risk difference of at least 5%.</p> </li> </ul> </p> </section> <section id="CD013071-sec-0036"> <p><b>Prostate‐related events</b></p> <p> <ul id="CD013071-list-0012"> <li> <p>Such as incidence of prostate biopsy, prostate enlargement, elevated PSA, and prostate cancer. </p> </li> <li> <p>If the authors of eligible studies reported prostate‐related events separately, we used the available information described in the studies. </p> </li> <li> <p>We considered a MCID to be an absolute risk difference of at least 5%.</p> </li> </ul> </p> </section> <section id="CD013071-sec-0037"> <p><b>Lower urinary tract symptoms</b></p> <p> <ul id="CD013071-list-0013"> <li> <p>Evaluated by validated questionnaires such as the International Prostate Symptom Score (IPSS) on a scale from 0 to 35, with higher scores indicating worse symptoms (0 to 7 points: mild; 8 to 19 points: moderate; 20 to 35 points: severe symptoms). </p> </li> <li> <p>We considered the MCID on the IPSS to be three points (<a href="./references#CD013071-bbs2-0131" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker-CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?Journal of Urology1995;154(5):1770-4.">Barry 1995</a>). </p> </li> </ul> </p> </section> </section> <section id="CD013071-sec-0038"> <h6 class="title">Timing of outcome measurement</h6> <p>We considered outcomes measured up to and including 12 months after randomization as short‐term, and later than 12 months as long‐term. </p> </section> </section> </section> </section> <section id="CD013071-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013071-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources from the inception of each database to 29 August 2023 (date of last search) and placed no restrictions on publication language or publication status. </p> <p> <ul id="CD013071-list-0014"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL 2023, Issue 8) and Cochrane Database of Systematic Reviews (the Cochrane Library via Wiley; from 1991). </p> </li> <li> <p>MEDLINE via Ovid (from 1946).</p> </li> <li> <p>Embase via embase.com (from 1947).</p> </li> <li> <p>LILACS (Latin American and the Caribbean Health Sciences Literature; from 1982).</p> </li> </ul> </p> <p>We also searched for the following.</p> <p> <ul id="CD013071-list-0015"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int</a>). </p> </li> <li> <p>Canadian Agency for Drugs and Technologies in Health (<a href="https://www.cadth.ca/" target="_blank">www.cadth.ca/</a>). </p> </li> <li> <p>DART‐Europe E‐theses Portal (<a href="https://www.dart-europe.org/basic-search.php" target="_blank">www.dart-europe.org/basic-search.php</a>). </p> </li> </ul> </p> </section> <section id="CD013071-sec-0041"> <h4 class="title">Searching other resources</h4> <p>We attempted to identify other potentially eligible trials or ancillary publications by searching through the reference lists of included trials, systematic reviews, meta‐analyses, and health technology assessment reports. In addition, we tried to contact the authors of the included trials to identify any additional information on the retrieved trials or any further trials that we may have missed. </p> </section> </section> <section id="CD013071-sec-0042"> <h3 class="title" id="CD013071-sec-0042">Data collection and analysis</h3> <section id="CD013071-sec-0043"> <h4 class="title">Selection of studies</h4> <p>Two review authors (HJL, ECH, SL, or JHJ) independently screened the abstract, title, or both of every record retrieved by the literature searches to determine which trials should be assessed further using <a href="./references#CD013071-bbs2-0141" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 29 July 2023. Available at www.covidence.org.">Covidence</a>. We obtained the full text of all potentially relevant records. Any disagreements were resolved through consensus or by recourse to a third review author (PD). In the event that a disagreement could not be resolved, we categorized the trial as a 'study awaiting classification' and contacted the trial authors for clarification. We reported inter‐rater agreement calculated by <a href="./references#CD013071-bbs2-0141" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 29 July 2023. Available at www.covidence.org.">Covidence</a>. We presented an adapted PRISMA flow diagram to show the process of trial selection (<a href="./references#CD013071-bbs2-0189" title="PageMJ , McKenzieJE , BossuytPM , BoutronI , HoffmannTC , MulrowCD , et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021 ;372:n71.">Page 2021</a>). We listed all articles excluded after full‐text assessment in a <a href="./references#CD013071-sec-0175" title="">Characteristics of excluded studies</a> table and provided the reasons for their exclusion. </p> </section> <section id="CD013071-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (HJL, ECH, SL, or JHJ) independently extracted key participant and intervention characteristics for the included trials. We described interventions according to the 'template for intervention description and replication' (TIDieR) checklist (<a href="./references#CD013071-bbs2-0166" title="HoffmannTC , GlasziouPP , BoutronI , MilneR , PereraR , MoherD , et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ2014;348:g1687.">Hoffmann 2014</a>; <a href="./references#CD013071-bbs2-0167" title="HoffmannTC , OxmanAD , IoannidisJP , MoherD , LassersonTJ , ToveyDI , et al. Enhancing the usability of systematic reviews by improving the consideration and description of interventions. BMJ2017;358:j2998.">Hoffmann 2017</a>). </p> <p>We extracted data on efficacy outcomes and adverse events using standardized data extraction sheets from Cochrane Metabolic and Endocrine Disorders (CMED). Any disagreements were resolved by discussion or consulting a third review author (PD) if necessary. </p> <p>We provided information, including trial identifiers for potentially relevant ongoing trials, in the <a href="./references#CD013071-sec-0177" title="">Characteristics of ongoing studies</a> table. </p> <p>We contacted the authors of all the included trials to ask if they would be willing to answer questions regarding their trials. We presented the results of this survey in an appendix (<a href="./appendices#CD013071-sec-0163">Appendix 1</a>). We thereafter sought relevant missing information on the trial from the primary trial author(s), if required. </p> <section id="CD013071-sec-0045"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents, or multiple reports of a primary trial, we maximized the information yield by collating all available data and used the most complete data set aggregated across all known publications. We listed duplicate publications, companion documents, multiple reports of a primary trial, and trial documents of included trials (such as trial registry information) as secondary references under the study ID of the included trial. Furthermore, we also listed duplicate publications, companion documents, multiple reports of a trial, and trial documents of excluded trials (such as trial registry information) as secondary references under the study ID of the excluded trial. </p> </section> <section id="CD013071-sec-0046"> <h5 class="title">Data from clinical trials registers</h5> <p>If data from included trials were available as study results in clinical trial registers such as ClinicalTrials.gov or similar sources, we made full use of this information and extracted the data. If there was also a full publication of the trial, we collated and critically appraised all available data. If an included trial was marked as a completed study in a clinical trial register, but no additional information (study results, publication, or both) was available, we added this trial to the <a href="./references#CD013071-sec-0176" title="">Characteristics of studies awaiting classification</a> table. </p> </section> </section> <section id="CD013071-sec-0047"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (HJL, SL, and JHJ) independently assessed the risk of bias for each included trial. Any disagreements were resolved by consensus or by consulting a third review author (PD) when necessary. In case of disagreement, we consulted the remainder of the review author team and made a judgment based on consensus. If adequate information was not available from the publications, trial protocols, or other sources, we contacted the trial authors for more detail to request missing data on risk of bias items. </p> <p>We used the Cochrane risk of bias tool for randomized trials (1.0) (<a href="./references#CD013071-bbs2-0163" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>), assigning assessments of low, high, or unclear risk of bias. We evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> according to the criteria and associated categorizations contained therein (<a href="./references#CD013071-bbs2-0163" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <section id="CD013071-sec-0048"> <h5 class="title">Summary assessment of the risk of bias</h5> <p>We presented a risk of bias summary figure.</p> <p>We distinguished between self‐reported and investigator‐assessed and adjudicated outcome measures. </p> <p>We considered the following self‐reported outcomes.</p> <p> <ul id="CD013071-list-0016"> <li> <p>Erectile function</p> </li> <li> <p>Sexual quality of life</p> </li> <li> <p>Lower urinary tract symptoms</p> </li> </ul> </p> <p>We considered the following outcomes to be investigator‐assessed.</p> <p> <ul id="CD013071-list-0017"> <li> <p>Cardiovascular mortality</p> </li> <li> <p>Treatment withdrawal due to adverse event</p> </li> <li> <p>Prostate‐related events</p> </li> </ul> </p> <section id="CD013071-sec-0049"> <h6 class="title">Risk of bias for a trial across outcomes</h6> <p>Some risk of bias domains, such as selection bias (sequence generation and allocation sequence concealment), affect the risk of bias across all outcome measures in a trial. In case of a high risk of selection bias, we marked all endpoints investigated in the associated trial as being at high risk. Otherwise, we did not perform a summary assessment of the risk of bias across all outcomes for a trial. </p> </section> <section id="CD013071-sec-0050"> <h6 class="title">Risk of bias for an outcome within a trial and across domains</h6> <p>We assessed the risk of bias for an outcome measure by including all entries relevant to that outcome (i.e. both trial‐level entries and outcome‐specific entries). We considered low risk of bias to denote a low risk of bias for all key domains, unclear risk to denote an unclear risk of bias for one or more key domains, and high risk to denote a high risk of bias for one or more key domains. </p> </section> <section id="CD013071-sec-0051"> <h6 class="title">Risk of bias for an outcome across trials and across domains</h6> <p>These were the main summary assessments that we incorporated into our judgments about the certainty of the evidence in the summary of findings tables. We defined outcomes as at low risk of bias when most information came from trials at low risk of bias; unclear risk when most information came from trials at low or unclear risk of bias; and high risk when a sufficient proportion of information came from trials at high risk of bias. </p> </section> </section> </section> <section id="CD013071-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>When at least two included trials were available for a comparison and a given outcome, we attempted to express dichotomous data as a risk ratio (RR) or odds ratio (OR) with 95% confidence intervals (CIs). For continuous outcomes measured on the same scale (e.g. lower urinary tract symptoms), we estimated the intervention effect using the mean difference (MD) with 95% CIs. For continuous outcomes that measured the same underlying concept (e.g. erectile function, sexual quality of life), but use different measurement scales, we converted to natural units of the most familiar instrument such as IIEF or reported all measurement scales to prevent selective reporting, instead of using the standardized mean difference, to facilitate direct interpretation. </p> </section> <section id="CD013071-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. We took into account the level at which randomization occurred, such as cross‐over trials, cluster‐randomized trials, and multiple observations for the same outcome. </p> <p>For cross‐over trials, we planned to incorporate the results into a meta‐analysis in accordance with guidance provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (e.g. based on the available data, treating the trial as a parallel‐group trial, or including only data from the first period) (<a href="./references#CD013071-bbs2-0164" title="Higgins JP, ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated August 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022a</a>)<i>.</i> However, no cross‐over trial was included in the quantitative analysis. </p> <p>Although we had planned to attempt to reanalyze cluster‐randomized trials that had not appropriately adjusted for the potential clustering of participants within clusters in their analyses, we did not find any cluster‐randomized trials. </p> <p>If more than one comparison from the same trial was eligible for inclusion in the same meta‐analysis, we either combined groups to create a single pair‐wise comparison or appropriately reduced the sample size so that the same participants did not contribute data to the meta‐analysis more than once (splitting the 'shared' group into two or more groups). While the latter approach offers some solutions to adjust the precision of the comparison, it does not account for correlation arising from the same set of participants being in multiple comparisons (<a href="./references#CD013071-bbs2-0165" title="HigginsJPT , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022b</a>). However, in the event there were no candidate trials for combining the groups. </p> </section> <section id="CD013071-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>If possible, we obtained missing data from the authors of the included trials. We carefully evaluated important numerical data such as screened, randomly assigned participants, as well as intention‐to‐treat, as‐treated, and per‐protocol populations. We investigated attrition rates (e.g. dropouts, losses to follow‐up, withdrawals) and critically appraised issues concerning missing data and use of imputation methods (e.g. last observation carried forward). </p> <p>In trials where the standard deviation (SD) of the outcome was not available at follow‐up, or we could not recreate it, we standardized by the mean of the pooled baseline SD from those trials that reported this information. </p> <p>Where included trials did not report means and SDs for outcomes, and we were unable to obtain the necessary information from trial authors, we imputed these values by estimating the mean and variance from the median, range, and size of the sample (<a href="./references#CD013071-bbs2-0168" title="HozoSP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;5:13.">Hozo 2005</a>). </p> <p>We investigated the impact of imputation on meta‐analyses by performing sensitivity analyses, and we reported every outcome where trials had imputed SDs. </p> </section> <section id="CD013071-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of substantial clinical or methodological heterogeneity, we did not report trial results as the pooled effect estimate in a meta‐analysis. </p> <p>We identified heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard Chi² test with a significance level of α = 0.1 (<a href="./references#CD013071-bbs2-0143" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available at www.training.cochrane.org/handbook.">Deeks 2017</a>). In view of the low power of this test, we also considered the I² statistic, which quantifies inconsistency across trials, to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD013071-bbs2-0161" title="HigginsJPT , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58.">Higgins 2002</a>; <a href="./references#CD013071-bbs2-0162" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analysis. BMJ2003;327(7414):557-60.">Higgins 2003</a>); we interpreted the I² statistic as follows (<a href="./references#CD013071-bbs2-0143" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available at www.training.cochrane.org/handbook.">Deeks 2017</a>). </p> <p> <ul id="CD013071-list-0018"> <li> <p>0% to 40%: may not be important.</p> </li> <li> <p>30% to 60%: may indicate moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may indicate substantial heterogeneity.</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>When we found heterogeneity, we attempted to determine the possible reasons for it by examining individual trial and subgroup characteristics. </p> </section> <section id="CD013071-sec-0056"> <h4 class="title">Assessment of reporting biases</h4> <p>If 10 or more trials were included that investigated a particular outcome, we used funnel plots to assess small‐trial effects. Several explanations might account for funnel plot asymmetry, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials), and publication bias (<a href="./references#CD013071-bbs2-0207" title="SterneJAC , EggerM , MoherD , BoutronI , editor(s). Chapter 10: Addressing reporting biases. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available at www.training.cochrane.org/handbook.">Sterne 2017</a>). We therefore interpreted the results carefully (<a href="./references#CD013071-bbs2-0206" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ2011;343:d4002.">Sterne 2011</a>). </p> </section> <section id="CD013071-sec-0057"> <h4 class="title">Data synthesis</h4> <p>We planned to undertake (or display) a meta‐analysis only if we judged participants, interventions, comparisons, and outcomes to be sufficiently similar to ensure an answer that was clinically meaningful. We summarized data using a random‐effects model, in accordance with Cochrane Urology editorial guidance, as it is likely to provide the more conservative effect size estimate (in most cases). We performed statistical analyses according to the statistical guidelines contained in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013071-bbs2-0164" title="Higgins JP, ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated August 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022a</a>). For dichotomous outcomes, we used the Mantel‐Haenszel method; for continuous outcomes, we used the inverse variance method. We used Review Manager Web software to perform the analyses, pooling studies only when appropriate (<a href="./references#CD013071-bbs2-0194" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). </p> </section> <section id="CD013071-sec-0058"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity and planned to carry out the following subgroup analyses limited to the primary outcomes, including investigation of interactions (<a href="./references#CD013071-bbs2-0128" title="AltmanDG , BlandJM . Interaction revisited: the difference between two estimates. BMJ2003;326(7382):219.">Altman 2003</a>). </p> <p> <ul id="CD013071-list-0019"> <li> <p>Participant age (less than 65 years versus ≥ 65 years).</p> </li> <li> <p>Baseline testosterone serum level (less than 8 nmol/L versus ≥ 8 nmol/L), obtained between 7:00 and 11:00 AM. </p> </li> <li> <p>The presence or absence of at least one of the metabolic syndrome components is defined as the standard criteria at the time of the beginning of the trial (<a href="./references#CD013071-bbs2-0155" title="GrundySM , CleemanJI , DanielsSR , DonatoKA , EckelRH , FranklinBA , et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation2005;112(17):2735-52.">Grundy 2005</a>). </p> </li> </ul> </p> <p>These subgroup analyses were based on the following observations.</p> <p> <ul id="CD013071-list-0020"> <li> <p>Sexual dysfunction is strongly associated with age (<a href="./references#CD013071-bbs2-0148" title="FeldmanHA , GoldsteinI , HatzichristouDG , KraneRJ , McKinlayJB . Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. Journal of Urology1994;151(1):54-61.">Feldman 1994</a>; <a href="./references#CD013071-bbs2-0187" title="O'LearyMP , RhodesT , GirmanCJ , JacobsonDJ , RobertsRO , LieberMM , et al. Distribution of the Brief Male Sexual Inventory in community men. International Journal of Impotence Research2003;15(3):185-91.">O'Leary 2003</a>). The tolerability of testosterone in elderly men remains controversial but may differ by age, as testosterone treatment might be associated with increased cardiovascular risks (<a href="./references#CD013071-bbs2-0048" title="BasariaS , CovielloAD , TravisonTG , StorerTW , FarwellWR , JetteAM , et al. Adverse events associated with testosterone administration. New England Journal of Medicine2010;363(2):109-22. [DOI: 10.1056/NEJMoa1000485]">Basaria 2010</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>). The age cut‐off is based on the WHO definition of old age (<a href="./references#CD013071-bbs2-0213" title="World Health Organization. Definition of an older or elderly person. www.who.int/healthinfo/survey/ageingdefnolder/en/ (accessed prior to 22 September 2017).">WHO 2002</a>). </p> </li> <li> <p>In clinical practice, TRT can be administered to people with borderline and low testosterone levels but appears most meaningful in the latter group of individuals (<a href="./references#CD013071-bbs2-0173" title="KheraM , AdaikanG , BuvatJ , CarrierS , El-MeliegyA , HatzimouratidisK , et al. Diagnosis and treatment of testosterone deficiency: recommendations from the Fourth International Consultation on Sexual Medicine (ICSM 2015). Journal of Sexual Medicine2016;13(12):1787-804.">Khera 2016a</a>; <a href="./references#CD013071-bbs2-0176" title="LunenfeldB , MskhalayaG , KalinchenkoS , TishovaY . Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. Aging Male2013;16(4):143-50.">Lunenfeld 2013</a>; <a href="./references#CD013071-bbs2-0212" title="WangC , NieschlagE , SwerdloffR , BehreHM , HellstromWJ , GoorenLJ , et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. International Journal of Impotence Research2009;21(1):1-8.">Wang 2009</a>). </p> </li> <li> <p>The prevalence of erectile dysfunction was positively associated with metabolic syndrome, and serum testosterone levels were also significantly lower in men with metabolic syndrome (<a href="./references#CD013071-bbs2-0152" title="Garcia-CruzE , Leibar-TamayoA , RomeroJ , PiquerasM , LuqueP , CardenosaO , et al. Metabolic syndrome in men with low testosterone levels: relationship with cardiovascular risk factors and comorbidities and with erectile dysfunction. Journal of Sexual Medicine2013;10(10):2529-38.">Garcia‐Cruz 2013</a>). The magnitude of the effect of TRT may therefore differ in men with metabolic syndrome (<a href="./references#CD013071-bbs2-0170" title="IsidoriAM , GiannettaE , GianfrilliD , GrecoEA , BonifacioV , AversaA , et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clinical Endocrinology2005;63(4):381-94.">Isidori 2005</a>). </p> </li> </ul> </p> </section> <section id="CD013071-sec-0059"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes by restricting the analysis to the following. </p> <p> <ul id="CD013071-list-0021"> <li> <p>Restricting the analysis by taking into account the risk of bias, excluding studies at 'high risk' or 'unclear risk'. </p> </li> </ul> </p> </section> <section id="CD013071-sec-0060"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <section id="CD013071-sec-0061"> <h5 class="title">Certainty of the evidence</h5> <p>We presented the overall certainty of the evidence for each outcome specified below according to the GRADE approach, which took into account issues related not only to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity, such as directness of results<i>.</i> Two review authors (HJL, ECH, SL, or JHJ) independently rated the certainty of the evidence for each outcome. Any differences in the assessment were resolved by discussion or by consulting a third review author (PD). </p> <p>We used GRADEpro Guideline Development Tool (GDT) software (<a href="./references#CD013071-bbs2-0154" title="GRADEpro GDT. Version (accessed 12 February 2018). Hamilton (ON): McMaster University (developed by Evidence Prime, Inc.), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a>). If meta‐analysis was not possible, we planned to present the results in a narrative format in the summary of findings tables. We justified all decisions to downgrade the certainty of trials using footnotes and made comments to aid the reader's understanding of the Cochrane review where necessary. </p> </section> <section id="CD013071-sec-0062"> <h5 class="title">Summary of findings tables</h5> <p>We presented a summary of the evidence in a summary of findings tables. This provides key information about the best estimate of the magnitude of the effect, in relative terms and as absolute differences, for each relevant comparison of alternative management strategies, numbers of participants and trials addressing each important outcome, and a rating of overall confidence in effect estimates for each outcome. We created the summary of findings tables based on the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013071-bbs2-0200" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al, on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available at www.training.cochrane.org/handbook.">Schünemann 2017</a>), employing the Review Manager 5 table editor (<a href="./references#CD013071-bbs2-0193" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We reported the following outcomes, listed according to priority. </p> <p> <ol id="CD013071-list-0022"> <li> <p>Erectile function</p> </li> <li> <p>Sexual quality of life</p> </li> <li> <p>Cardiovascular mortality</p> </li> <li> <p>Treatment withdrawal for any reason</p> </li> <li> <p>Prostate‐related events</p> </li> <li> <p>Lower urinary tract symptoms</p> </li> </ol> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013071-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013071-sec-0063"></div> <section id="CD013071-sec-0064"> <h3 class="title">Description of studies</h3> <section id="CD013071-sec-0065"> <h4 class="title">Results of the search</h4> <p>We identified 16,582 records through electronic database searching, including 807 records found in trials registers. We found three records in the grey literature repository. Four additional records (protocols for studies) were identified through handsearching of reference lists of the included trials, systematic reviews/meta‐analyses, and HTA reports (<a href="./references#CD013071-bbs2-0071" title="FuiMNT , HoermannR , NolanB , MichelleC , JeffreyDZ , MathisG . Effect of testosterone treatment on bone remodelling markers and mineral density in obese dieting men in a randomized clinical trial. Scientific Reports2018;8(1):9099. FuiMNT , HoermannR , PrendergastL , ZajacJD , GrossmannM . Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial. Endocrine Reviews2017;38(Suppl 1):420-6. FuiMNT , HoermannR , PrendergastLA , ZajacJD , GrossmannM . Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial. International Journal of Obesity2017;41(3):420-6. [DOI: 10.1038/ijo.2016.242]FuiMNT , PrendergastLA , DupuisP , ZajacJD , GrossmannM . Dieting but not testosterone treatment improves androgen deficiency-like symptoms in obese men with lowered testosterone. Clinical Endocrinology2017;86:15. [DOI: 10.1111/cen.13259]NCT01616732. Testosterone and weight loss. clinicaltrials.gov/ct2/show/NCT01616732 (first received 8 June 2012). ">Fui 2017</a>; <a href="./references#CD013071-bbs2-0085" title="KonakaH , SugimotoK , OrikasaH , IwamotoT , TakamuraT , TakedaY , et al. Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: a multicenter randomized controlled trial in Japan (EARTH Study). Asian Journal of Andrology2016;18(1):25-34. [DOI: 10.4103/1008-682X.148720]KonakaH , SugimotoK , SigeharaK , KadonoY , KohE , NamikiM . Effects of long-term androgen replacement therapy on physical and mental status in aging males with late-onset hypogonadism: results of a phase III, multicenter, randomized, controlled trial. Journal of Urology2013;189(4 Suppl 1):e506. [DOI: 10.1016/j.juro.2013.02.2590]ShigeharaK , KonakaH , KohE , IzumiK , KitagawaY , MizokamiA , et al. Effects of testosterone replacement therapy on nocturia and quality of life in men with hypogonadism: a subanalysis of a previous prospective randomized controlled study in Japan. Aging Male2015;18(3):169-74. [DOI: 10.3109/13685538.2015.1038990]ShigeharaK, KonakaH , KatoY , IijimaM , NakashimaK , KawaguchiS , et al. Effect of testosterone replacement therapy on sexual function and glycemic control among hypogonadal men with type 2 diabetes mellitus. International Journal of Impotence Research2019;31(1):25-30. [DOI: 10.1038/s41443-018-0065-z]">Konaka 2016</a>; <a href="./references#CD013071-bbs2-0090" title="ACTRN12615000071527. Testosterone for androgen deficiency-like symptoms. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12615000071527 (first received 9 January 2015). MokSF , FennellC , SavkovicS , TurnerL , JayadevV , ConwayA , HandelsmanDJ . Testosterone for androgen deficiency-like symptoms in men without pathologic hypogonadism: a randomized, placebo-controlled cross-over with masked choice extension clinical trial. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2020;75(9):1723-31. [DOI: 10.1093/gerona/glz195]">Mok 2020</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>). After removing duplicates, we screened the titles and abstracts of 11,095 records, and excluded 10,883 records. We screened 212 full‐text articles and excluded 72 studies (103 records) that did not meet the inclusion criteria or were not relevant to our question. We ultimately included 43 studies (97 records) in the review. We found four ongoing trials and categorized eight studies as 'awaiting classification'. Agreement between review authors was 96% and 80% for title and abstract screening and full‐text review, respectively. The flow of literature through the assessment process is shown in the PRISMA flow chart (<a href="#CD013071-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013071-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD013071-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD013071-sec-0066"> <h4 class="title">Included studies</h4> <p>Details of the included studies are presented elsewhere (see <a href="./references#CD013071-sec-0174" title="">Characteristics of included studies</a>; <a href="#CD013071-tbl-0005">Table 1</a>). </p> <div class="table" id="CD013071-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial period (year to year)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting/country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Inclusion criteria</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention and comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomized (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Testosterone (nmol/L)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Erectile function<sup>*</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0023"> <li> <p>IIEF‐5: 8 to 21 points</p> </li> <li> <p>AMS questionnaire: more than 26 points</p> </li> <li> <p>IPSS index: lower than 18 points</p> </li> <li> <p>Plasma content of total testosterone: less than 12 nmol/L</p> </li> <li> <p>PSA: less than 4 ng/mL</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.67 ± 9.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.37 ± 2.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.50 ± 3.87<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE‐5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.85 ± 9.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.24 ± 4.1<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2001 to 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0024"> <li> <p>Age: 55 years and over</p> </li> <li> <p>Serum testosterone level: less than 15 nmol/L</p> </li> <li> <p>Non‐obese (BMI &lt; 30 kg/m² and waist circumference &lt; 102 cm)</p> </li> <li> <p>Non‐smokers in good general health</p> </li> <li> <p>Symptoms consistent with testosterone deficiency</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1 ± 5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.6 ± 2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9 ± 10.2<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.5 ± 7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.5 ± 3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.3 ± 8.5<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Middle‐aged men with late‐onset hypogonadism and MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0025"> <li> <p>Age: between 50 and 65 years</p> </li> <li> <p>History: MS and/or type 2 DM</p> </li> <li> <p>Serum total testosterone level: &lt; 3.20 ng/mL (11 nmol/L) or calculated free testosterone levels: &lt; 250 pmol/L (10 pg/mL) </p> </li> <li> <p>2 symptoms of hypogonadism</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone (IM/oral)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 ± 10/57 ± 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.25 ± 2.1/8.91 ± 2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 ± 2/17 ± 3<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 ± 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.91 ± 2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 ± 2<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0026"> <li> <p>Age: between 45 and 65 years</p> </li> <li> <p>History: MS and/or type 2 DM</p> </li> <li> <p>Total testosterone serum level below 3.0 ng/mL (11 nmol/L) or calculated free testosterone levels &lt; 250 pmol/L (10 pg/mL) </p> </li> <li> <p>At least 2 symptoms of hypogonadism</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 ± 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.33 ± 2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 ± 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 ± 1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0006" title="AydinS , OdabasO , ErcanM , KaraH , AgargunMY . Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British Journal of Urology1996;77(2):256-60. [PMID: 8800895]">Aydin 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men of various ages complaining of an inability to create or maintain an erection sufficient for intercourse </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0027"> <li> <p>Age: 50 to 80 years</p> </li> <li> <p>Symptoms of testosterone deficiency</p> </li> <li> <p>Serum total testosterone &lt; 15 nmol/L (&lt; 4.3 ng/mL)</p> </li> <li> <p>Bioavailable testosterone &lt; 6.68 nmol/L (&lt; 1.93 ng/mL)</p> </li> <li> <p>AMS rating scale total score &gt; 36</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.9 ± 6.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4 ± 2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.0 ± 3.1<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1± 6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.6 ± 2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.7 ± 3.0<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0008" title="BenkertO , WittW , AdamW , LeitzA . Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Archives of Sexual Behavior1979;8(6):471-9. ">Benkert 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0028"> <li> <p>Sexual impotence with reduced or nonexistent ability to have an erection during intercourse, persistent for at least 1 year, due to unknown etiology, and a prior history of normal penile erection </p> </li> <li> <p>Age: under 60 years old</p> </li> <li> <p>Regular female sexual partner, at least 1 attempt at coitus per week</p> </li> <li> <p>Normal findings in an andrological examination</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1 ± 6.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.2 ± 7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Bulgaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0029"> <li> <p>Aged between 45 and 65 years</p> </li> <li> <p>Be married or living in a stable relationship with a female sexual partner for at least 6 months </p> </li> <li> <p>Waist‐hip ratio of at least 0.9</p> </li> <li> <p>Type 2 diabetes mellitus and symptoms of andropause or erectile dysfunction</p> </li> <li> <p>Serum testosterone levels below the normal range for young adults or in the lower third of this range (total testosterone &lt; 15.1 nmol/L) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.56 ± 2.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.25 ± 0.67<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.76 ± 3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.50 ± 0.75<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men 18 years old or older with 2 total testosterone levels less than 300 ng/dL (11 nmol/L) measured 1 week or more apart and at least 1 symptom of testosterone deficiency </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.7 ± 10.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0 ± 2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.9 ± 11.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0 ± 2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005 to 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0030"> <li> <p>ED complaint ongoing for over 3 months</p> </li> <li> <p>Age: between 45 and 80 years old</p> </li> <li> <p>Stable heterosexual relationship for more than 3 months and anticipates having the same partner for the whole study </p> </li> <li> <p>Not responded adequately to the highest available dosage of tadalafil or other PDE5I</p> </li> <li> <p>Low or low‐to‐normal serum testosterone level</p> </li> <li> <p>Agrees to make at least 4 attempts at sexual intercourse on 4 separate days during the 4‐week run‐in period with daily tadalafil 10 mg </p> </li> <li> <p>At least 50% of attempts during this period must be unsuccessful</p> </li> <li> <p>Agrees not to use any other ED drug or non‐drug treatment during the full course of the study </p> </li> <li> <p>Providing a signed informed consent</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel + PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.3 ± 7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.7 ± 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 ± 4.2<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.9 ± 7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.7 ± 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.8 ± 4.1<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1981 to 1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged 19 years old or older presenting with complaint of difficulty in achieving or maintaining a full erection during sexual activity, not secondary to loss of sexual interest or obvious physical or mental illness </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2002 to 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Taiwan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0031"> <li> <p>Age: between 20 and 75 years</p> </li> <li> <p>Men diagnosed with testosterone deficiency that required testosterone replacement were considered eligible </p> </li> <li> <p>Men had never taken androgen replacement therapy or had withdrawn from testosterone supplements for 6 weeks before the study began </p> </li> <li> <p>Hypogonadal men were eligible if their morning serum testosterone concentrations were &lt; 300 ng/dL (if total testosterone was ≥ 300 ng/dL, free testosterone concentrations were to be &lt; 8.7 pg/mL) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20 to 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4 ± 5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.7 ± 4.9<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1 ± 6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9 ± 6.6<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0014" title="GilbertRN , GrahamCW , ReganJB . Double blind cross-over trial of testosterone enanthate in impotent men with low or low-normal serum testosterone levels. Journal of Urology1992;147(Suppl 4):264. ">Gilbert 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with low testosterone and impotence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005 to 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged between 35 and 70 years old, with total testosterone levels below 12.0 nmol/L or a calculated free testosterone level below 225 pmol/L, and a diagnosis of MS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.0<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.1<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0016" title="GoorenLJ , BoulouxPM , GiltayEJ , SaadF . The effect of 6 months' treatment with testosterone gel versus placebo on body composition and health-related quality of life in hypogonadal men. Journal of Diabetes2011;3:147. [DOI: 10.1111/j.1753-0407.2011.00122.x]">Gooren 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged 50 to 80 years with total testosterone &lt; 15 nmol/L and AMS rating scale total score &gt; 36 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2014 to 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Slovenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged &gt; 35 years, with confirmed late‐onset hypogonadism, total testosterone level &lt; 11 nmol/L, BMI ≥ 30 kg/m<sup>2</sup>, type 2 DM treated exclusively with non‐insulin antidiabetic medications </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.2 ± 7.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.24 ± 1.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1 ± 5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.96 ± 1.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2008 to 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged 18 to 80 years with symptoms of hypogonadism defined by the AMS together with an initial total testosterone ≤ 12.0 nmol/L or free testosterone ≤ 0.25 nmol/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.2 ± 10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2 ± 3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.24 ± 7.5<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.0 ± 9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9 ± 3.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.64 ± 9.0<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with arteriogenic ED as evaluated by dynamic color duplex ultrasound studies, normal sexual desire but testosterone and free testosterone in the lower quartile of normal range, not responding to tadalafil treatment on 6 consecutive attempts </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0032"> <li> <p>Aged 60 years or older</p> </li> <li> <p>At least 2 symptoms on the Androgen Deficiency in Aging Males questionnaire</p> </li> <li> <p>Free testosterone index between 0.3 and 0.5</p> </li> <li> <p>Total testosterone greater than 8 nmol/L</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0021" title="HisasueSI , IdeH , TsujimuraA , NagayaN , KimuraM , AbdelhamedA , et al. Testosterone gel treatment significantly ameliorates urinary urgency and sleep disturbance: double-blind, placebo-controlled clinical trial. Journal of Urology2015;193(4 Suppl):e772-3. [DOI: 10.1016/j.juro.2015.02.2269]">Hisasue 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with late‐onset hypogonadism symptoms (total testosterone &lt; 450 ng/dL and total AMS scores ≥ 27) and ≥ 40 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2008 to 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Malaysia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0033"> <li> <p>Age 40 to 70 years</p> </li> <li> <p>At least 'mild' symptoms for all 3 AMS domains (scores of ≥ 9 in the somatic, ≥ 6 in the psychological, and ≥ 6 in the sexual domain) or total AMS scores ≥ 27 </p> </li> <li> <p>Early morning total testosterone level &lt; 12 nmol/L on 2 occasions</p> </li> <li> <p>PSA level of &lt; 4 ng/mL</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.4 ± 7.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9 ± 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>48 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 ± 8.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1 ± 1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0034"> <li> <p>Rarefaction of nocturnal penile tumescence (once or less per week; frequency of early morning erections together with libido are known to have correlation with serum androgen levels) </p> </li> <li> <p>At least one of the following andropause symptoms: decreased libido, ED, urinary disorders, asthenia, or depressive mood </p> </li> <li> <p>Total testosterone ≤ 15 nmol/L</p> </li> <li> <p>Sex hormone‐binding globulin ≥ 30 nmol/L</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dihydrotestosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.3 ± 4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.26 ± 1.41<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.6 ± 5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.53 ± 1.44<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2001 to 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0035"> <li> <p>At least 50 years of age</p> </li> <li> <p>BMI between 18 and 34 kg/m<sup>2</sup> </p> </li> <li> <p>Symptoms of androgen deficiency (as indicated by a positive score on the ADAM questionnaire)</p> </li> <li> <p>Calculated free testosterone &gt; 0.26 nmol/L</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral (80/160/240 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78/82/77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.5 ± 6.5/58.4 ± 5.7/58.6 ± 5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA/NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA/NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.4 ± 5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0036"> <li> <p>Married men with living spouse</p> </li> <li> <p>Men with late‐onset hypogonadism symptoms</p> </li> <li> <p>Physical symptoms plus vasomotor symptoms, total score ≥ 5 points; or mental and psychological symptoms ≥ 4 points; or symptoms of sexual dysfunction ≥ 8 points </p> </li> <li> <p>IIEF‐5 score &lt; 21 points and course 3. More than a month</p> </li> <li> <p>Serum total testosterone &lt; 12.0 nmol/L or free testosterone &lt; 0.225 nmol/L</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral + PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.1 ± 1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.7 ± 3.9<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2 ± 1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.6 ± 3.8<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged 50 to 70 years who have reliable, fixed sexual partners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral + PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0028" title="LunglmayrG , StellamorM , SponaJ . Androgen therapy of impotentia coeundi in elderly men. Psychological and endocrinological investigations. Wiener Klinische Wochenschrift 1980;92(7):243-2471980;92(7):243-7. ">Lunglmayr 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA/Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0037"> <li> <p>Men who had suffered from non‐partner‐related erectile impotence for more than 1 year</p> </li> <li> <p>Deterioration of state of mind (in the sense of the so‐called 'climacterium virile')</p> </li> <li> <p>At least 6 of the 32 items from at least 3 different classes were correct and the disorders had only occurred in the last 2 years </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5 ± 5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9 ± 5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0038"> <li> <p>At least 18 years of age</p> </li> <li> <p>Total testosterone level lower than 300 ng/dL (10.4 nmol/L)</p> </li> <li> <p>At least 1 symptom of testosterone deficiency (decreased energy or decreased sexual drive) </p> </li> <li> <p>PSA level lower than 4 ng/mL</p> </li> <li> <p>No use of oral or topical testosterone therapy within 14 days</p> </li> <li> <p>Stable doses of lipid‐lowering medications, insulin, antidepressants, anxiolytics, or therapy for benign prostatic hyperplasia for at least 3 months </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.7 ± 10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.9 ± 11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA/UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0039"> <li> <p>Men over 40 years presenting to the Sheffield male sexual dysfunction clinic were screened with measurement of serum total testosterone </p> </li> <li> <p>Serum total testosterone &lt; 10 nmol/L and/or a free androgen index &lt; 30%</p> </li> <li> <p>Absence of known prostate or breast cancer, prostatic hypertrophy, raised serum PSA (&gt; 2.5 μg/L), uncontrolled hypertension, diabetes mellitus, uncontrolled cardiac disease, renal failure (creatinine &gt;150 μmol/L), liver disease, polycythemia (hematocrit &gt; 50%), history of aggressive behavior, alcohol or drug abuse, anticoagulant therapy or testosterone replacement </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006 to 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0040"> <li> <p>Men 45 to 70 years of age with a primary complaint of sexual dysfunction</p> </li> <li> <p>Clinical picture compatible with testosterone deficiency syndrome</p> </li> <li> <p>History of sexual dysfunction for &gt; 3 months with IIEF scores of &lt; 25 on questions 1 to 5 and 15 </p> </li> <li> <p>History of hypoactive sexual desire disorder for &gt; 3 months with scores of &gt; 6 for questions 11 and 12 of the IIEF and serum total testosterone levels &lt; 12 nmol/L and DHEAS of &lt; 3.5 μmol/L </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.0 ± 10.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2 ± 4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.2 ± 9.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0 ± 5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011 to 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Canada, Mexico, USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0041"> <li> <p>Community‐dwelling, sexually active men 26 years of age and older</p> </li> <li> <p>Total testosterone levels &lt; 300 ng/dL (10.41 nmol/L) on 2 occasions</p> </li> <li> <p>One or more of the following symptoms: delayed ejaculation, anejaculation, decreased force of ejaculation, or decreased ejaculate volume </p> </li> <li> <p>PSA levels &lt; 4 ng/mL and willingness to masturbate</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.4 ± 9.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4 ± 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 ± 6.4<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.7 ± 9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7 ± 1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 ± 6.3<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1996 to 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0042"> <li> <p>History of ED for more than 6 months</p> </li> <li> <p>Serum levels of testosterone, prolactin, and PSA within the normal range, and a serum DHEAS level below 1.5 μmol/L </p> </li> <li> <p>IPSS below 7 and a full erection after intracavernosal administration of 10 μg prostaglandin E1 </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0035" title="RothLW , SchwartzRS , MeachamRB . The impact of testosterone supplementation on sexual function in elderly men. Fertility and Sterility2011;96(3 Suppl 1):S1-2. [DOI: 10.1016/j.fertnstert.2011.07.014]">Roth 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men 60 years old or greater with borderline low testosterone with mild to moderate ED </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel (50 mg/25 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.5/16.1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.9<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0036" title="SchiaviRC , WhiteD , MandeliJ , LevineAC . Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Archives of Sexual Behavior1997;26(3):231-41. [PMID: 9146812]">Schiavi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1992 to 1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0043"> <li> <p>Age: 45 to 74</p> </li> <li> <p>Married or living with a sexual partner for at least 1 year</p> </li> <li> <p>Possession of a high school diploma</p> </li> <li> <p>English as the primary language</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.30 ± 1.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10 weeks cross‐over (including a washout period of 4 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.69 ± 7.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0037" title="SeftelAD , MackRJ , SecrestAR , SmithTM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. Journal of Andrology2004;25(6):963-72. [PMID: 15477371]SteidleC , SchwartzS , JacobyK , SebreeT , SmithT , BachandR . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism2003;88(6):2673-81. [DOI: 10.1210/jc.2002-021058]">Seftel 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0044"> <li> <p>Men between 20 and 80 years of age (mean age 58 years)</p> </li> <li> <p>Morning testosterone level ≤ 300 ng/dL (10.4 nmol/L) at screening</p> </li> <li> <p>One or more symptoms of low T (i.e. fatigue, decreased muscle mass, reduced libido, reduced sexual functioning of a non‐mechanical nature) </p> </li> <li> <p>Generally good health</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel (100 mg/50 mg), testosterone patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106/99, 102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.8 ± 10.6/58.1 ± 9.7, 60.5 ± 9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.05 ± 2.15/8.11 ± 1.98, 8.30 ± 2.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.8 ± 10.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.93 ± 2.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2001 to 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0045"> <li> <p>Men 18 to 80 years old</p> </li> <li> <p>ED for 3 months or greater</p> </li> <li> <p>Stable sexual relationship with a female partner for 6 months or greater</p> </li> <li> <p>Morning serum total testosterone level of 400 ng/dL or less</p> </li> <li> <p>Non‐responders to sildenafil monotherapy (defined as a score of 2 or 3 on questions 3 and 4 of IIEF) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel + PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.8 ± 10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.1 ± 8.4<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.1 ± 9.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.4 ± 10.3<sup>f</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010 to 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0046"> <li> <p>Age: more than 65 years</p> </li> <li> <p>Total testosterone values: initial testosterone &lt; 275 ng/dL, a second &lt; 300 ng/dL, and an average &lt; 275 ng/dL </p> </li> <li> <p>Derogatis Interview for Sexual Function Sexual Desire Domain: score &lt; 20</p> </li> <li> <p>Heterosexual partner willing to have sexual intercourse at least twice a month</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.1 ± 5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0 ± 2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 ± 8.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.3 ± 5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 ± 2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.8 ± 8.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006 to 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA/USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0047"> <li> <p>ED as defined by a score of 25 or less on the IIEF‐EF</p> </li> <li> <p>Age between 40 and 70 years</p> </li> <li> <p>Serum testosterone &lt; 11.5 nmol/L (330 ng/dL) and/or free testosterone &lt; 173 pmol/L (50 pg/mL) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.1 ± 8.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.61 ± 2.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.6 ± 8.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.81 ± 2.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0048"> <li> <p>Men aged between 24 and 76 years</p> </li> <li> <p>AMS scores over 27</p> </li> <li> <p>Total serum testosterone level below 350 ng/dL (12.1 nmol/L) who presented to the urology clinic with complaints of lower urinary tract symptoms and ED </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.6 ± 15.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6 ± 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.0 ± 5.0<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.7 ± 11.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.3 ± 1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.7 ± 4.6<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Type 2 diabetic men with ED</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8 ± 1.9<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3 ± 2.1<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2009 to 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0049"> <li> <p>Typical diabetes symptoms associated with blood glucose &gt; 11.1 mmol/L or fasting plasma glucose &gt; 7.0 mmol/L </p> </li> <li> <p>IIEF‐5 score &lt; 21</p> </li> <li> <p>Disease duration: more than 3 months</p> </li> <li> <p>Fixed sexual partner and regular sexual life, normal genital development</p> </li> <li> <p>Low total testosterone levels</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral + PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.0 ± 2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.0 ± 3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AMS: Aging Males' Symptoms; BMI: body mass index; DHEAS: dehydroepiandrosterone sulfate; DM: diabetes mellitus; ED: erectile dysfunction; IIEF‐EF: International Index of Erectile Function‐Erectile Function; IM: intramuscular; IPSS: International Prostate Symptom Score; MS: metabolic syndrome; NA: not available; PDE5I: phosphodiesterase 5 inhibitor; PSA: prostate specific antigen </p> <p><sup>*</sup>Erectile function measured by: <sup>a</sup>IIEF‐5/<sup>b</sup>IIEF‐EF/<sup>c</sup>Sexual domain of AMS/<sup>d</sup>Partial Androgen Deficiency of the Aging Male/<sup>e</sup>Ability to maintain erection during intercourse (1, always; 2, in 75% of intercourse; 3, in 50%; 4, in less than 25%; 5, in less than 10%; 6, never)/<sup>f</sup>Overall IIEF </p> </div> </div> </section> <section id="CD013071-sec-0067"> <h4 class="title">Sources of data</h4> <p>We identified the 35 published full‐text studies (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>; <a href="./references#CD013071-bbs2-0006" title="AydinS , OdabasO , ErcanM , KaraH , AgargunMY . Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British Journal of Urology1996;77(2):256-60. [PMID: 8800895]">Aydin 1996</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0008" title="BenkertO , WittW , AdamW , LeitzA . Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Archives of Sexual Behavior1979;8(6):471-9. ">Benkert 1979</a>; <a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>; <a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a>; <a href="./references#CD013071-bbs2-0028" title="LunglmayrG , StellamorM , SponaJ . Androgen therapy of impotentia coeundi in elderly men. Psychological and endocrinological investigations. Wiener Klinische Wochenschrift 1980;92(7):243-2471980;92(7):243-7. ">Lunglmayr 1980</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0036" title="SchiaviRC , WhiteD , MandeliJ , LevineAC . Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Archives of Sexual Behavior1997;26(3):231-41. [PMID: 9146812]">Schiavi 1997</a>; <a href="./references#CD013071-bbs2-0037" title="SeftelAD , MackRJ , SecrestAR , SmithTM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. Journal of Andrology2004;25(6):963-72. [PMID: 15477371]SteidleC , SchwartzS , JacobyK , SebreeT , SmithT , BachandR . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism2003;88(6):2673-81. [DOI: 10.1210/jc.2002-021058]">Seftel 2004</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>; <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>) and eight abstracts (<a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a>; <a href="./references#CD013071-bbs2-0014" title="GilbertRN , GrahamCW , ReganJB . Double blind cross-over trial of testosterone enanthate in impotent men with low or low-normal serum testosterone levels. Journal of Urology1992;147(Suppl 4):264. ">Gilbert 1992</a>; <a href="./references#CD013071-bbs2-0016" title="GoorenLJ , BoulouxPM , GiltayEJ , SaadF . The effect of 6 months' treatment with testosterone gel versus placebo on body composition and health-related quality of life in hypogonadal men. Journal of Diabetes2011;3:147. [DOI: 10.1111/j.1753-0407.2011.00122.x]">Gooren 2011</a>; <a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a>; <a href="./references#CD013071-bbs2-0021" title="HisasueSI , IdeH , TsujimuraA , NagayaN , KimuraM , AbdelhamedA , et al. Testosterone gel treatment significantly ameliorates urinary urgency and sleep disturbance: double-blind, placebo-controlled clinical trial. Journal of Urology2015;193(4 Suppl):e772-3. [DOI: 10.1016/j.juro.2015.02.2269]">Hisasue 2015</a>; <a href="./references#CD013071-bbs2-0033" title="RaoPM , JonesTH , KellyD . Testosterone improves symptom severity, quality of life (QOL), triglycerides and strength: a randomised placebo-controlled study in men with uncontrolled type-2 diabetes and hypogonadism: Stride study. Diabetic Medicine2023;40(Suppl 1):184. [DOI: 10.1111/dme.15048]">Rao 2023</a>; <a href="./references#CD013071-bbs2-0035" title="RothLW , SchwartzRS , MeachamRB . The impact of testosterone supplementation on sexual function in elderly men. Fertility and Sterility2011;96(3 Suppl 1):S1-2. [DOI: 10.1016/j.fertnstert.2011.07.014]">Roth 2011</a>; <a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>). Thirty‐nine trials were published in English, two in Mandarin (<a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a>), one in German (<a href="./references#CD013071-bbs2-0028" title="LunglmayrG , StellamorM , SponaJ . Androgen therapy of impotentia coeundi in elderly men. Psychological and endocrinological investigations. Wiener Klinische Wochenschrift 1980;92(7):243-2471980;92(7):243-7. ">Lunglmayr 1980</a>), and one in Russian (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>). While we attempted to contact the corresponding authors of the included trials that provided author information including email addresses to obtain additional information on study methods and results, we received replies from only one author regarding three relevant studies for the review (<a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a>; <a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>). </p> </section> <section id="CD013071-sec-0068"> <h4 class="title">Study design and settings</h4> <p>Forty studies were parallel‐group RCTs and three had cross‐over designs (<a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a>; <a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a>; <a href="./references#CD013071-bbs2-0036" title="SchiaviRC , WhiteD , MandeliJ , LevineAC . Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Archives of Sexual Behavior1997;26(3):231-41. [PMID: 9146812]">Schiavi 1997</a>). Eighteen studies were conducted at a single center (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a>; <a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>; <a href="./references#CD013071-bbs2-0006" title="AydinS , OdabasO , ErcanM , KaraH , AgargunMY . Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British Journal of Urology1996;77(2):256-60. [PMID: 8800895]">Aydin 1996</a>; <a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a>; <a href="./references#CD013071-bbs2-0014" title="GilbertRN , GrahamCW , ReganJB . Double blind cross-over trial of testosterone enanthate in impotent men with low or low-normal serum testosterone levels. Journal of Urology1992;147(Suppl 4):264. ">Gilbert 1992</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0036" title="SchiaviRC , WhiteD , MandeliJ , LevineAC . Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Archives of Sexual Behavior1997;26(3):231-41. [PMID: 9146812]">Schiavi 1997</a>), and 16 were multicenter trials (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0008" title="BenkertO , WittW , AdamW , LeitzA . Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Archives of Sexual Behavior1979;8(6):471-9. ">Benkert 1979</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0037" title="SeftelAD , MackRJ , SecrestAR , SmithTM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. Journal of Andrology2004;25(6):963-72. [PMID: 15477371]SteidleC , SchwartzS , JacobyK , SebreeT , SmithT , BachandR . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism2003;88(6):2673-81. [DOI: 10.1210/jc.2002-021058]">Seftel 2004</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>; <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>). The remaining studies did not report whether the study was a single center or multicenter trial. Almost all trials were conducted in European and American countries. Others were conducted in Taiwan (<a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>), Turkey (<a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>), and China (<a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>). <a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a> and <a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a> were reported as "open‐label". Six studies did not provide information regarding blinding (<a href="./references#CD013071-bbs2-0006" title="AydinS , OdabasO , ErcanM , KaraH , AgargunMY . Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British Journal of Urology1996;77(2):256-60. [PMID: 8800895]">Aydin 1996</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>; <a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>; <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>). The included studies were performed between 1981 and 2023. </p> </section> <section id="CD013071-sec-0069"> <h4 class="title">Participants</h4> <p>The 43 studies included 11,419 randomized participants. Most studies enrolled middle‐aged (aged 40 years and over) participants with sexual dysfunction. Eleven studies included younger males, but the average age of each study participant was 40 years or older (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0037" title="SeftelAD , MackRJ , SecrestAR , SmithTM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. Journal of Andrology2004;25(6):963-72. [PMID: 15477371]SteidleC , SchwartzS , JacobyK , SebreeT , SmithT , BachandR . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism2003;88(6):2673-81. [DOI: 10.1210/jc.2002-021058]">Seftel 2004</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>). <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a> included participants between 19 and 70, and did not present the average age. Nine studies did not define their inclusion criteria in terms of age (<a href="./references#CD013071-bbs2-0006" title="AydinS , OdabasO , ErcanM , KaraH , AgargunMY . Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British Journal of Urology1996;77(2):256-60. [PMID: 8800895]">Aydin 1996</a>; <a href="./references#CD013071-bbs2-0014" title="GilbertRN , GrahamCW , ReganJB . Double blind cross-over trial of testosterone enanthate in impotent men with low or low-normal serum testosterone levels. Journal of Urology1992;147(Suppl 4):264. ">Gilbert 1992</a>; <a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0028" title="LunglmayrG , StellamorM , SponaJ . Androgen therapy of impotentia coeundi in elderly men. Psychological and endocrinological investigations. Wiener Klinische Wochenschrift 1980;92(7):243-2471980;92(7):243-7. ">Lunglmayr 1980</a>; <a href="./references#CD013071-bbs2-0033" title="RaoPM , JonesTH , KellyD . Testosterone improves symptom severity, quality of life (QOL), triglycerides and strength: a randomised placebo-controlled study in men with uncontrolled type-2 diabetes and hypogonadism: Stride study. Diabetic Medicine2023;40(Suppl 1):184. [DOI: 10.1111/dme.15048]">Rao 2023</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>). </p> <p>To define sexual dysfunction, most studies used the IIEF, AMS, and symptoms of hypogonadism, such as reported inability to achieve an erection sufficient for intercourse. <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a> used the Derogatis Inventory of Sexual Function ‐ Male to assess decreased libido. Twenty studies used low total testosterone as an inclusion criterion, and below 12 nmol/L was the most frequently used as a cut‐off value (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a>; <a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a>; <a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0033" title="RaoPM , JonesTH , KellyD . Testosterone improves symptom severity, quality of life (QOL), triglycerides and strength: a randomised placebo-controlled study in men with uncontrolled type-2 diabetes and hypogonadism: Stride study. Diabetic Medicine2023;40(Suppl 1):184. [DOI: 10.1111/dme.15048]">Rao 2023</a>; <a href="./references#CD013071-bbs2-0035" title="RothLW , SchwartzRS , MeachamRB . The impact of testosterone supplementation on sexual function in elderly men. Fertility and Sterility2011;96(3 Suppl 1):S1-2. [DOI: 10.1016/j.fertnstert.2011.07.014]">Roth 2011</a>; <a href="./references#CD013071-bbs2-0037" title="SeftelAD , MackRJ , SecrestAR , SmithTM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. Journal of Andrology2004;25(6):963-72. [PMID: 15477371]SteidleC , SchwartzS , JacobyK , SebreeT , SmithT , BachandR . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism2003;88(6):2673-81. [DOI: 10.1210/jc.2002-021058]">Seftel 2004</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>; <a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>). However, seven studies included participants with a testosterone level of 12 nmol/L (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a>; <a href="./references#CD013071-bbs2-0016" title="GoorenLJ , BoulouxPM , GiltayEJ , SaadF . The effect of 6 months' treatment with testosterone gel versus placebo on body composition and health-related quality of life in hypogonadal men. Journal of Diabetes2011;3:147. [DOI: 10.1111/j.1753-0407.2011.00122.x]">Gooren 2011</a>; <a href="./references#CD013071-bbs2-0021" title="HisasueSI , IdeH , TsujimuraA , NagayaN , KimuraM , AbdelhamedA , et al. Testosterone gel treatment significantly ameliorates urinary urgency and sleep disturbance: double-blind, placebo-controlled clinical trial. Journal of Urology2015;193(4 Suppl):e772-3. [DOI: 10.1016/j.juro.2015.02.2269]">Hisasue 2015</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>). Thirteen studies did not report their inclusion criteria regarding baseline testosterone levels (<a href="./references#CD013071-bbs2-0006" title="AydinS , OdabasO , ErcanM , KaraH , AgargunMY . Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British Journal of Urology1996;77(2):256-60. [PMID: 8800895]">Aydin 1996</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0008" title="BenkertO , WittW , AdamW , LeitzA . Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Archives of Sexual Behavior1979;8(6):471-9. ">Benkert 1979</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0014" title="GilbertRN , GrahamCW , ReganJB . Double blind cross-over trial of testosterone enanthate in impotent men with low or low-normal serum testosterone levels. Journal of Urology1992;147(Suppl 4):264. ">Gilbert 1992</a>; <a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a>; <a href="./references#CD013071-bbs2-0028" title="LunglmayrG , StellamorM , SponaJ . Androgen therapy of impotentia coeundi in elderly men. Psychological and endocrinological investigations. Wiener Klinische Wochenschrift 1980;92(7):243-2471980;92(7):243-7. ">Lunglmayr 1980</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0036" title="SchiaviRC , WhiteD , MandeliJ , LevineAC . Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Archives of Sexual Behavior1997;26(3):231-41. [PMID: 9146812]">Schiavi 1997</a>; <a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>). Free testosterone was also used in 10 studies (<a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a>; <a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>). In addition, SHBG (<a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>), dehydroepiandrosterone sulfate (DHEAS) (<a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>), and free androgen index (<a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a>) were used for participant selection in select studies. </p> <p>While eight studies included participants with metabolic syndrome or type 2 diabetes mellitus (<a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a>; <a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0033" title="RaoPM , JonesTH , KellyD . Testosterone improves symptom severity, quality of life (QOL), triglycerides and strength: a randomised placebo-controlled study in men with uncontrolled type-2 diabetes and hypogonadism: Stride study. Diabetic Medicine2023;40(Suppl 1):184. [DOI: 10.1111/dme.15048]">Rao 2023</a>; <a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>; <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>), four studies excluded participants with hypertension and/or type 2 diabetes mellitus (<a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a>; <a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>). One study included participants with pre‐existing cardiovascular disease or an elevated cardiovascular risk (<a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>). The remaining studies did not address the presence or absence of metabolic syndrome components. </p> <p>Major exclusion criteria included hormone therapy (e.g. anabolic steroid injection), history of cancer, history of major diseases (e.g. New York Heart Association class III or above cardiac disease), elevated PSA, polycythemia, or an abnormal digital rectal examination (concern for prostate cancer). </p> </section> <section id="CD013071-sec-0070"> <h4 class="title">Intervention(s) and comparator(s)</h4> <p>In most studies, testosterone was administered in one of three forms: oral administration, intramuscular injection, or gel. </p> <p>Twelve studies used testosterone in an oral form, most of which used testosterone undecanoate (TU, 80 mg: <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>, <a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>; 120 mg: <a href="./references#CD013071-bbs2-0006" title="AydinS , OdabasO , ErcanM , KaraH , AgargunMY . Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British Journal of Urology1996;77(2):256-60. [PMID: 8800895]">Aydin 1996</a>; <a href="./references#CD013071-bbs2-0008" title="BenkertO , WittW , AdamW , LeitzA . Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Archives of Sexual Behavior1979;8(6):471-9. ">Benkert 1979</a>; <a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a>; <a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a>; 160 mg: <a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a>; <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>) at different dose levels. <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a> had three intervention groups, each taking 80 mg, 160 mg, and 240 mg of testosterone. <a href="./references#CD013071-bbs2-0028" title="LunglmayrG , StellamorM , SponaJ . Androgen therapy of impotentia coeundi in elderly men. Psychological and endocrinological investigations. Wiener Klinische Wochenschrift 1980;92(7):243-2471980;92(7):243-7. ">Lunglmayr 1980</a> used mesterolone 75 mg, and <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a> used DHEA 50 mg. <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a> used both TU 160 mg and 100 mg DHEA as interventions. </p> <p>Twelve studies used intramuscular injection, most of which used TU 1000 mg (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a>; <a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0033" title="RaoPM , JonesTH , KellyD . Testosterone improves symptom severity, quality of life (QOL), triglycerides and strength: a randomised placebo-controlled study in men with uncontrolled type-2 diabetes and hypogonadism: Stride study. Diabetic Medicine2023;40(Suppl 1):184. [DOI: 10.1111/dme.15048]">Rao 2023</a>). Two studies used testosterone enanthate (TE) 200 mg instead of TU (<a href="./references#CD013071-bbs2-0014" title="GilbertRN , GrahamCW , ReganJB . Double blind cross-over trial of testosterone enanthate in impotent men with low or low-normal serum testosterone levels. Journal of Urology1992;147(Suppl 4):264. ">Gilbert 1992</a>; <a href="./references#CD013071-bbs2-0036" title="SchiaviRC , WhiteD , MandeliJ , LevineAC . Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Archives of Sexual Behavior1997;26(3):231-41. [PMID: 9146812]">Schiavi 1997</a>). <a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a> used an injection containing four components: testosterone propionate 30 mg, testosterone phenylpropionate 60 mg, testosterone isocaproate 60 mg, and testosterone 100 mg. </p> <p>Sixteen studies used gel containing testosterone. Eight studies used 50 mg testosterone (5 g, 1% solution) (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a>; <a href="./references#CD013071-bbs2-0035" title="RothLW , SchwartzRS , MeachamRB . The impact of testosterone supplementation on sexual function in elderly men. Fertility and Sterility2011;96(3 Suppl 1):S1-2. [DOI: 10.1016/j.fertnstert.2011.07.014]">Roth 2011</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>). Others used 1.67% testosterone (<a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>), 25 mg testosterone (2.5% solution) (<a href="./references#CD013071-bbs2-0021" title="HisasueSI , IdeH , TsujimuraA , NagayaN , KimuraM , AbdelhamedA , et al. Testosterone gel treatment significantly ameliorates urinary urgency and sleep disturbance: double-blind, placebo-controlled clinical trial. Journal of Urology2015;193(4 Suppl):e772-3. [DOI: 10.1016/j.juro.2015.02.2269]">Hisasue 2015</a>), 60 mg testosterone (2% solution) (<a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>), and 100 mg testosterone (10 g, 1% solution) (<a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>). <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a> had three intervention groups, each taking 125 mg, 187.5 mg, and 250 mg dihydrotestosterone gel. Three studies applied dosage adjustment, which changes the amount of testosterone according to the patient's condition (<a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>: 60~120 mg testosterone 2% solution; <a href="./references#CD013071-bbs2-0016" title="GoorenLJ , BoulouxPM , GiltayEJ , SaadF . The effect of 6 months' treatment with testosterone gel versus placebo on body composition and health-related quality of life in hypogonadal men. Journal of Diabetes2011;3:147. [DOI: 10.1111/j.1753-0407.2011.00122.x]">Gooren 2011</a>: 5~7.5 mg testosterone 1% solution; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>: 30~120 mg testosterone). </p> <p>Two studies used 5 mg testosterone patches (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a>). The other two studies used more than one form of testosterone (<a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0037" title="SeftelAD , MackRJ , SecrestAR , SmithTM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. Journal of Andrology2004;25(6):963-72. [PMID: 15477371]SteidleC , SchwartzS , JacobyK , SebreeT , SmithT , BachandR . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism2003;88(6):2673-81. [DOI: 10.1210/jc.2002-021058]">Seftel 2004</a>). <a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a> had two intervention groups; the first group intramuscularly injected 1000 mg of TU, and the second group added 80 mg of oral testosterone to intramuscular injection. <a href="./references#CD013071-bbs2-0037" title="SeftelAD , MackRJ , SecrestAR , SmithTM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. Journal of Andrology2004;25(6):963-72. [PMID: 15477371]SteidleC , SchwartzS , JacobyK , SebreeT , SmithT , BachandR . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism2003;88(6):2673-81. [DOI: 10.1210/jc.2002-021058]">Seftel 2004</a> had three intervention groups, each using 100 mg gel, 50 mg gel, and 24.4 mg patch. </p> <p>Five studies used PDE5I in combination with testosterone (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a>). <a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a> had two intervention groups: one used only TU 1000 mg intramuscular injection alone, and the other used intramuscular injection with PDE5I. <a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a> used a mixture of oral TU, PDE5I, and vitamin E (Vit E). </p> <p>Most studies used only an identical placebo as a comparator. On the other hand, four studies used PDE5I only as a comparator (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>; <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>). Others used a combination of PDE5I and Vit E (<a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a>) and a combination of PDE5I and placebo (<a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>). <a href="./references#CD013071-bbs2-0006" title="AydinS , OdabasO , ErcanM , KaraH , AgargunMY . Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British Journal of Urology1996;77(2):256-60. [PMID: 8800895]">Aydin 1996</a> used two comparators: trazodone 150 mg and placebo. <a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a> compared testosterone to no treatment. </p> </section> <section id="CD013071-sec-0071"> <h4 class="title">Comparisons</h4> <p>Most studies compared the intervention to a matched placebo. Three studies compared testosterone to PDE5I (<a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>; <a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>; <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>), and four studies compared testosterone with PDE5I to PDE5I (<a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a>). <a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a> compared testosterone and testosterone with PDE5I to PDE5I. </p> </section> <section id="CD013071-sec-0072"> <h4 class="title">Outcomes</h4> <p>Sixteen studies reported both erectile function and sexual quality of life (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0033" title="RaoPM , JonesTH , KellyD . Testosterone improves symptom severity, quality of life (QOL), triglycerides and strength: a randomised placebo-controlled study in men with uncontrolled type-2 diabetes and hypogonadism: Stride study. Diabetic Medicine2023;40(Suppl 1):184. [DOI: 10.1111/dme.15048]">Rao 2023</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>). Eleven studies reported erectile function only (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0006" title="AydinS , OdabasO , ErcanM , KaraH , AgargunMY . Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British Journal of Urology1996;77(2):256-60. [PMID: 8800895]">Aydin 1996</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0014" title="GilbertRN , GrahamCW , ReganJB . Double blind cross-over trial of testosterone enanthate in impotent men with low or low-normal serum testosterone levels. Journal of Urology1992;147(Suppl 4):264. ">Gilbert 1992</a>; <a href="./references#CD013071-bbs2-0021" title="HisasueSI , IdeH , TsujimuraA , NagayaN , KimuraM , AbdelhamedA , et al. Testosterone gel treatment significantly ameliorates urinary urgency and sleep disturbance: double-blind, placebo-controlled clinical trial. Journal of Urology2015;193(4 Suppl):e772-3. [DOI: 10.1016/j.juro.2015.02.2269]">Hisasue 2015</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0035" title="RothLW , SchwartzRS , MeachamRB . The impact of testosterone supplementation on sexual function in elderly men. Fertility and Sterility2011;96(3 Suppl 1):S1-2. [DOI: 10.1016/j.fertnstert.2011.07.014]">Roth 2011</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>; <a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>), and two studies reported sexual quality of life only (<a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a>; <a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a>). Eight studies reported cardiovascular mortality as an outcome (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>). Nine studies did not report any primary outcomes (<a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>; <a href="./references#CD013071-bbs2-0008" title="BenkertO , WittW , AdamW , LeitzA . Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Archives of Sexual Behavior1979;8(6):471-9. ">Benkert 1979</a>; <a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a>; <a href="./references#CD013071-bbs2-0016" title="GoorenLJ , BoulouxPM , GiltayEJ , SaadF . The effect of 6 months' treatment with testosterone gel versus placebo on body composition and health-related quality of life in hypogonadal men. Journal of Diabetes2011;3:147. [DOI: 10.1111/j.1753-0407.2011.00122.x]">Gooren 2011</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0028" title="LunglmayrG , StellamorM , SponaJ . Androgen therapy of impotentia coeundi in elderly men. Psychological and endocrinological investigations. Wiener Klinische Wochenschrift 1980;92(7):243-2471980;92(7):243-7. ">Lunglmayr 1980</a>; <a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a>; <a href="./references#CD013071-bbs2-0036" title="SchiaviRC , WhiteD , MandeliJ , LevineAC . Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Archives of Sexual Behavior1997;26(3):231-41. [PMID: 9146812]">Schiavi 1997</a>; <a href="./references#CD013071-bbs2-0037" title="SeftelAD , MackRJ , SecrestAR , SmithTM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. Journal of Andrology2004;25(6):963-72. [PMID: 15477371]SteidleC , SchwartzS , JacobyK , SebreeT , SmithT , BachandR . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism2003;88(6):2673-81. [DOI: 10.1210/jc.2002-021058]">Seftel 2004</a>). One study reported cardiovascular mortality as a time‐to‐event outcome, but we were unable to use the data for meta‐analysis because the study is event‐driven (reported as cumulative incidence) (<a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>). </p> <p>Nineteen studies used different versions of the IIEF instrument to report erectile function (IIEF‐15: <a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a>; <a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>; IIEF‐5: <a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>; <a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>; <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>; IIEF‐EF: <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; modified IIEF: <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; not defined: <a href="./references#CD013071-bbs2-0033" title="RaoPM , JonesTH , KellyD . Testosterone improves symptom severity, quality of life (QOL), triglycerides and strength: a randomised placebo-controlled study in men with uncontrolled type-2 diabetes and hypogonadism: Stride study. Diabetic Medicine2023;40(Suppl 1):184. [DOI: 10.1111/dme.15048]">Rao 2023</a>). While <a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a> used IIEF‐5, we were also unable to use the data for meta‐analysis as the study was nested within the parent trial (inclusion of men with low libido only). Two studies used AMS (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>), and five used other questionnaires (Sexual Health Inventory For Men: <a href="./references#CD013071-bbs2-0021" title="HisasueSI , IdeH , TsujimuraA , NagayaN , KimuraM , AbdelhamedA , et al. Testosterone gel treatment significantly ameliorates urinary urgency and sleep disturbance: double-blind, placebo-controlled clinical trial. Journal of Urology2015;193(4 Suppl):e772-3. [DOI: 10.1016/j.juro.2015.02.2269]">Hisasue 2015</a>, <a href="./references#CD013071-bbs2-0035" title="RothLW , SchwartzRS , MeachamRB . The impact of testosterone supplementation on sexual function in elderly men. Fertility and Sterility2011;96(3 Suppl 1):S1-2. [DOI: 10.1016/j.fertnstert.2011.07.014]">Roth 2011</a>; Derogatis Interview For Sexual Functioning Self‐Report: <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; Male Sexual Health Questionnaire ‐ Ejaculatory Dysfunction Short Form: <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; question 4 of the Psychosexual Daily Questionnaire: <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>). <a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a> used IIEF‐5 and the sexual domain of AMS, and <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a> used three measurements: IIEF‐EF, IIEF‐15, and Male Sexual Health Questionnaire. <a href="./references#CD013071-bbs2-0014" title="GilbertRN , GrahamCW , ReganJB . Double blind cross-over trial of testosterone enanthate in impotent men with low or low-normal serum testosterone levels. Journal of Urology1992;147(Suppl 4):264. ">Gilbert 1992</a> used a sexual questionnaire, and <a href="./references#CD013071-bbs2-0006" title="AydinS , OdabasO , ErcanM , KaraH , AgargunMY . Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British Journal of Urology1996;77(2):256-60. [PMID: 8800895]">Aydin 1996</a> did not report measurement tools for erectile function. </p> <p>Ten studies used AMS to report sexual quality of life (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a>; <a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0033" title="RaoPM , JonesTH , KellyD . Testosterone improves symptom severity, quality of life (QOL), triglycerides and strength: a randomised placebo-controlled study in men with uncontrolled type-2 diabetes and hypogonadism: Stride study. Diabetic Medicine2023;40(Suppl 1):184. [DOI: 10.1111/dme.15048]">Rao 2023</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>), and six studies used the IIEF overall satisfaction domain (<a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>). <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a> and <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a> used both the total AMS score and IIEF overall satisfaction domain. Five studies used other questionnaires (self‐rating: <a href="./references#CD013071-bbs2-0008" title="BenkertO , WittW , AdamW , LeitzA . Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Archives of Sexual Behavior1979;8(6):471-9. ">Benkert 1979</a>; Partial Androgen Deficiency of Aging Men: <a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a>; <a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a>; Global Assessment Question: <a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a>; Androgen Deficiency of Aging Men: <a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a>; Sexual Encounter Profile: <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>). Two studies did not report how to measure the sexual quality of life (<a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>; <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>). While 24 studies reported the number of participants with treatment withdrawal due to adverse events (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0008" title="BenkertO , WittW , AdamW , LeitzA . Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Archives of Sexual Behavior1979;8(6):471-9. ">Benkert 1979</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>), 10 studies only reported cardiovascular mortality (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>). Nine and 14 studies reported lower urinary tract symptoms using IPSS (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0021" title="HisasueSI , IdeH , TsujimuraA , NagayaN , KimuraM , AbdelhamedA , et al. Testosterone gel treatment significantly ameliorates urinary urgency and sleep disturbance: double-blind, placebo-controlled clinical trial. Journal of Urology2015;193(4 Suppl):e772-3. [DOI: 10.1016/j.juro.2015.02.2269]">Hisasue 2015</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>) and prostate‐related events (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>), respectively. </p> <p>While three studies reported long‐term outcomes (later than 12 months; <a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a>; <a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>), the remaining studies reported only short‐term outcomes (up to and including 12 months). </p> </section> <section id="CD013071-sec-0073"> <h4 class="title">Funding sources and conflicts of interest</h4> <p>Twenty‐one studies reported funding sources. Six studies were supported by Bayer Pharma AG (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>), and three studies were supported by Eli Lilly and Co. (<a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>). Ten studies received grants or study medication from other pharmaceutical companies (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>; <a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0037" title="SeftelAD , MackRJ , SecrestAR , SmithTM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. Journal of Andrology2004;25(6):963-72. [PMID: 15477371]SteidleC , SchwartzS , JacobyK , SebreeT , SmithT , BachandR . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism2003;88(6):2673-81. [DOI: 10.1210/jc.2002-021058]">Seftel 2004</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>), and three studies received grants from the National Institutes of Health or an academic institution (<a href="./references#CD013071-bbs2-0036" title="SchiaviRC , WhiteD , MandeliJ , LevineAC . Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Archives of Sexual Behavior1997;26(3):231-41. [PMID: 9146812]">Schiavi 1997</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>). Five studies declared potential conflicts of interest with pharmaceutical companies (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a>; <a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>). </p> </section> <section id="CD013071-sec-0074"> <h4 class="title">Excluded studies</h4> <p>We excluded 72 studies (103 records) after evaluating the full‐text publications. Most of the excluded studies (50 studies) used the wrong participants and, most often, participants were recruited regardless of erectile dysfunction. Other reasons for exclusion were the recruitment of participants with specific diseases (<a href="./references#CD013071-bbs2-0044" title="AmiazR , PopeH , SeidmanSN , WeiserM . Testosterone gel replacement improves sexual function in hypogonadal depressed men taking antidepressants. European Neuropsychopharmacology2010;20(Suppl 3):S374. AmiazR , PopeHG , MahneT , KellyJF , BrennanBP , KanayamaG , et al. Testosterone gel replacement improves sexual function in depressed men taking serotonergic antidepressants: a randomized, placebo-controlled clinical trial. Journal of Sex &amp; Marital Therapy2011;37(4):243-54. [DOI: 10.1080/0092623X.2011.582425]SeidmanS , PopeH , AmiazR , WeiserM . Testosterone gel replacement improves sexual function in depressed men taking serotonergic antidepressants: a randomized, placebo-controlled clinical trial. Gender Medicine2010;7(5):529. ">Amiaz 2011</a>; <a href="./references#CD013071-bbs2-0045" title="AtkinsonRA , Srinivas-ShankarU , RobertsSA , ConnollyMJ , AdamsJE , OldhamJA , et al. Effects of testosterone on skeletal muscle architecture in intermediate-frail and frail elderly men. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2010;65(11):1215-9. [DOI: 10.1093/gerona/glq118]">Atkinson 2010</a>; <a href="./references#CD013071-bbs2-0047" title="BakhshiV , ElliottM , GentiliA , GodschalkM , MulliganT . Testosterone improves rehabilitation outcomes in ill older men. Journal of the American Geriatrics Society2000;48(5):550-3. [DOI: 10811549]">Bakhshi 2000</a>; <a href="./references#CD013071-bbs2-0048" title="BasariaS , CovielloAD , TravisonTG , StorerTW , FarwellWR , JetteAM , et al. Adverse events associated with testosterone administration. New England Journal of Medicine2010;363(2):109-22. [DOI: 10.1056/NEJMoa1000485]">Basaria 2010</a>; <a href="./references#CD013071-bbs2-0049" title="BasariaS , DavdaMN , TravisonTG , UlloorJ , SinghR , BhasinS . Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2013;68(2):153-60. [DOI: 10.1093/gerona/gls138]">Basaria 2013</a>; <a href="./references#CD013071-bbs2-0063" title="Del FabbroE , GarciaJ , DeBakeyME , DevR , PalmerL . A double-blind placebo controlled trial of testosterone replacement for fatigue in males with advanced cancer (TH307-B). Journal of Pain and Symptom Management2013;45(2):336-7. [DOI: 10.1016/j.jpainsymman.2012.10.039]Del FabbroE , GarciaJ , DevR , Palmer JL , Klingner-WintonC , Roberts LE , et al. A randomized placebo-controlled trial of testosterone replacement for fatigue in male hypogonadic patients with advanced cancer. Journal of Clinical Oncology2011;29(15 Suppl 1):TPS238. [DOI: 10.1200/jco.2011.29.15_suppl.tps238]Del FabbroE , GarciaJ , DevR , PulivarthiK , PalmerL , BrueraE . Testosterone replacement for fatigue in male hypogonadic patients with advanced cancer: a preliminary double-blind, placebo-controlled trial. Supportive Care in Cancer2012;20:S249-50. [DOI: 10.1007/s00520-012-1479-7]Del FabbroE , GarciaJM , DevR , HuiD , WilliamsJ , EngineerD , et al. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial. Supportive Care in Cancer2013;21(9):2599-607. [DOI: 10.1007/s00520-013-1832-5]">Del Fabbro 2013</a>; <a href="./references#CD013071-bbs2-0066" title="EnglishKM , SteedsRP , JonesTH , DiverMJ , ChannerKS . Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation2000;102(16):1906-11. [PMID: 11034937]">English 2000</a>; <a href="./references#CD013071-bbs2-0076" title="GregoriG , CelliA , BarnouinY , PaudyalA , Armamento-VillarealR , NapoliN , et al. Cognitive response to testosterone replacement added to intensive lifestyle intervention in older men with obesity and hypogonadism: prespecified secondary analyses of a randomized clinical trial. American Journal of Clinical Nutrition2021;114(5):1590-9. [DOI: 10.1093/ajcn/nqab253]">Gregori 2021</a>; <a href="./references#CD013071-bbs2-0096" title="NCT01377103. Testosterone therapy in heart failure. clinicaltrials.gov/show/NCT01377103 (first received 18 May 2011). ">NCT01377103</a>; <a href="./references#CD013071-bbs2-0097" title="NCT02712944. Testosterone replacement in renal failure. clinicaltrials.gov/show/NCT02712944 (first received 9 March 2016). ">NCT02712944</a>; <a href="./references#CD013071-bbs2-0098" title="NCT02803073. Effect of testosterone replacement on exercise capacity in hypogonadal men after a recent myocardial infarction. clinicaltrials.gov/show/NCT02803073 (first received 8 June 2016). ">NCT02803073</a>; <a href="./references#CD013071-bbs2-0102" title="ParkHJ , ParkJH , ParkNC . Can testosterone therapy improve the treatment response of tadalafil in patients with BPH/LUTS and late onset hypogonadism?European Urology Open Science2020;19:e135. [DOI: 10.1016/S2666-1683(20)32634-3]">Park 2020a</a>; <a href="./references#CD013071-bbs2-0106" title="RastrelliG , CiprianiS , LottiF , CellaiI , ComeglioP , BoddiV , et al. Testosterone replacement therapy is able to reduce prostate inflammation in men with BPH, metabolic syndrome and hypogonadism: preliminary results from a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(7):S160. [DOI: 10.1016/j.jsxm.2018.04.084]">Rastrelli 2018</a>; <a href="./references#CD013071-bbs2-0108" title="SeidmanSN , RooseSP . The sexual effects of testosterone replacement in depressed men: randomized, placebo-controlled clinical trial. Journal of Sex and Marital Therapy2006;32(3):267-73. [DOI: 10.1080/00926230600575355]SeidmanSN , SpatzE , RizzoC , RooseSP . Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. Journal of Clinical Psychiatry2001;62(6):406-12. ">Seidman 2001</a>; <a href="./references#CD013071-bbs2-0111" title="Srinivas-ShankarU , RobertsSA , ConnollyMJ , O'ConnellMD , AdamsJE , OldhamJA , et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology &amp; Metabolism2010;95(2):639-50. [DOI: 10.1210/jc.2009-1251]">Srinivas‐Shankar 2010</a>), participants that were younger than defined in our inclusion/exclusion criteria (<a href="./references#CD013071-bbs2-0054" title="BrownGA , VukovichMD , ReifenrathTA , UhlNL , ParsonsKA , SharpRL , et al. Effects of anabolic precursors on serum testosterone concentrations and adaptations to resistance training in young men. International Journal of Sport Nutrition and Exercise Metabolism2000;10(3):340-59. [PMID: 10997957]">Brown 2000</a>; <a href="./references#CD013071-bbs2-0055" title="ButrovaSA , KoganBS . The effectiveness of sex hormone replacement therapy in male hypogonadism. Problems of Endocrinology (Mosk)1971;17(5):43-7. ">Butrova 1971</a>; <a href="./references#CD013071-bbs2-0062" title="CrawfordBA , LiuPY , KeanMT , BleaselJF , HandelsmanDJ . Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. Journal of Clinical Endocrinology &amp; Metabolism2003;88(7):3167-76. [DOI: 10.1210/jc.2002-021827]">Crawford 2003</a>; <a href="./references#CD013071-bbs2-0067" title="Fernández-GarcíaJC , Barrios-RodríguezR , Asenjo-PlazaM , Ramos-MolinaB , Molina-VegaM , Guzmán-GuzmánA , et al. Metformin, testosterone, or both in men with obesity and low testosterone: a double-blind, parallel-group, randomized controlled trial. Metabolism2022;136:155290. [DOI: 10.1016/j.metabol.2022.155290]">Fernández‐García 2022</a>; <a href="./references#CD013071-bbs2-0070" title="FrederiksenL , HøjlundK , HougaardDM , MosbechTH , LarsenR , FlyvbjergA , et al. Testosterone therapy decreased adiponectin and subcutaneous fat in aging men. Endocrine Reviews2011;32(Suppl 1):2544. [DOI: 10.1093/edrv/32.supp.1]FrederiksenL , HøjlundK , HougaardDM , MosbechTH , LarsenR , FlyvbjergA , et al. Testosterone therapy decreases subcutaneous fat and adiponectin in aging men. European Journal of Endocrinology2012;166(3):469-76. [DOI: 10.1530/EJE-11-0565]">Frederiksen 2012</a>; <a href="./references#CD013071-bbs2-0080" title="JPRN-jRCT1071210006. Administration study on preparation of testosterone undecanoate to healthy adult males. rctportal.niph.go.jp/en/detail?trial_id=jRCT1071210006 (first received 7 April 2021). ">JPRN‐jRCT1071210006</a>; <a href="./references#CD013071-bbs2-0095" title="NCT00433199. Testosterone treatment for hypogonadal men. clinicaltrials.gov/show/NCT00433199 (first received 8 February 2007). ">NCT00433199</a>; <a href="./references#CD013071-bbs2-0104" title="PasiakosSM , BerrymanCE , KarlJ , LiebermanHR , OrrJS , MargolisLE , et al. Effects of testosterone supplementation on body composition and lower-body muscle function during severe exercise- and diet-induced energy deficit: a proof-of-concept, single centre, randomised, double-blind, controlled trial. EBioMedicine2019;46:411-22. [DOI: 10.1016/j.ebiom.2019.07.059]">Pasiakos 2019</a>), and participants with primary erectile dysfunction (<a href="./references#CD013071-bbs2-0087" title="KwanM , GreenleafWJ , MannJ . The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. Journal of Clinical Endocrinology and Metabolism1983;57(3):557-62. [DOI: 10.1210/jcem-57-3-557]">Kwan 1983</a>; <a href="./references#CD013071-bbs2-0101" title="ParkNC , YanBQ , ChungJM , LeeKM . Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency. Aging Male2003;6(2):86-93. [PMID: 12898792]">Park 2003</a>; <a href="./references#CD013071-bbs2-0110" title="SkakkebaekNE , BancroftJ , DavidsonDW , WarnerP . Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clinical Endocrinology1981;14(1):49-61. [PMID: 7014044]">Skakkebaek 1981</a>). Nine studies used the wrong comparator; specifically, six compared different types of testosterone without another comparator (<a href="./references#CD013071-bbs2-0057" title="Carson IIIC , KheraM , DobsA , WangC , KaminetskyJ , MinerM , et al. Hypogonadal men with sexual function disorder benefit from LPCN 1021 (oral testosterone)-SOAR (study of androgen replacement) trial. Journal of Urology2016;195(4 Suppl):e1010-1. [DOI: 10.1016/j.juro.2016.02.1861]">Carson 2016</a>; <a href="./references#CD013071-bbs2-0075" title="GonzalezD , KreschE , OryJ , NackeeranS , Blachman-BraunR , RamasamyR . Impact of testosterone therapy on polycythemia: evaluation of data from two ongoing open-label randomized single-center clinical trials. Fertility and Sterility2021;116(3):e347. [DOI: 10.1016/j.fertnstert.2021.07.931]">Gonzalez 2021</a>; <a href="./references#CD013071-bbs2-0079" title="HonigS , JedK , GittelmanM , SwerdloffR , DanoffT , DudleyR . Treatment of hypogonadal men with oral testosterone undecanoate (TU) improves psycho-sexual, well-being and body composition parameters. Journal of Urology2020;203:e547. [DOI: 10.1097/JU.0000000000000883.010]SeoBW , SwerdloffR , AmoryJ , DobsA , WangC , DanoffT , et al. New oral testosterone undecanoate (TU) formulation improves testosterone concentrations, as well as, psychosexual, well-being and body composition and bone desity parameters in hypogonadal men. Endocrine Practice2020;26(Suppl 2):239. SwerdloffR , HonigS , WangC , GittelmanM , SeoBW , RohowskyN , et al. Two-year administration data of an oral testosterone undecanoate (TU) formulation in hypogonadal men. Journal of Sexual Medicine2022;19(5):S128. [DOI: 10.1016/j.jsxm.2022.03.548]SwerdloffR , KavoussiP , GittelmanM , WangC , SeoBW , RohowskyN , et al. Safety analysis of an oral testosterone undecanoate (TU) formulation following 2 years of administration in hypogonadal men. Journal of Urology2021;206(Suppl 3):e369-70. [DOI: 10.1097/JU.0000000000002009.07]SwerdloffR , WangC , AmoryJK , GittelmanM , SeoBW , RohowskyN , et al. Safety analysis of an oral testosterone undecanoate (TU) formulation following 2 years of administration in hypogonadal men. Endocrine Practice2021;27(6):S138. [DOI: 10.1016/j.eprac.2021.04.758]">Honig 2020</a>; <a href="./references#CD013071-bbs2-0082" title="KheraM , WangC , KaminetskyJ , DobsA , GoldsteinI , DelconteA , et al. Hypogonadal men with sexual dysfunction benefit from LPCN 1021 (oral testosterone)-SOAR (study of androgen replacement) trial. Andrology2016;4:118-9. [DOI: 10.1111/andr.12201]">Khera 2016b</a>; <a href="./references#CD013071-bbs2-0088" title="LipshultzL , WestfieldG , GuidryM , BrysonN , KheraM . Clinical improvements in erectile function and mood in hypogonadal men treated with 4.5% nasal testosterone gel (natesto). Journal of Sexual Medicine2018;15(2 Suppl 1):S79-80. LipshultzL , WestfieldG , GuidryM , BrysonN , KheraM . Clinical improvements in erectile function and mood in hypogonadal men treated with 4.5% nasal testosterone gel. Journal of Urology2017;197(4 Suppl 1):e1346-7. ">Lipshultz 2017</a>; <a href="./references#CD013071-bbs2-0109" title="ShiraiM , MizushimaK , TsuruT , KurosawaM , KureA , UesakaY , et al. Novel testosterone gel improves aging males' symptoms in patients with late-onset hypogonadism: active control equivalence, randomized, double-blind, crossover pilot study. Journal of Sexual Medicine2022;19(5):S177. [DOI: 10.1016/j.jsxm.2022.03.403]">Shirai 2022</a>), and two compared testosterone with PDE5I versus testosterone (<a href="./references#CD013071-bbs2-0078" title="HarikaiS , SohJ , KanemitsuN , OchiaiA , OhnishiN , OguraR , et al. Effects of testosterone replacement therapy on quality of life in patients with chronic kidney disease. International Journal of Urology2018;25:250. [DOI: 10.1111/iju.13751]">Harikai 2018</a>; <a href="./references#CD013071-bbs2-0092" title="NarukawaT , SohJ , KanemitsuN , HarikaiS , FujiharaA , UkimuraO . Efficacy of testosterone replacement therapy plus alternate-day tadalafil for patients with late-onset hypogonadism: an open-label, randomized, crossover study. International Journal of Urology2021;28(4):376-81. [DOI: 10.1111/iju.14468]">Narukawa 2021</a>). <a href="./references#CD013071-bbs2-0114" title="WuM , HaoBJ , LiangWN , LiYZ , GengQ , ShandXJ . Jiarong tablets combined with testosterone undecanoate capsules for late-onset hypogonadism in males: a multicentered clinical trial. Zhonghua Nan Ke Xue2020;26(4):346-50. ">Wu 2020</a> used Chinese medicine as a comparator. Eight studies used an ineligible study design (non‐randomized study: <a href="./references#CD013071-bbs2-0064" title="DudekP , KozakowskiJ , ZgliczyńskiW . The effects of testosterone replacement therapy in men with age-dependent hypogonadism on body composition, and serum levels of leptin, adiponectin, and C-reactive protein. Endokrynologia Polska2020;71(5):382-7. [10.5603/EP.a2020.0048]">Dudek 2020</a>; <a href="./references#CD013071-bbs2-0081" title="JungHJ , ShinHS . Effect of testosterone replacement therapy on cognitive performance and depression in men with testosterone deficiency syndrome. World Journal of Men's Health2016;34(3):194-9. [DOI: 10.5534/wjmh.2016.34.3.194]ShinH , ChoH , ParkJ , KimD . The effect of testosterone replacement therapy in men with testosterone deficiency syndrome on cognitive function and depression. Urology2012;80(3 Suppl 1):S311-2. ShinHS , ParkJS , MoonKH , KimKH . The effect of testosterone replacement in men with testosterone deficiency syndrome on cognitive performance and depression. Journal of Sexual Medicine2012;9:238. ShinHS , ParkJS , MoonKH . The effect of testosterone replacement in men with testosterone deficiency syndrome on cognitive performance and depression. European Urology, Supplements2016;15(3):e1008. ">Jung 2016</a>; <a href="./references#CD013071-bbs2-0083" title="KoganMI , AvadievaNE , GevorkyanLS , LoginovYA , MetelkinAM , MitinAA , et al. The results of the multicenter prospective comparative study of Androgel in men with endogenous testosterone deficiency and lower urinary tract symptoms, associated with benign prostate hyperplasia (POTOK). Urologiia2023;2:32-40. [PMID: 37401702]">Kogan 2023</a>; <a href="./references#CD013071-bbs2-0091" title="NankinHR , LinT , OstermanJ . Chronic testosterone cypionate therapy in men with secondary impotence. Fertility and Sterility1986;46(2):300-7. ">Nankin 1986</a>; <a href="./references#CD013071-bbs2-0115" title="YassinDJ , DorosG , HammererPG , YassinAA . Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. The Journal of Sexual Medicine2014;11(6):1567-76. [https://dx.doi.org/10.1111/jsm.12523]">Yassin 2014</a>; and others: <a href="./references#CD013071-bbs2-0077" title="HackettG , ColeN , MulayA , StrangeRC , RamachandranS . Long-term testosterone therapy in type 2 diabetes is associated with decreasing waist circumference and improving erectile function. World Journal of Men's Health2020;38(1):68-77. [DOI: 10.5534/wjmh.180052M]HackettG , ColeN , MulayA , StrangeRC , RamachandranS . Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors. BJU International2019;123(3):519-29. [DOI: 10.1111/bju.14536]">Hackett 2019</a>; <a href="./references#CD013071-bbs2-0090" title="ACTRN12615000071527. Testosterone for androgen deficiency-like symptoms. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12615000071527 (first received 9 January 2015). MokSF , FennellC , SavkovicS , TurnerL , JayadevV , ConwayA , HandelsmanDJ . Testosterone for androgen deficiency-like symptoms in men without pathologic hypogonadism: a randomized, placebo-controlled cross-over with masked choice extension clinical trial. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2020;75(9):1723-31. [DOI: 10.1093/gerona/glz195]">Mok 2020</a>; <a href="./references#CD013071-bbs2-0094" title="NCT00161304. Study to determine the effects of testosterone replacement therapy in aging men with androgen deficiency. clinicaltrials.gov/show/NCT00161304 (first received 8 September 2005). ">NCT00161304</a>). Four studies used the wrong intervention, like a combination of testosterone and another active drug (<a href="./references#CD013071-bbs2-0059" title="ChoDY , YeoJK , ChoSI , JungJE , YangSJ , KongDH , et al. Exercise improves the effects of testosterone replacement therapy and the durability of response after cessation of treatment: a pilot randomized controlled trial. Asian Journal of Andrology2017;19(5):602-7. [DOI: 10.4103/1008-682X.184269]">Cho 2016</a>; <a href="./references#CD013071-bbs2-0069" title="FontenotG , PodolskiJ . Oral enclomid (androxal) raises free and total serum testosterone in hypogonadal men: comparison with a topical gel. Journal of Sexual Medicine.2014;11:162. ">Fontenot 2014</a>; <a href="./references#CD013071-bbs2-0074" title="GomaaAA , HamedHA . Improvement of sexual function in partial testosterone-deficient ageing men treated with cream containing testosterone and vasoactive agents. Journal of Men's Health &amp; Gender2006;3(1):47-55. [DOI: 10.1016/j.jmhg.2004.12.013]">Gomaa 2006</a>; <a href="./references#CD013071-bbs2-0103" title="ParkHJ , ParkJH , ParkNC . Effects of testosterone therapy on hypogonadal patients with obstructive sleep apnea syndrome: an open label randomized consecutive study. European Urology Open Science2020;19:e133. [DOI: 10.1016/S2666-1683(20)32632-X]">Park 2020b</a>). One study was withdrawn (<a href="./references#CD013071-bbs2-0100" title="NCT05484167. Natesto testosterone nasal gel for hypogonadal men. clinicalTrials.gov/show/NCT05484167 (first received 9 June 2022). ">NCT05484167</a>). Details of these excluded studies are presented in the <a href="./references#CD013071-sec-0175" title="">Characteristics of excluded studies</a> section. </p> </section> <section id="CD013071-sec-0075"> <h4 class="title">Studies awaiting classification and ongoing trials</h4> <p>We found eight studies that are awaiting classification (<a href="./references#CD013071-bbs2-0116" title="NCT00163566. Study of DHT-Gel to treat the symptoms of low testosterone in men 55-80. clinicaltrials.gov/show/NCT00163566 (first received 9 September 2005). ">NCT00163566</a>; <a href="./references#CD013071-bbs2-0117" title="NCT00185198. Efficacy and safety of testogel® in men with partial androgen deficiency of aging males (PADAM). clinicaltrials.gov/show/NCT00185198 (first received 9 September 2005). ">NCT00185198</a>; <a href="./references#CD013071-bbs2-0118" title="NCT00254553. A study to test a measure of symptoms of older men with low testosterone on and off testosterone replacement treatment (P05815). clinicaltrials.gov/show/NCT00254553 (first received 14 November 2005). ">NCT00254553</a>; <a href="./references#CD013071-bbs2-0119" title="NCT00349362. Testosterone for men with insulin treated type 2 diabetes. clinicaltrials.gov/show/NCT00349362 (first received 6 July 2006). ">NCT00349362</a>; <a href="./references#CD013071-bbs2-0120" title="NCT00504712. Testosterone for peripheral vascular disease. clinicaltrials.gov/show/NCT00504712 (first received 19 July 2007). ">NCT00504712</a>; <a href="./references#CD013071-bbs2-0121" title="NCT00710827. Nebido versus placebo in elderly men with typical symptoms of late onset hypogonadism over a period of 54 weeks. clinicaltrials.gov/show/NCT00710827 (first received 2 July 2008). ">NCT00710827</a>; <a href="./references#CD013071-bbs2-0122" title="NCT01092858. NEBIDO in symptomatic late onset hypogonadism (SLOH). clinicaltrials.gov/show/NCT01092858 (first received 24 March 2010). ">NCT01092858</a>; <a href="./references#CD013071-bbs2-0123" title="NCT01786473. Testogel (testosterone gel 50mg/5g) in the treatment of male hypogonadism. clinicaltrials.gov/show/NCT01786473 (first received 6 February 2013). ">NCT01786473</a>). </p> <p>We also found four potentially relevant ongoing trials (<a href="./references#CD013071-bbs2-0124" title="IoakeimidisN , AngelisA , RokkasK , Terentes-PrintziosD , SaadF , TousoulisD , et al. Effect of long-term testosterone replacement therapy on arterial stiffness and systemic endothelial function in male patients with hypogonadism. European Heart Journal2021;42(Suppl 1):2832. ">Ioakeimidis 2021</a>; <a href="./references#CD013071-bbs2-0125" title="IRCT20181106041575N1. Testosterone therapy in type 2 diabetes mellitus patients with erectile dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20181106041575N1 (first received 17 May 2019). ">IRCT20181106041575N1</a>; <a href="./references#CD013071-bbs2-0126" title="NCT03281187. Efficacy and safety of testosterone nasal gel for treating hypogonadism in men. clinicaltrials.gov/show/NCT03281187 (first received 11 September 2017). ">NCT03281187</a>; <a href="./references#CD013071-bbs2-0127" title="RussoV , ColleluoriG , ChenR , MediwalaS , QuallsC , LiebschnerM , et al. Testosterone therapy and bone quality in men with diabetes and hypogonadism: study design and protocol. Contemporary Clinical Trials Communications2021;21:100723. ">Russo 2021</a>). </p> <p>Further details of these studies are presented in the <a href="./references#CD013071-sec-0176" title="">Characteristics of studies awaiting classification</a> and <a href="./references#CD013071-sec-0177" title="">Characteristics of ongoing studies</a> sections. </p> </section> </section> <section id="CD013071-sec-0076"> <h3 class="title">Risk of bias in included studies</h3> <p>See the risk of bias tables within the <a href="./references#CD013071-sec-0174" title="">Characteristics of included studies</a> for further details and <a href="#CD013071-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD013071-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD013071-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013071-sec-0077"> <h4 class="title">Allocation</h4> <section id="CD013071-sec-0078"> <h5 class="title">Random sequence generation</h5> <p>We rated 20 studies as at low risk of bias since each of them described an appropriate method for random sequence generation (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>). The remaining studies were at an unclear risk of bias. </p> </section> <section id="CD013071-sec-0079"> <h5 class="title">Allocation concealment</h5> <p>We rated 16 studies as at low risk of bias (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>). Each of them provided assurance that concealment of the allocation sequence was adequately performed. The remaining studies were at an unclear risk of bias. </p> </section> </section> <section id="CD013071-sec-0080"> <h4 class="title">Blinding</h4> <section id="CD013071-sec-0081"> <h5 class="title">Performance bias</h5> <p>We rated 18 studies at low risk of bias since they reported appropriate methods of blinding of study personnel (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0037" title="SeftelAD , MackRJ , SecrestAR , SmithTM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. Journal of Andrology2004;25(6):963-72. [PMID: 15477371]SteidleC , SchwartzS , JacobyK , SebreeT , SmithT , BachandR . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism2003;88(6):2673-81. [DOI: 10.1210/jc.2002-021058]">Seftel 2004</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>). We rated two studies at high risk of bias since they had an open‐label design (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a>). We rated the remaining studies as at unclear risk of bias. </p> </section> <section id="CD013071-sec-0082"> <h5 class="title">Detection bias</h5> <p>We rated 19 studies at low risk of bias due to adequate blinding (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>). The same two open‐label studies were also rated at high risk of detection bias (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a>). The remaining studies were at unclear risk of bias. </p> </section> </section> <section id="CD013071-sec-0083"> <h4 class="title">Incomplete outcome data</h4> <p> <ul id="CD013071-list-0050"> <li> <p>Erectile function: we judged 14 trials at low risk of bias (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0006" title="AydinS , OdabasO , ErcanM , KaraH , AgargunMY . Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British Journal of Urology1996;77(2):256-60. [PMID: 8800895]">Aydin 1996</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0036" title="SchiaviRC , WhiteD , MandeliJ , LevineAC . Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Archives of Sexual Behavior1997;26(3):231-41. [PMID: 9146812]">Schiavi 1997</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>), and nine trials at high risk of bias (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0008" title="BenkertO , WittW , AdamW , LeitzA . Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Archives of Sexual Behavior1979;8(6):471-9. ">Benkert 1979</a>; <a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0014" title="GilbertRN , GrahamCW , ReganJB . Double blind cross-over trial of testosterone enanthate in impotent men with low or low-normal serum testosterone levels. Journal of Urology1992;147(Suppl 4):264. ">Gilbert 1992</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0037" title="SeftelAD , MackRJ , SecrestAR , SmithTM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. Journal of Andrology2004;25(6):963-72. [PMID: 15477371]SteidleC , SchwartzS , JacobyK , SebreeT , SmithT , BachandR . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism2003;88(6):2673-81. [DOI: 10.1210/jc.2002-021058]">Seftel 2004</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>). The remaining studies were at an unclear risk of bias. </p> </li> <li> <p>Sexual quality of life: we judged 13 trials at low risk of bias (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>), and four trials at high risk of bias (<a href="./references#CD013071-bbs2-0008" title="BenkertO , WittW , AdamW , LeitzA . Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Archives of Sexual Behavior1979;8(6):471-9. ">Benkert 1979</a>; <a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>). The remaining studies were at an unclear risk of bias. </p> </li> <li> <p>Cardiovascular mortality: we judged 11 trials at low risk of bias (<a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>). The remaining studies were at an unclear risk of bias. </p> </li> <li> <p>Treatment withdrawal due to adverse events: we judged 13 trials at an unclear risk of bias (<a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a>; <a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a>; <a href="./references#CD013071-bbs2-0014" title="GilbertRN , GrahamCW , ReganJB . Double blind cross-over trial of testosterone enanthate in impotent men with low or low-normal serum testosterone levels. Journal of Urology1992;147(Suppl 4):264. ">Gilbert 1992</a>; <a href="./references#CD013071-bbs2-0016" title="GoorenLJ , BoulouxPM , GiltayEJ , SaadF . The effect of 6 months' treatment with testosterone gel versus placebo on body composition and health-related quality of life in hypogonadal men. Journal of Diabetes2011;3:147. [DOI: 10.1111/j.1753-0407.2011.00122.x]">Gooren 2011</a>; <a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a>; <a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>; <a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a>; <a href="./references#CD013071-bbs2-0028" title="LunglmayrG , StellamorM , SponaJ . Androgen therapy of impotentia coeundi in elderly men. Psychological and endocrinological investigations. Wiener Klinische Wochenschrift 1980;92(7):243-2471980;92(7):243-7. ">Lunglmayr 1980</a>; <a href="./references#CD013071-bbs2-0033" title="RaoPM , JonesTH , KellyD . Testosterone improves symptom severity, quality of life (QOL), triglycerides and strength: a randomised placebo-controlled study in men with uncontrolled type-2 diabetes and hypogonadism: Stride study. Diabetic Medicine2023;40(Suppl 1):184. [DOI: 10.1111/dme.15048]">Rao 2023</a>; <a href="./references#CD013071-bbs2-0035" title="RothLW , SchwartzRS , MeachamRB . The impact of testosterone supplementation on sexual function in elderly men. Fertility and Sterility2011;96(3 Suppl 1):S1-2. [DOI: 10.1016/j.fertnstert.2011.07.014]">Roth 2011</a>; <a href="./references#CD013071-bbs2-0036" title="SchiaviRC , WhiteD , MandeliJ , LevineAC . Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Archives of Sexual Behavior1997;26(3):231-41. [PMID: 9146812]">Schiavi 1997</a>; <a href="./references#CD013071-bbs2-0037" title="SeftelAD , MackRJ , SecrestAR , SmithTM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. Journal of Andrology2004;25(6):963-72. [PMID: 15477371]SteidleC , SchwartzS , JacobyK , SebreeT , SmithT , BachandR . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism2003;88(6):2673-81. [DOI: 10.1210/jc.2002-021058]">Seftel 2004</a>; <a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>). The remaining studies were at low risk of bias. </p> </li> <li> <p>Prostate‐related events: we rated 16 trials at low risk of bias (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>), and one study at a high risk of bias (<a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>). The remaining trials were at an unclear risk of bias. </p> </li> <li> <p>Lower urinary tract symptoms: we judged five studies at low risk bias (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>), and one study at high risk of bias (<a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>). The remaining trials were at an unclear risk of bias. </p> </li> </ul> </p> </section> <section id="CD013071-sec-0084"> <h4 class="title">Selective reporting</h4> <p>We judged nine studies at low risk of bias given that reporting corresponded with a prior written protocol (<a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>). We rated the remaining trials at an unclear risk of bias, mainly due to lack of a published protocol. </p> </section> <section id="CD013071-sec-0085"> <h4 class="title">Other potential sources of bias</h4> <p>We judged eight studies as having an unclear risk of bias since only abstracts were available (<a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a>; <a href="./references#CD013071-bbs2-0014" title="GilbertRN , GrahamCW , ReganJB . Double blind cross-over trial of testosterone enanthate in impotent men with low or low-normal serum testosterone levels. Journal of Urology1992;147(Suppl 4):264. ">Gilbert 1992</a>; <a href="./references#CD013071-bbs2-0016" title="GoorenLJ , BoulouxPM , GiltayEJ , SaadF . The effect of 6 months' treatment with testosterone gel versus placebo on body composition and health-related quality of life in hypogonadal men. Journal of Diabetes2011;3:147. [DOI: 10.1111/j.1753-0407.2011.00122.x]">Gooren 2011</a>; <a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a>; <a href="./references#CD013071-bbs2-0021" title="HisasueSI , IdeH , TsujimuraA , NagayaN , KimuraM , AbdelhamedA , et al. Testosterone gel treatment significantly ameliorates urinary urgency and sleep disturbance: double-blind, placebo-controlled clinical trial. Journal of Urology2015;193(4 Suppl):e772-3. [DOI: 10.1016/j.juro.2015.02.2269]">Hisasue 2015</a>; <a href="./references#CD013071-bbs2-0033" title="RaoPM , JonesTH , KellyD . Testosterone improves symptom severity, quality of life (QOL), triglycerides and strength: a randomised placebo-controlled study in men with uncontrolled type-2 diabetes and hypogonadism: Stride study. Diabetic Medicine2023;40(Suppl 1):184. [DOI: 10.1111/dme.15048]">Rao 2023</a>; <a href="./references#CD013071-bbs2-0035" title="RothLW , SchwartzRS , MeachamRB . The impact of testosterone supplementation on sexual function in elderly men. Fertility and Sterility2011;96(3 Suppl 1):S1-2. [DOI: 10.1016/j.fertnstert.2011.07.014]">Roth 2011</a>; <a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>). We rated one study at an unclear risk of bias due to unexplained discrepancies between two published articles (<a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>). The remaining trials were at a low risk of bias. </p> </section> </section> <section id="CD013071-sec-0086"> <h3 class="title" id="CD013071-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD013071-tbl-0001"><b>Summary of findings 1</b> Testosterone compared to placebo in men with sexual dysfunction (short‐term: sensitivity analysis)</a>; <a href="./full#CD013071-tbl-0002"><b>Summary of findings 2</b> Testosterone compared to placebo in men with sexual dysfunction (long‐term)</a>; <a href="./full#CD013071-tbl-0003"><b>Summary of findings 3</b> Testosterone compared to PDE5I in men with sexual dysfunction (short‐term)</a>; <a href="./full#CD013071-tbl-0004"><b>Summary of findings 4</b> Testosterone as an add‐on to PDE5I compared to PDE5I alone in men with sexual dysfunction (short‐term)</a> </p> <p>See <a href="./full#CD013071-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013071-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD013071-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD013071-tbl-0004">summary of findings Table 4</a>. </p> <p>Due to high clinical and methodological heterogeneity in the overall analysis comparing testosterone to placebo (short‐term), <a href="./full#CD013071-tbl-0001">summary of findings Table 1</a> was based on the sensitivity analysis, which excluded studies at high or unclear risk of bias. </p> <p>We downgraded the certainty of evidence mostly due to study limitations and indirectness across all comparisons. In terms of indirectness, participants in the included studies may differ from those of interest in the review for the reasons below. </p> <p> <ul id="CD013071-list-0051"> <li> <p>Age: including young participants under 40 years old (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0037" title="SeftelAD , MackRJ , SecrestAR , SmithTM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. Journal of Andrology2004;25(6):963-72. [PMID: 15477371]SteidleC , SchwartzS , JacobyK , SebreeT , SmithT , BachandR . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism2003;88(6):2673-81. [DOI: 10.1210/jc.2002-021058]">Seftel 2004</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>), or no description of the age criteria (<a href="./references#CD013071-bbs2-0006" title="AydinS , OdabasO , ErcanM , KaraH , AgargunMY . Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British Journal of Urology1996;77(2):256-60. [PMID: 8800895]">Aydin 1996</a>; <a href="./references#CD013071-bbs2-0014" title="GilbertRN , GrahamCW , ReganJB . Double blind cross-over trial of testosterone enanthate in impotent men with low or low-normal serum testosterone levels. Journal of Urology1992;147(Suppl 4):264. ">Gilbert 1992</a>; <a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0028" title="LunglmayrG , StellamorM , SponaJ . Androgen therapy of impotentia coeundi in elderly men. Psychological and endocrinological investigations. Wiener Klinische Wochenschrift 1980;92(7):243-2471980;92(7):243-7. ">Lunglmayr 1980</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>). </p> </li> <li> <p>Baseline serum testosterone level: including participants with over 12 nmol/L testosterone (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a>; <a href="./references#CD013071-bbs2-0016" title="GoorenLJ , BoulouxPM , GiltayEJ , SaadF . The effect of 6 months' treatment with testosterone gel versus placebo on body composition and health-related quality of life in hypogonadal men. Journal of Diabetes2011;3:147. [DOI: 10.1111/j.1753-0407.2011.00122.x]">Gooren 2011</a>; <a href="./references#CD013071-bbs2-0021" title="HisasueSI , IdeH , TsujimuraA , NagayaN , KimuraM , AbdelhamedA , et al. Testosterone gel treatment significantly ameliorates urinary urgency and sleep disturbance: double-blind, placebo-controlled clinical trial. Journal of Urology2015;193(4 Suppl):e772-3. [DOI: 10.1016/j.juro.2015.02.2269]">Hisasue 2015</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>), or no description of testosterone criteria (<a href="./references#CD013071-bbs2-0006" title="AydinS , OdabasO , ErcanM , KaraH , AgargunMY . Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British Journal of Urology1996;77(2):256-60. [PMID: 8800895]">Aydin 1996</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0008" title="BenkertO , WittW , AdamW , LeitzA . Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Archives of Sexual Behavior1979;8(6):471-9. ">Benkert 1979</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0014" title="GilbertRN , GrahamCW , ReganJB . Double blind cross-over trial of testosterone enanthate in impotent men with low or low-normal serum testosterone levels. Journal of Urology1992;147(Suppl 4):264. ">Gilbert 1992</a>; <a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a>; <a href="./references#CD013071-bbs2-0028" title="LunglmayrG , StellamorM , SponaJ . Androgen therapy of impotentia coeundi in elderly men. Psychological and endocrinological investigations. Wiener Klinische Wochenschrift 1980;92(7):243-2471980;92(7):243-7. ">Lunglmayr 1980</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0036" title="SchiaviRC , WhiteD , MandeliJ , LevineAC . Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Archives of Sexual Behavior1997;26(3):231-41. [PMID: 9146812]">Schiavi 1997</a>; <a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>). </p> </li> <li> <p>Comorbidities, namely metabolic syndrome: only 14 studies reported their inclusion criteria related to metabolic syndrome (<a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a>; <a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a>; <a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>; <a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a>; <a href="./references#CD013071-bbs2-0033" title="RaoPM , JonesTH , KellyD . Testosterone improves symptom severity, quality of life (QOL), triglycerides and strength: a randomised placebo-controlled study in men with uncontrolled type-2 diabetes and hypogonadism: Stride study. Diabetic Medicine2023;40(Suppl 1):184. [DOI: 10.1111/dme.15048]">Rao 2023</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>; <a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a>; <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>). </p> </li> </ul> </p> <section id="CD013071-sec-0087"> <h4 class="title">1. Testosterone versus placebo (short‐term)</h4> <section id="CD013071-sec-0088"> <h5 class="title">1.1. Primary outcomes</h5> <section id="CD013071-sec-0089"> <h6 class="title">1.1.1. Erectile function</h6> <p>Three RCTs with 792 participants (testosterone 476, placebo 316) reported short‐term erectile function using the AMS‐sexual domain (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>). Testosterone likely results in little to no difference in erectile function (MD ‐1.15, 95% CI ‐1.76 to ‐0.54; I² = 8%; moderate‐certainty evidence) (<a href="./references#CD013071-fig-0003" title="">Analysis 1.1</a>). We downgraded the certainty of evidence for serious indirectness (–1) due to the inclusion of younger men. </p> <p>Ten RCTs with 2223 participants (testosterone 1135, placebo 1088) reported erectile function using the IIEF‐EF (<a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>) or IIEF‐5 (<a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>) (<a href="./references#CD013071-fig-0004" title="">Analysis 1.2</a>). Pooling across these studies by converting data from IIEF‐5 to IIEF‐EF, testosterone may improve erectile function (MD 5.69, 95% CI ‐0.02 to 11.40; I² = 99%; low‐certainty evidence; <a href="./references#CD013071-fig-0005" title="">Analysis 1.3</a>). We downgraded the certainty of evidence for serious study limitations (‐1) and serious indirectness (‐1) due to the inclusion of younger participants. The observed heterogeneity was explained in the predefined sensitivity analysis that excluded studies at high risk of bias. Due to the resulting higher certainty of evidence, the sensitivity analysis became the basis of the summary of findings table (<a href="./full#CD013071-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD013071-sec-0090"> <h6 class="title">1.1.2. Sexual quality of life</h6> <p>Six RCTs with 1092 participants (testosterone 622, placebo 470) reported sexual quality of life using overall AMS (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>). Testosterone may result in little to no difference in sexual quality of life (MD ‐5.09, 95% CI ‐9.45 to ‐0.72; I² = 90%; low‐certainty evidence) (<a href="./references#CD013071-fig-0006" title="">Analysis 1.4</a>). We downgraded the certainty of evidence for serious study limitations (–1) and serious indirectness (‐1). The observed heterogeneity was explained in the predefined sensitivity analyses that excluded studies at high risk of bias. Due to the resulting higher certainty of evidence, this sensitivity analysis became the basis of the summary of findings table (<a href="./full#CD013071-tbl-0001">summary of findings Table 1</a>). </p> <p>In addition, four RCTs with 846 participants (testosterone 426, placebo 420) reported sexual quality of life using IIEF‐overall satisfaction (<a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>). Testosterone may result in little to no difference in sexual quality of life (MD 2.21, 95% CI ‐1.23 to 5.64; I² = 99%; low‐certainty evidence) (<a href="./references#CD013071-fig-0007" title="">Analysis 1.5</a>). We downgraded the certainty of evidence for serious study limitations (‐1) and serious indirectness (‐1). The observed heterogeneity was explained in the predefined sensitivity analysis that excluded studies at high risk of bias. Due to the resulting higher certainty of evidence, this sensitivity analysis became the basis of the summary of findings table (<a href="./full#CD013071-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD013071-sec-0091"> <h6 class="title">1.1.3. Cardiovascular mortality</h6> <p>Ten RCTs with 3525 participants (testosterone 1860, placebo 1665) reported cardiovascular mortality (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>). Testosterone likely results in little to no difference in cardiovascular mortality (RR 0.83, 95% CI 0.21 to 3.26; I² = 0%; moderate‐certainty evidence); this corresponds to 0 cardiovascular mortality per 1000 men (95% CI 1 fewer to 4 more) (<a href="./references#CD013071-fig-0008" title="">Analysis 1.6</a>). We downgraded the certainty of evidence for serious indirectness (‐1). Publication bias was not strongly suspected. </p> </section> </section> <section id="CD013071-sec-0092"> <h5 class="title">1.2. Secondary outcomes</h5> <section id="CD013071-sec-0093"> <h6 class="title">1.2.1. Treatment withdrawal due to adverse events</h6> <p>Nineteen RCTs with 3340 participants (testosterone 1787, placebo 1553) reported treatment withdrawal due to adverse events (<a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0008" title="BenkertO , WittW , AdamW , LeitzA . Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Archives of Sexual Behavior1979;8(6):471-9. ">Benkert 1979</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>). Testosterone may result in little to no difference in treatment withdrawal due to adverse events (RR 0.74, 95% CI 0.52 to 1.05; I² = 0%; low‐certainty evidence); this corresponds to 11 fewer treatment withdrawals due to adverse events per 1000 men (95% CI 20 fewer to 2 more) (<a href="./references#CD013071-fig-0009" title="">Analysis 1.7</a>). We downgraded the certainty of evidence for serious study limitations (–1) and serious indirectness (‐1); we did not downgrade further for inconsistency. </p> <p>Results of a predefined sensitivity analysis that excluded studies at high risk of bias yielded similar results with regard to the effect size but resulted in a higher certainty of evidence; therefore, this sensitivity analysis became the basis of the summary of findings table (<a href="./full#CD013071-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD013071-sec-0094"> <h6 class="title">1.2.2. Prostate‐related events</h6> <p>Eleven RCTs with 3477 participants (testosterone 1812, placebo 1665) reported prostate‐related events (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>). Testosterone likely results in little to no difference in prostate‐related events (RR 1.65, 95% CI 1.08 to 2.51; I² = 0%; moderate‐certainty evidence); this corresponds to 12 more prostate‐related events per 1000 men (95% CI 2 more to 29 more) (<a href="./references#CD013071-fig-0010" title="">Analysis 1.8</a>). We downgraded the certainty of evidence for serious indirectness (‐1). Publication bias was not strongly suspected. </p> </section> <section id="CD013071-sec-0095"> <h6 class="title">1.2.3. Lower urinary tract symptoms</h6> <p>Nine RCTs with 1644 participants (testosterone 882, placebo 762) reported lower urinary tract symptoms using IPSS (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>; <a href="./references#CD013071-bbs2-0021" title="HisasueSI , IdeH , TsujimuraA , NagayaN , KimuraM , AbdelhamedA , et al. Testosterone gel treatment significantly ameliorates urinary urgency and sleep disturbance: double-blind, placebo-controlled clinical trial. Journal of Urology2015;193(4 Suppl):e772-3. [DOI: 10.1016/j.juro.2015.02.2269]">Hisasue 2015</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a>). Testosterone may result in little to no difference in lower urinary tract symptoms (MD ‐0.62, 95% CI ‐1.51 to 0.27; I² = 63%; low‐certainty evidence) (<a href="./references#CD013071-fig-0011" title="">Analysis 1.9</a>). We downgraded the certainty of evidence for serious study limitations (–1) and serious indirectness (‐1); we did not downgrade further for inconsistency despite moderate heterogeneity, given that it is likely not clinically meaningful. </p> <p>Results of a predefined sensitivity analysis that excluded studies at high risk of bias yielded similar results with regard to the effect size but resulted in a higher certainty of evidence; therefore, this sensitivity analysis became the basis of the summary of findings table (<a href="./full#CD013071-tbl-0001">summary of findings Table 1</a>). </p> </section> </section> <section id="CD013071-sec-0096"> <h5 class="title">1.3. Subgroup analysis</h5> <section id="CD013071-sec-0097"> <h6 class="title">1.3.1 Participant age (less than 65 years versus ≥ 65 years)</h6> <p> <ul id="CD013071-list-0052"> <li> <p>Erectile function: we found that only one RCT with participants aged ≥ 65 years reported erectile function assessed by the IIEF‐EF (MD 2.10, 95% CI 0.93 to 3.27) (<a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>) (<a href="./references#CD013071-fig-0012" title="">Analysis 1.10</a>). Since no study reported the data for participants aged less than 65 years old, we were unable to perform the subgroup analysis. </p> </li> <li> <p>Sexual quality of life: we were unable to perform the predefined subgroup analysis because there were no relevant data. </p> </li> <li> <p>Cardiovascular mortality: <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a> only included participants aged ≥ 65 years (RR 0.33, 95% CI 0.01 to 8.16) (<a href="./references#CD013071-fig-0013" title="">Analysis 1.11</a>). Since no study reported the data for participants aged less than 65 years old, we were unable to perform the subgroup analysis. </p> </li> </ul> </p> </section> <section id="CD013071-sec-0098"> <h6 class="title">1.3.2 Baseline testosterone serum level (less than 8 nmol/L versus ≥ 8 nmol/L)</h6> <p> <ul id="CD013071-list-0053"> <li> <p>Erectile function: we found that only one RCT included participants with testosterone levels less than 8 nmol/L and reported erectile function assessed by the IIEF‐EF (MD 2.10, 95% CI 0.93 to 3.27) (<a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>) (<a href="./references#CD013071-fig-0012" title="">Analysis 1.10</a>). Since no study reported data in participants with testosterone levels ≥ 8 nmol/L separately, we were unable to perform the subgroup analysis. </p> </li> <li> <p>Sexual quality of life: we were unable to perform the predefined subgroup analysis because there were no relevant data. </p> </li> <li> <p>Cardiovascular mortality: <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a> only included participants with testosterone levels less than 8 nmol/L (RR 0.33, 95% CI 0.01 to 8.16) (<a href="./references#CD013071-fig-0013" title="">Analysis 1.11</a>). Since no study reported data for participants with testosterone levels ≥ 8 nmol/L separately, we were unable to perform the subgroup analysis. </p> </li> </ul> </p> </section> <section id="CD013071-sec-0099"> <h6 class="title">1.3.3 The presence or absence of at least one metabolic syndrome component</h6> <p> <ul id="CD013071-list-0054"> <li> <p>Erectile function: <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a> and <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a> included participants with metabolic syndrome and <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a>and <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a> included participants without metabolic syndrome. The effect on erectile function assessed by IIEF‐EF in participants with metabolic syndrome was an MD of 3.14 (95% CI 1.16 to 5.12) and the MD in the participants without metabolic syndrome was 16.06 (95% CI 6.42 to 25.70). The test of interaction was significant (P = 0.01, I<sup>2</sup> = 84.9%) (<a href="./references#CD013071-fig-0014" title="">Analysis 1.12</a>). </p> </li> <li> <p>Sexual quality of life: <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>and <a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a> reported sexual quality of life assessed by total AMS score. The effect on sexual quality of life in participants with metabolic syndrome was an MD of ‐0.17 (95% CI ‐3.52 to 3.18) and the MD in participants without metabolic syndrome was ‐22.60 (95% CI ‐28.30 to ‐16.90). The test of interaction was significant (P &lt; 0.00001, I<sup>2</sup> = 97.7%) (<a href="./references#CD013071-fig-0015" title="">Analysis 1.13</a>). Additionally, <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a> and <a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a> reported sexual quality of life assessed with the overall satisfaction domain of the IIEF. The effect on sexual quality of life in participants with metabolic syndrome was an MD of 0.07 (95% CI ‐0.77 to 0.91) and the MD in participants without metabolic syndrome was 6.88 (95% CI 6.33 to 7.43). The test of interaction was significant (P &lt; 0.00001, I<sup>2</sup> = 99.4%) (<a href="./references#CD013071-fig-0016" title="">Analysis 1.14</a>). </p> </li> <li> <p>Cardiovascular mortality: three RCTs included participants with metabolic syndrome (<a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>) (RR 0.21, 95% CI 0.01 to 5.10), but the remaining studies in the analysis included participants without any information regarding metabolic syndrome. Therefore, we were unable to perform the subgroup analysis (<a href="./references#CD013071-fig-0017" title="">Analysis 1.15</a>). </p> </li> </ul> </p> </section> </section> <section id="CD013071-sec-0100"> <h5 class="title">1.4. Sensitivity analysis</h5> <p>The high degree of heterogeneity in the primary analyses was explained in our predefined sensitivity analyses, which excluded studies at unclear or high risk bias. Since we have greater confidence in the results of these analyses, they provide the basis for our summary of findings tables for this comparison (<a href="./full#CD013071-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD013071-sec-0101"> <h6 class="title">1.4.1. Erectile function</h6> <p>All three studies using the AMS‐sexual domain were rated as low risk of bias (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>); therefore, these results did not change (<a href="./references#CD013071-fig-0003" title="">Analysis 1.1</a>). </p> <p>Of all 11 studies, six were rated as low risk of bias in the analysis that used the IIEF‐5 or IIEF‐EF (MD 2.37, 95% CI 1.67 to 3.08; I² = 0%; 6 RCTs, 2016 participants; moderate‐certainty evidence; <a href="./references#CD013071-fig-0018" title="">Analysis 1.16</a>) (<a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>). We downgraded the certainty of evidence for serious indirectness (‐1) due to the inclusion of younger participants. The high degree of inconsistency observed in the main analysis was now absent; we therefore did not downgrade further. We were unable to assess this analysis for funnel plot asymmetry given the paucity of studies. </p> </section> <section id="CD013071-sec-0102"> <h6 class="title">1.4.2. Sexual quality of life</h6> <p>Five of six studies assessing this outcome using the overall AMS were rated as low risk of bias (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>). Based on this analysis, testosterone likely results in little or no difference in sexual quality of life (MD ‐2.31, 95% CI ‐3.63 to ‐1.00; I² = 0%; 5 RCTs, 1030 participants; moderate‐certainty evidence; <a href="./references#CD013071-fig-0019" title="">Analysis 1.17</a>). We downgraded the certainty of evidence for serious indirectness (–1) due to the inclusion of younger participants. </p> <p>Only two studies were at low risk of bias when assessing IIEF‐overall satisfaction (MD 0.56, 95% CI ‐0.11 to 1.23; I² = 65%; 2 RCTs, 786 participants; moderate‐certainty evidence; <a href="./references#CD013071-fig-0020" title="">Analysis 1.18</a>) (<a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>). Therefore, similarly, we found that testosterone likely results in little or no difference in sexual quality of life. We downgraded the certainty of evidence for serious indirectness (‐1) due to the inclusion of younger participants. </p> </section> <section id="CD013071-sec-0103"> <h6 class="title">1.4.3. Cardiovascular mortality</h6> <p>All 10 studies included in this analysis were rated as low risk of bias (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>); therefore this analysis did not change (<a href="./references#CD013071-fig-0008" title="">Analysis 1.6</a>). </p> </section> <section id="CD013071-sec-0104"> <h6 class="title">1.4.4. Treatment withdrawal due to adverse events</h6> <p>Twelve RCTs of 19 included in the main analysis were rated as low risk of bias (<a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a>; <a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>). Based on this analysis, testosterone likely results in little or no difference in treatment withdrawal due to adverse events (RR 0.81, 95% CI 0.56 to 1.19; I² = 0%; 2966 participants; moderate‐certainty evidence; <a href="./references#CD013071-fig-0021" title="">Analysis 1.19</a>); this corresponds to seven fewer treatment withdrawals due to adverse events per 1000 men (95% CI 16 fewer to 7 more). These results are similar to those in the main analysis (<a href="./references#CD013071-fig-0009" title="">Analysis 1.7</a>). </p> </section> <section id="CD013071-sec-0105"> <h6 class="title">1.4.5. Prostate‐related events</h6> <p>Based on 10 RCTs at low risk of bias (among 11 overall), testosterone likely results in little or no difference in prostate‐related events (RR 1.65, 95% CI 1.08 to 2.51; I² = 0%; 3439 participants; moderate‐certainty evidence) (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a>; <a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>; <a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a>); this corresponds to 13 more prostate‐related events per 1000 men (95% CI 2 more to 29 more). These results are identical to those in the main analysis (<a href="./references#CD013071-fig-0010" title="">Analysis 1.8</a>) since the excluded study did not contribute any events (<a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a>). </p> </section> <section id="CD013071-sec-0106"> <h6 class="title">1.4.6. Lower urinary tract symptoms</h6> <p>Based on six RCTs (of nine) at low risk of bias, testosterone likely results in little or no difference in lower urinary tract symptoms (MD ‐0.37, 95% CI ‐1.39 to 0.64; I² = 66%; 1488 participants; moderate‐certainty evidence; <a href="./references#CD013071-fig-0023" title="">Analysis 1.21</a>) (<a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a>; <a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a>; <a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a>; <a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a>; <a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a>; <a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a>). These results are similar to those in the main analysis (<a href="./references#CD013071-fig-0011" title="">Analysis 1.9</a>). </p> </section> </section> </section> <section id="CD013071-sec-0107"> <h4 class="title">2. Testosterone versus placebo (long‐term)</h4> <section id="CD013071-sec-0108"> <h5 class="title">2.1. Primary outcomes</h5> <section id="CD013071-sec-0109"> <h6 class="title">2.1.1. Erectile function</h6> <p>Only one RCT with 42 participants (testosterone 17, placebo 25) reported erectile function using the IIEF‐EF (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>). We are very uncertain about the effect of testosterone on erectile function (MD 4.20, 95% CI ‐2.03 to 10.43; very low‐certainty evidence) (<a href="./references#CD013071-fig-0024" title="">Analysis 2.1</a>). We downgraded the certainty of evidence for serious study limitations (‐1), serious indirectness (‐1), and very serious imprecision (‐2). </p> </section> <section id="CD013071-sec-0110"> <h6 class="title">2.1.2. Sexual quality of life</h6> <p>The RCT did not compare testosterone versus placebo for sexual quality of life.</p> </section> <section id="CD013071-sec-0111"> <h6 class="title">2.1.3. Cardiovascular mortality</h6> <p>The RCT did not compare testosterone versus placebo for cardiovascular mortality.</p> </section> </section> <section id="CD013071-sec-0112"> <h5 class="title">2.2. Secondary outcomes</h5> <section id="CD013071-sec-0113"> <h6 class="title">2.2.1. Treatment withdrawal due to adverse events</h6> <p>Two RCTs with 122 participants (testosterone 81, placebo 41) reported treatment withdrawal due to adverse events (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>; <a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a>). We are very uncertain about the effect of testosterone on treatment withdrawal due to adverse events (RR 1.04, 95% CI 0.58 to 1.86; I² = 0%; very low‐certainty evidence); this corresponds to 13 more treatment withdrawals due to adverse events per 1000 men (95% CI 133 fewer to 273 more) (<a href="./references#CD013071-fig-0025" title="">Analysis 2.2</a>). We downgraded the certainty of evidence for serious study limitations (‐1), serious indirectness (‐1), and very serious imprecision (‐2). </p> </section> <section id="CD013071-sec-0114"> <h6 class="title">2.2.2. Prostate‐related events</h6> <p>The RCT did not compare testosterone versus placebo for prostate‐related events.</p> </section> <section id="CD013071-sec-0115"> <h6 class="title">2.2.3. Lower urinary tract symptoms</h6> <p>The RCT did not compare testosterone versus placebo for lower urinary tract symptoms.</p> </section> </section> <section id="CD013071-sec-0116"> <h5 class="title">2.3. Subgroup analyses</h5> <p>We were unable to perform any predefined secondary analyses because there were no relevant data (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>: men aged 55 years and over, testosterone less than 15 nmol/L, non‐obese participants). </p> </section> <section id="CD013071-sec-0117"> <h5 class="title">2.4. Sensitivity analyses</h5> <p>We were unable to perform the predefined sensitivity analyses since all included studies had a similar risk of bias (high or unclear risk of bias). </p> </section> </section> <section id="CD013071-sec-0118"> <h4 class="title">3. Testosterone versus PDE5I (short‐term)</h4> <p>Only one RCT with 64 participants (testosterone 30, PDE5I 34) reported erectile function, sexual quality of life, and prostate‐related events in this comparison (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>). </p> <section id="CD013071-sec-0119"> <h5 class="title">3.1. Primary outcomes</h5> <section id="CD013071-sec-0120"> <h6 class="title">3.1.1. Erectile function</h6> <p>We are very uncertain about the effect of testosterone on erectile function assessed by IIEF‐5 (MD ‐3.40, 95% CI ‐5.47 to ‐1.33; very low‐certainty evidence) (<a href="./references#CD013071-fig-0026" title="">Analysis 3.1</a>). We downgraded the certainty of evidence for serious study limitations (‐1) and very serious imprecision (‐2). </p> </section> <section id="CD013071-sec-0121"> <h6 class="title">3.1.2. Sexual quality of life</h6> <p>We are very uncertain about the effect of testosterone on sexual quality of life assessed by AMS (MD ‐3.82, 95% CI ‐6.85 to ‐0.79; very low‐certainty evidence; <a href="./references#CD013071-fig-0027" title="">Analysis 3.2</a>). We downgraded the certainty of evidence for serious study limitations (‐1) and very serious imprecision (‐2). </p> </section> <section id="CD013071-sec-0122"> <h6 class="title">3.1.3. Cardiovascular mortality</h6> <p>The study did not compare testosterone versus PDE5I for cardiovascular mortality.</p> </section> </section> <section id="CD013071-sec-0123"> <h5 class="title">3.2. Secondary outcomes</h5> <section id="CD013071-sec-0124"> <h6 class="title">3.2.1. Treatment withdrawal due to adverse events</h6> <p>The study did not compare testosterone versus PDE5I for treatment withdrawal due to adverse events. </p> </section> <section id="CD013071-sec-0125"> <h6 class="title">3.2.2. Prostate‐related events</h6> <p>There were no prostate‐related events in either study group (<a href="./references#CD013071-fig-0028" title="">Analysis 3.3</a>). We downgraded the certainty of evidence for serious study limitations (‐1) and very serious imprecision (‐2). </p> </section> <section id="CD013071-sec-0126"> <h6 class="title">3.2.3. Lower urinary tract symptoms</h6> <p>The study did not compare testosterone versus PDE5I for lower urinary tract symptoms.</p> </section> </section> <section id="CD013071-sec-0127"> <h5 class="title">3.3. Subgroup analyses</h5> <p>We were unable to perform secondary analyses because there were no relevant data or too few data in the included study. </p> </section> <section id="CD013071-sec-0128"> <h5 class="title">3.4. Sensitivity analyses</h5> <p>We were unable to perform the predefined sensitivity analyses since we only included a single trial. </p> </section> </section> <section id="CD013071-sec-0129"> <h4 class="title">4. Testosterone as an add‐on to PDEI5I versus PDE5I alone (short‐term)</h4> <section id="CD013071-sec-0130"> <h5 class="title">4.1. Primary outcomes</h5> <section id="CD013071-sec-0131"> <h6 class="title">4.1.1. Erectile function</h6> <p>Four RCTs with 430 participants (testosterone + PDE5I 215, PDE5I 215) reported erectile function using the IIEF‐EF (<a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>) or IIEF‐5 (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>) (<a href="./references#CD013071-fig-0029" title="">Analysis 4.1</a>). Testosterone as an add‐on to PDEI5I may result in little or no difference in erectile function (MD 2.79, 95% CI 1.25 to 4.33; I² = 12%; low‐certainty evidence) after converting data from IIEF‐5 to IIEF‐EF (<a href="./references#CD013071-fig-0030" title="">Analysis 4.2</a>). We downgraded the certainty of evidence for serious study limitations (‐1) and serious imprecision (‐1). </p> </section> <section id="CD013071-sec-0132"> <h6 class="title">4.1.2. Sexual quality of life</h6> <p>Two RCTs with 282 participants (testosterone + PDE5I 141, PDE5I 141) reported sexual quality of life using IIEF‐overall satisfaction (<a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>). Testosterone as an add‐on to PDEI5I may result in little to no difference in sexual quality of life (MD 0.34, 95% CI ‐0.76 to 1.45; I² = 72%; low‐certainty evidence) (<a href="./references#CD013071-fig-0031" title="">Analysis 4.3</a>). We downgraded the certainty of evidence for serious inconsistency (‐1) and serious imprecision (‐1). </p> <p>Only one RCT with 64 participants (testosterone + PDE5I 30, PDE5I 34) reported sexual quality of life using AMS (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>). We are very uncertain about the effect of testosterone as an add‐on to PDEI5I on sexual quality of life (MD ‐5.32, 95% CI ‐8.48 to ‐2.16; very low‐certainty evidence) (<a href="./references#CD013071-fig-0032" title="">Analysis 4.4</a>). We downgraded the certainty of evidence for serious study limitations (‐1) and very serious imprecision (‐2). </p> <p>Based on the body of evidence from RCTs that provided evidence of higher certainty, there may be little to no difference in sexual quality of life (low‐certainty evidence). </p> </section> <section id="CD013071-sec-0133"> <h6 class="title">4.1.3. Cardiovascular mortality</h6> <p>The RCTs did not compare testosterone as an add‐on to PDEI5I versus PDE5I for cardiovascular mortality. </p> </section> </section> <section id="CD013071-sec-0134"> <h5 class="title">4.2. Secondary outcomes</h5> <section id="CD013071-sec-0135"> <h6 class="title">4.2.1. Treatment withdrawal due to adverse events</h6> <p>Three RCTs with 388 participants (testosterone + PDE5I 196, PDE5I 192) reported treatment withdrawal due to adverse events (<a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>). Testosterone as an add‐on to PDEI5I may result in little to no difference in treatment withdrawal due to adverse events (RR 1.26, 95% CI 0.32 to 4.91; I² = 31%; low‐certainty evidence); this corresponds to 11 more treatment withdrawals due to adverse events per 1000 men (95% CI 28 fewer to 163 more) (<a href="./references#CD013071-fig-0033" title="">Analysis 4.5</a>). We downgraded the certainty of evidence for serious study limitations (‐1) and serious imprecision (‐1). </p> </section> <section id="CD013071-sec-0136"> <h6 class="title">4.2.2. Prostate‐related events</h6> <p>Three RCTs with 373 participants (testosterone + PDE5I 185, PDE5I 188) reported prostate‐related events (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>; <a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>). We are very uncertain about the effect of testosterone as an add‐on to PDEI5I on prostate‐related events (RR 6.83, 95% CI 0.84 to 55.37; I² = 0%; very low‐certainty evidence); there were no events in the control group (<a href="./references#CD013071-fig-0034" title="">Analysis 4.6</a>). We downgraded the certainty of evidence for serious indirectness (‐1) and very serious imprecision (‐2). </p> </section> <section id="CD013071-sec-0137"> <h6 class="title">4.2.3. Lower urinary tract symptoms</h6> <p>The RCTs did not compare testosterone combination therapy with PDE5I versus PDE5I for lower urinary tract symptoms. </p> </section> </section> <section id="CD013071-sec-0138"> <h5 class="title">4.3. Subgroup analysis</h5> <section id="CD013071-sec-0139"> <h6 class="title">4.3.1 Participant age (less than 65 years versus ≥ 65 years)</h6> <p>We were unable to perform any predefined subgroup analysis because there were no relevant data. </p> </section> <section id="CD013071-sec-0140"> <h6 class="title">4.3.2 Baseline testosterone serum level (less than 8 nmol/L versus ≥ 8 nmol/L)</h6> <p>We were unable to perform any predefined subgroup analysis because there were no relevant data. </p> </section> <section id="CD013071-sec-0141"> <h6 class="title">4.3.3 The presence or absence of at least one metabolic syndrome component</h6> <p> <ul id="CD013071-list-0055"> <li> <p>Erectile function: <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a> included participants with diabetes mellitus (MD 5.80, 95% CI 2.20 to 9.40) (<a href="./references#CD013071-fig-0035" title="">Analysis 4.7</a>). Since no study reported data for participants without metabolic syndrome, we were unable to perform the subgroup analysis. </p> </li> <li> <p>Sexual quality of life and cardiovascular mortality: we were unable to perform any predefined subgroup analysis because there were no relevant data. </p> </li> </ul> </p> </section> </section> <section id="CD013071-sec-0142"> <h5 class="title">4.4. Sensitivity analysis</h5> <section id="CD013071-sec-0143"> <h6 class="title">4.4.1. Erectile function</h6> <p>Based on the studies rated as low risk of bias (<a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a>; <a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a>), testosterone as an add‐on to PDEI5I likely results in little or no difference in erectile function (MD 2.37, 95% CI 0.65 to 4.10; I² = 0%; 2 RCTs, 282 participants); this finding is consistent with that of the main analysis (<a href="./references#CD013071-fig-0029" title="">Analysis 4.1</a>). </p> </section> <section id="CD013071-sec-0144"> <h6 class="title">4.4. 2. Sexual quality of life</h6> <p>As all studies that reported sexual quality of life using IIEF‐overall satisfaction were rated as low risk of bias, this analysis did not materially differ from the analysis including all studies. In contrast, the study that reported sexual quality of life using AMS was rated as high or unclear risk of bias. </p> </section> <section id="CD013071-sec-0145"> <h6 class="title">4.4.3. Cardiovascular mortality</h6> <p>The RCTs did not compare testosterone as an add‐on to PDEI5I versus PDE5I for cardiovascular mortality. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013071-sec-0146" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013071-sec-0146"></div> <section id="CD013071-sec-0147"> <h3 class="title" id="CD013071-sec-0147">Summary of main results</h3> <p>We identified 43 studies that informed three comparisons, namely testosterone versus placebo, testosterone versus PDE5I, and testosterone as an add‐on to PDEI5I versus PDE5I alone. </p> </section> <section id="CD013071-sec-0148"> <h3 class="title" id="CD013071-sec-0148">Testosterone versus placebo</h3> <p>For the comparison of TRT versus placebo, in an analysis that combined data obtained with both the IIEF‐5 instrument and the IIEF‐EF, and included all studies including those with study limitations and short‐term follow‐up (up to 12 months), we found that TRT may improve erectile function. This analysis was notable for a high degree of heterogeneity (I² = 99%), prompting us to downgrade the certainty of evidence. Based on a predefined sensitivity analysis that excluded those studies with methodological limitations, the observed heterogeneity was markedly reduced (I² = 0%), as was the pooled effect size. Based on these findings, TRT likely has little to no effect on erectile dysfunction. Similarly, TRT likely has little to no effect on the two other primary outcomes of this review, sexual quality of life (moderate certainty of evidence) and cardiovascular mortality (moderate certainty of evidence). The same was true for the three secondary outcomes, treatment withdrawal due to adverse events (moderate certainty of evidence), prostate‐related events (moderate certainty of evidence), and LUTS (moderate certainty of evidence). Our ability to perform predefined subgroup analyses based on participant age, baseline testosterone level, and presence of indicators of metabolic syndrome was severely limited due to lack of data. Findings were suggestive of a potentially larger impact of testosterone on both erectile function and sexual quality of life in patients without metabolic syndrome compared to those with metabolic syndrome. </p> <p>Long‐term data (&gt; 12 months' follow‐up) were limited, with a single eligible trial that only informed select outcomes. Based on our analyses, we are very uncertain how testosterone compares to placebo in regard to erectile function (very low certainty of evidence) and treatment withdrawal due to adverse events (very low certainty of evidence). For all other outcomes, we found no RCT data. No subgroup or sensitivity analyses could be conducted. </p> </section> <section id="CD013071-sec-0149"> <h3 class="title" id="CD013071-sec-0149">Testosterone versus PDE5I</h3> <p>Results for the comparison of TRT to PDE5I were limited to short‐term data (up to 12 months) and to two primary outcomes and a single secondary outcome. Based on these findings, we are very uncertain how effects on erectile function, sexual quality of life, and prostate‐related events compare. We found no data for any other outcomes and were unable to perform any secondary analyses. </p> </section> <section id="CD013071-sec-0150"> <h3 class="title" id="CD013071-sec-0150">Testosterone as an add‐on to PDEI5I versus PDE5I</h3> <p>Data were once again limited to short‐term outcomes (up to 12 months). We found that testosterone as an add‐on to PDEI5I may result in little to no difference in erectile function (low certainty of evidence) or sexual quality of life (low certainty of evidence). We found no RCT data to inform the outcome of cardiovascular mortality. There may be little to no difference in treatment withdrawal due to adverse events (low certainty of evidence) and we are very uncertain about how prostate‐related events are affected. We found no RCT data for the outcome of LUTS. We were unable to perform any pre‐planned subgroup analyses. A sensitivity analysis based on risk of bias could only be performed for the outcome of erectile function and yielded results similar to that of the main analysis. </p> </section> <section id="CD013071-sec-0151"> <h3 class="title" id="CD013071-sec-0151">Overall completeness and applicability of evidence</h3> <p>Both the United States Food and Drug Agency (FDA) and the European Union (EU) European Medicines Agency (EMA) limit the use of TRT to men with current medical conditions preventing the release of normal testosterone levels. Specifically, the FDA restricts the use of testosterone therapy drugs to those men who have an actual medical condition, such as a tumor or genetic disorder, restricting the body’s normal release of testosterone. The EMA’s decision also noted that testosterone levels naturally fall somewhat with age, and that restoration of these levels in healthy older men is not an authorized use of medicine in the EU (<a href="./references#CD013071-bbs2-0181" title="MordenNE , WoloshinS , BrooksCG , SchwartzLM . Trends in testosterone prescribing for age-related hypogonadism in men with and without heart disease. JAMA Internal Medicine2019;179(3):446-8. [DOI: 10.1001/jamainternmed.2018.6505]">Morden 2019</a>). Therefore, use of TRT in men without a defined cause for low testosterone levels is an off‐label indication. Nevertheless, major professional societies in andrology and endocrinology recommend testosterone in the treatment of erectile dysfunction and problems with libido arising from low testosterone levels in aging men without other medical causes of low testosterone (<a href="./references#CD013071-bbs2-0134" title="BurnettAL , NehraA , BreauRH , CulkinDJ , FaradayMM , HakimLS , et al. Erectile dysfunction: AUA guideline. Journal of Urology2018;200(3):633-41.">Burnett 2018</a>; <a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0173" title="KheraM , AdaikanG , BuvatJ , CarrierS , El-MeliegyA , HatzimouratidisK , et al. Diagnosis and treatment of testosterone deficiency: recommendations from the Fourth International Consultation on Sexual Medicine (ICSM 2015). Journal of Sexual Medicine2016;13(12):1787-804.">Khera 2016a</a>; <a href="./references#CD013071-bbs2-0176" title="LunenfeldB , MskhalayaG , KalinchenkoS , TishovaY . Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. Aging Male2013;16(4):143-50.">Lunenfeld 2013</a>; <a href="./references#CD013071-bbs2-0183" title="MulhallJP , TrostLW , BranniganRE , KurtzEG , RedmonJB , ChilesKA , et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology2018;200(2):423-32. [DOI: 10.1016/j.juro.2018.03.115]">Mulhall 2018</a>; <a href="./references#CD013071-bbs2-0212" title="WangC , NieschlagE , SwerdloffR , BehreHM , HellstromWJ , GoorenLJ , et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. International Journal of Impotence Research2009;21(1):1-8.">Wang 2009</a>). Our review would draw the evidence base for these recommendations into question. </p> <p> <ul id="CD013071-list-0056"> <li> <p>We included many studies assessing the use of TRT in men with erectile dysfunction as presenting symptoms in the absence of a discernible organic etiology for low testosterone levels. We therefore believe that this evidence is broadly applicable to patients presenting with these erectile dysfunctions exploring the use of TRT. We included all approved formulations of testosterone overall (approximately a third of trials used topical gel, intramuscular, or oral formulations) but we did not explore how these compared. Based on their short‐acting pharmacokinetics, topical formulations are preferred. It has been suggested that testosterone injections may pose a greater risk of cardiovascular events due to spikes in serum testosterone levels (<a href="./references#CD013071-bbs2-0145" title="DimopoulouC , CeausuI , DepypereH , LambrinoudakiI , MueckA , Pérez-LópezFR , et al. EMAS position statement: testosterone replacement therapy in the aging male. Maturitas2016;84:94-9. [DOI: 10.1016/j.maturitas.2015.11.003]">Dimopoulou 2016</a>). However, given the lack of direct comparisons among different testosterone products, the evidence on the relative merits of different formulations remains inconclusive. </p> </li> <li> <p>The inclusion criteria of the included studies differed by age or baseline testosterone (i.e. the definition of low testosterone differed between studies). Currently, available guidelines suggest that TRT may improve sexual function in aging men with low testosterone. However, testosterone deficiency combined with sexual symptoms may occur in a small minority of aging men (<a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>; <a href="./references#CD013071-bbs2-0173" title="KheraM , AdaikanG , BuvatJ , CarrierS , El-MeliegyA , HatzimouratidisK , et al. Diagnosis and treatment of testosterone deficiency: recommendations from the Fourth International Consultation on Sexual Medicine (ICSM 2015). Journal of Sexual Medicine2016;13(12):1787-804.">Khera 2016a</a>; <a href="./references#CD013071-bbs2-0183" title="MulhallJP , TrostLW , BranniganRE , KurtzEG , RedmonJB , ChilesKA , et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology2018;200(2):423-32. [DOI: 10.1016/j.juro.2018.03.115]">Mulhall 2018</a>). Given that the included studies in this review did not limit the participants to those in whom the deficiency has been confirmed by laboratory tests, our results appear applicable to people with sexual dysfunction regardless of their serum testosterone levels. </p> </li> <li> <p>Few studies compared testosterone monotherapy or combination therapy to PDE5I, which is the current gold standard for the treatment of erectile dysfunction. Studies of the effects of TRT compared to current standard therapy would be of particular interest. </p> </li> <li> <p>Two observational studies found that TRT may increase the risk of myocardial infarction (<a href="./references#CD013071-bbs2-0149" title="FinkleWD , GreenlandS , RidgewayGK , AdamsJL , FrascoMA , CookMB , et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLOS One2014;9(1):e85805.">Finkle 2014</a>; <a href="./references#CD013071-bbs2-0210" title="VigenR , O'DonnellCI , BaronAE , GrunwaldGK , MaddoxTM , BradleySM , et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA2013;310(17):1829-36.">Vigen 2013</a>). However, these findings were not confirmed by the evidence from RCTs. There are several risk factors, such as smoking, physical inactivity, and an unhealthy diet, which can increase the likelihood of developing cardiovascular disease. Therefore, further studies should address potential measured and unmeasured risk factors. Additionally, older people, who may be most affected by their already poor health (i.e. prior cardiovascular disease), are usually not considered as appropriate candidates in typical RCTs. </p> </li> <li> <p>The existing body of evidence was limited to relatively short‐term outcomes (up to 12 months' follow‐up). In particular, this appears insufficient to provide assurance of long‐term cardiovascular risk. More high‐quality studies with long‐term follow‐up are needed to address these limitations. </p> </li> </ul> </p> </section> <section id="CD013071-sec-0152"> <h3 class="title" id="CD013071-sec-0152">Quality of the evidence</h3> <p>The certainty of evidence assessed using GRADE ranged from moderate to very low, indicating that we downgraded at least once for each outcome. The reasons for downgrading were as follows: </p> <p> <ul id="CD013071-list-0057"> <li> <p>Whereas many included studies were at overall low risk of bias, a subset of studies had issues around unclear methods of randomization and allocation concealment (selection bias), unclear blinding of participants and personnel (performance bias) and unclear blinding of outcome assessors (detection bias), and unclear proportions of randomized participants included in the outcome analyses (attrition bias), as well as a lack of registered or published a priori protocol (selective reporting). These issues prompted us to downgrade for study limitations. When conducting the predefined sensitivity analyses when comparing testosterone to placebo, removing these studies increased the certainty of evidence. </p> </li> <li> <p>We also downgraded for inconsistency, referring to (unexplained) heterogeneity of study results. In the main analysis for testosterone versus placebo, exclusion of the studies at unclear risk of bias (see above) resolved this issue entirely. We also downgraded for inconsistency in the testosterone as an add‐on to PDE5I versus PDE5I comparison. </p> </li> <li> <p>Another reason for downgrading was imprecision due to small aggregate sample sizes (despite the pooling of two or more studies) and low event rates. </p> </li> <li> <p>We also noted some degree of indirectness related to our PICO question (population, interventions, comparators, and outcomes) and the studies identified with regard to the participants; namely, several of the included studies involved participants under the age of 40 in whom erectile dysfunction may have had a different etiology. </p> </li> </ul> </p> </section> <section id="CD013071-sec-0153"> <h3 class="title" id="CD013071-sec-0153">Potential biases in the review process</h3> <p>This review was performed using standard Cochrane methodology and without any restrictions regarding the language or date of publication. Despite a comprehensive search strategy with no publication or language restrictions, we may have missed additional RCTs that may be unpublished or were published in languages other than English, or both. </p> <p>With the exception of the comparison of testosterone versus placebo, the small number of studies included in the review comparisons was insufficient to generate funnel plots; therefore, the risk of publication bias may have been underestimated. Additionally, some of the studies that were included in the qualitative analysis did not report any primary outcomes. Again, therefore, the risk of publication bias may have been underestimated. </p> <p>MCIDs for the AMS and overall satisfaction domain of the IIEF were not available from any published literature. The same goes for the other predefined outcomes and the proposed thresholds were based on the clinical experience of the review authors who have clinical expertise in urology (ECH, CKO, HSY, HWK, JHJ, and PD) and endocrinology (WT and JSL). We realize that using an alternative MCID level would lead to different interpretations (<a href="./references#CD013071-bbs2-0169" title="HultcrantzM , RindD , AklEA , TreweekS , MustafaRA , IorioA , et al. The GRADE Working Group clarifies the construct of certainty of evidence. Journal of Clinical Epidemiology2017;87:4-13.">Hultcrantz 2017</a>). However, interpretation of the analyzed results based on the IIEF‐EF and IIEF‐5 was based on established MCID thresholds. </p> </section> <section id="CD013071-sec-0154"> <h3 class="title" id="CD013071-sec-0154">Agreements and disagreements with other studies or reviews</h3> <p>The most comparable systematic review is the evidence report by Diem et al (<a href="./references#CD013071-bbs2-0144" title="DiemSJ , GreerNL , MacDonaldR , McKenzieLG , DahmP , Ercan-FangN , et al. Efficacy and safety of testosterone treatment in men: an evidence report for a clinical practice guideline by the American College of Physicians. Annals of Internal Medicine2020;172(2):105-18.">Diem 2020</a>), which included one of the authors of this review (PD) and helped to inform the American College of Physicians guidelines on TRT in adult men with age‐related low testosterone levels (<a href="./references#CD013071-bbs2-0191" title="QaseemA , HorwitchCA , VijanS , Etxeandia-IkobaltzetaI , KansagaraD , Clinical Guidelines Committee of the American College of Physicians, et al. Testosterone treatment in adult men with age-related low testosterone: a clinical guideline from the American College of Physicians. Annals of Internal Medicine2020;172(2):126-33.">Qaseem 2020</a>). The guidelines made a recommendation for discussing the initiation of TRT in men with age‐related low testosterone levels wanting to improve sexual function (conditional recommendation for; low‐certainty evidence) and to re‐evaluate these men within 12 months (conditional recommendation for; low‐certainty evidence). While including many of the same RCTs, our review differs in the inclusion only of those studies in which participants presented with a baseline complaint of sexual dysfunction (although they may also have had other complaints). As a result, different studies were included in the analysis of the effect of TRT on erectile function, for which the authors reported a SMD of 0.27 (95% CI 0.09 to 0.44) based on seven trials from sensitivity analyses that excluded four trials rated as being at high risk of bias due to non‐placebo controls. This pooled body of evidence was rated as being of low certainty. The authors used Cohen's definition of 0.20 as the threshold for a small effect size, thereby concluding that TRT may improve sexual functioning and quality of life, although effect sizes were small. These findings correspond broadly to ours: as mentioned above, interpretation of this body of evidence is highly dependent on assumed thresholds of what represents the MCID. We used single thresholds, for example, an MCID of 5 for the IIEF‐5 based on a minimally contextualized GRADE approach (<a href="./references#CD013071-bbs2-0216" title="ZengL , Brignardello-PetersenR , HultcrantzM , MustafaRA , MuradMH , IorioA , et al. GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. Journal of Clinical Epidemiology2022;150:216-24.">Zeng 2022</a>), rather than several thresholds as one would in a more fully contextualized GRADE approach that distinguishes between effect sizes being trivial or none, small, moderate, or large (<a href="./references#CD013071-bbs2-0199" title="SchunemannHJ , NeumannI , HultcrantzM , Brignardello-PetersenR , ZengL , MuradMH , et al. GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions. Journal of Clinical Epidemiology2022;150:225-42.">Schunemann 2022</a>). </p> <p>A prior systematic review included RCTs with hypogonadal men (<a href="./references#CD013071-bbs2-0190" title="PonceOJ , Spencer-BonillaG , Alvarez-VillalobosN , SerranoV , Singh-OspinaN , Rodriguez-GutierrezR , et al. The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: a systematic review and meta-analysis of randomized, placebo-controlled trials. Journal of Clinical Endocrinology &amp; Metabolism2018;103(5):1745–54.">Ponce 2018</a>). They included four trials and reported an effect on erectile function of a SMD of 0.16 (95% CI 0.06 to 0.27), which we would regard as trivial. The authors did not rate the certainty of evidence. </p> <p><a href="./references#CD013071-bbs2-0147" title="ElliottJ , KellySE , MillarAC , PetersonJ , ChenL , JohnstonA , et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open2017;7(11):e015284.">Elliott 2017</a> reported a protocol‐driven systematic review with network meta‐analysis that also included non‐randomized trials, although these were not included in the quantitative analysis. Based on the pairwise comparisons of TRT versus placebo, they found a SMD of 0.25 (95% CI 0.10 to 0.412) in favor of TRT. Removing trials that included men with major comorbidities reduced heterogeneity and increased the effect size to a SMD of 0.36 (95% CI 0.21 to 0.51). The network meta‐analysis found no significant differences in erectile function between placebo and various forms of testosterone. The authors did not rate the certainty of evidence. </p> <p><a href="./references#CD013071-bbs2-0140" title="CoronaG , RastrelliG , MorgentalerA , SforzaA , MannucciE , MaggiM . Meta-analysis of results of testosterone therapy on sexual function based on International Index of Erectile Function Scores. European Urology2017;72(6):1000-11.">Corona 2017</a> was an influential systematic review since it informed the chapter on hypogonadism in the European Association of Urology guideline on Sexual and Reproductive Health (<a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a>). This systematic review lacked a protocol and included all placebo‐controlled trials in men investigating the effect of TRT, which, as for <a href="./references#CD013071-bbs2-0144" title="DiemSJ , GreerNL , MacDonaldR , McKenzieLG , DahmP , Ercan-FangN , et al. Efficacy and safety of testosterone treatment in men: an evidence report for a clinical practice guideline by the American College of Physicians. Annals of Internal Medicine2020;172(2):105-18.">Diem 2020</a>, led to the inclusion of overlapping, but also somewhat different bodies of evidence. In their primary analysis of 14 trials that reported outcomes using the IIEF‐ED or IIEF‐5, employing a fixed‐effect model, they reported a SMD of 0.32 (95% CI 0.28 to 0.41). The authors concluded that TRT significantly improves erectile function and other sexual parameters without further qualifying the effect size or rating the certainty of evidence. <a href="./references#CD013071-bbs2-0146" title="EAU guidelines Sexual and Reproductive Health. https://uroweb.org/guidelines/sexual-and-reproductive-health (accessed 08 July 2023).">EAU 2023</a> currently makes a strong recommendation to use testosterone therapy as a first‐line therapy in patients with symptomatic hypogonadism and mild erectile dysfunction. </p> <p>Several older studies have raised concerns about an increased cardiovascular risk associated with TRT (<a href="./references#CD013071-bbs2-0149" title="FinkleWD , GreenlandS , RidgewayGK , AdamsJL , FrascoMA , CookMB , et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLOS One2014;9(1):e85805.">Finkle 2014</a>; <a href="./references#CD013071-bbs2-0209" title="US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. www.fda.gov/Drugs/DrugSafety/ucm436259.htm (accessed prior to 28 October 2022).">US Food and Drug Administration</a>; <a href="./references#CD013071-bbs2-0210" title="VigenR , O'DonnellCI , BaronAE , GrunwaldGK , MaddoxTM , BradleySM , et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA2013;310(17):1829-36.">Vigen 2013</a>). While <a href="./references#CD013071-bbs2-0215" title="XuL , FreemanG , CowlingBJ , SchoolingCM . Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Medicine2013;11:108.">Xu 2013</a> showed that TRT increased the risk of a cardiovascular‐related event (not mortality), recent systematic reviews did not confirm these findings based on an analysis of RCT evidence, similar to our findings (<a href="./references#CD013071-bbs2-0129" title="AyeleHT , BrunettiVC , RenouxC , TagalakisV , FilionKB . Testosterone replacement therapy and the risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials. Thrombosis Research2021;199:123-31.">Ayele 2021</a>; <a href="./references#CD013071-bbs2-0144" title="DiemSJ , GreerNL , MacDonaldR , McKenzieLG , DahmP , Ercan-FangN , et al. Efficacy and safety of testosterone treatment in men: an evidence report for a clinical practice guideline by the American College of Physicians. Annals of Internal Medicine2020;172(2):105-18.">Diem 2020</a>). Recently, a RCT with 5204 participants, included in this review, reported that in men with hypogonadism and pre‐existing cardiovascular disease or a high risk of cardiovascular disease, TRT was non‐inferior to placebo in terms of the incidence of major adverse cardiac events (hazard ratio 0.96, 95% CI 0.78 to 1.17) and cardiovascular mortality (hazard ratio 0.84, 95% CI 0.63 to 1.12) (<a href="./references#CD013071-bbs2-0026" title="BhasinS , LincoffAM , BasariaS , BauerDC , BodenWE , CunninghamGR , et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study. American Heart Journal2022;245:41-50. LincoffAM , BhasinS , FlevarisP , MitchellLM , BasariaS , BodenWE , et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine2023;389(2):107-17. [DOI: 10.1056/NEJMoa2215025]NCT03518034. A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). clinicaltrials.gov/show/NCT03518034 (first received 3 May 2018). PencinaKM , TravisonTG , CunninghamGR , LincoffAM , NissenSE , KheraM , et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. Journal of Clinical Endocrinology &amp; Metabolism 2023 Aug 17 [Epub ahead of print]. [DOI: 10.1210/clinem/dgad484]">Lincoff 2023</a>). A large cohort study in men without a history of prevalent cardiovascular disease also found that TRT was not associated with an increased risk of incident cardiovascular events (<a href="./references#CD013071-bbs2-0203" title="ShoresMM , WalshTJ , KorpakA , KrakauerC , ForsbergCW , FoxAE , et al. Association between testosterone treatment and risk of incident cardiovascular events among us male veterans with low testosterone levels and multiple medical comorbidities. Journal of the American Heart Association2021;10(17):e020562.">Shores 2021</a>). In addition, <a href="./references#CD013071-bbs2-0129" title="AyeleHT , BrunettiVC , RenouxC , TagalakisV , FilionKB . Testosterone replacement therapy and the risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials. Thrombosis Research2021;199:123-31.">Ayele 2021</a> found that TRT may not be associated with venous thromboembolism compared with placebo (RR 1.03, 95% CI 0.49 to 2.14; I<sup>2</sup> = 0%; low‐quality evidence), but qualified their results by stating that the estimates had wide 95% CIs, and a clinically important increased risk could not be ruled out. In our review, we found moderate‐certainty evidence of little to no effect but no long‐term evidence. Given that TRT therapy is often prescribed long‐term, this is an important limitation. </p> <p>In a systematic review that also included 14 RCTs and focused on LUTS, <a href="./references#CD013071-bbs2-0175" title="KohnTP , MataDA , RamasamyR , LipshultzLI . Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. European Urology2016;69(6):1083-90.">Kohn 2016</a> found little to no difference in International Prostatism Symptom Score (IPSS) among patients receiving TRT versus placebo. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013071-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013071-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD013071-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 1: Erectile function (AMS sexual)" data-id="CD013071-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 1: Erectile function (AMS sexual) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 2: Erectile function (IIEF)" data-id="CD013071-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 2: Erectile function (IIEF) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 3: Erectile function (conversion to IIEF‐EF)" data-id="CD013071-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 3: Erectile function (conversion to IIEF‐EF) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 4: Sexual quality of life (AMS total)" data-id="CD013071-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 4: Sexual quality of life (AMS total) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 5: Sexual quality of life (IIEF‐overall satisfaction)" data-id="CD013071-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 5: Sexual quality of life (IIEF‐overall satisfaction) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 6: Cardiovascular mortality" data-id="CD013071-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 6: Cardiovascular mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 7: Treatment withdrawal due to adverse events" data-id="CD013071-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 7: Treatment withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 8: Prostate‐related events" data-id="CD013071-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 8: Prostate‐related events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 9: Lower urinary tract symptoms" data-id="CD013071-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 9: Lower urinary tract symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 10: Erectile function (subgroup: age and testosterone level, conversion to IIEF‐EF)" data-id="CD013071-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 10: Erectile function (subgroup: age and testosterone level, conversion to IIEF‐EF) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 11: Cardiovascular mortality (subgroup: age and testosterone level)" data-id="CD013071-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 11: Cardiovascular mortality (subgroup: age and testosterone level) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 12: Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF‐EF)" data-id="CD013071-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 12: Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF‐EF) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 13: Sexual quality of life (subgroup: metabolic syndrome (MS), AMS total)" data-id="CD013071-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 13: Sexual quality of life (subgroup: metabolic syndrome (MS), AMS total) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 14: Sexual quality of life (subgroup: metabolic syndrome (MS), IIEF ‐ overall satisfaction)" data-id="CD013071-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 14: Sexual quality of life (subgroup: metabolic syndrome (MS), IIEF ‐ overall satisfaction) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 15: Cardiovascular mortality (subgroup: metabolic syndrome (MS))" data-id="CD013071-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 15: Cardiovascular mortality (subgroup: metabolic syndrome (MS)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 16: Erectile function (conversion to IIEF‐EF; sensitivity analysis)" data-id="CD013071-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 16: Erectile function (conversion to IIEF‐EF; sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 17: Sexual quality of life (AMS total; sensitivity analysis)" data-id="CD013071-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 17: Sexual quality of life (AMS total; sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 18: Sexual quality of life (IIEF‐overall satisfaction; sensitivity analysis)" data-id="CD013071-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 18: Sexual quality of life (IIEF‐overall satisfaction; sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 19: Treatment withdrawal due to adverse events (sensitivity analysis)" data-id="CD013071-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 19: Treatment withdrawal due to adverse events (sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 20: Prostate‐related events (sensitivity analysis)" data-id="CD013071-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 20: Prostate‐related events (sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Testosterone versus placebo (short‐term), Outcome 21: Lower urinary tract symptoms (sensitivity analysis)" data-id="CD013071-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Testosterone versus placebo (short‐term), Outcome 21: Lower urinary tract symptoms (sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Testosterone versus placebo (long‐term), Outcome 1: Erectile function (IIEF‐EF)" data-id="CD013071-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Testosterone versus placebo (long‐term), Outcome 1: Erectile function (IIEF‐EF) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Testosterone versus placebo (long‐term), Outcome 2: Treatment withdrawal due to adverse events" data-id="CD013071-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Testosterone versus placebo (long‐term), Outcome 2: Treatment withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Testosterone versus PDE5I (short‐term) , Outcome 1: Erectile function (IIEF‐5)" data-id="CD013071-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Testosterone versus PDE5I (short‐term) , Outcome 1: Erectile function (IIEF‐5) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Testosterone versus PDE5I (short‐term) , Outcome 2: Sexual quality of life (AMS total)" data-id="CD013071-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Testosterone versus PDE5I (short‐term) , Outcome 2: Sexual quality of life (AMS total) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Testosterone versus PDE5I (short‐term) , Outcome 3: Prostate‐related events" data-id="CD013071-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Testosterone versus PDE5I (short‐term) , Outcome 3: Prostate‐related events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Testosterone + PDE5I versus PDE5I (short‐term), Outcome 1: Erectile function" data-id="CD013071-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Testosterone + PDE5I versus PDE5I (short‐term), Outcome 1: Erectile function </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Testosterone + PDE5I versus PDE5I (short‐term), Outcome 2: Erectile function (conversion to IIEF‐EF)" data-id="CD013071-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Testosterone + PDE5I versus PDE5I (short‐term), Outcome 2: Erectile function (conversion to IIEF‐EF) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Testosterone + PDE5I versus PDE5I (short‐term), Outcome 3: Sexual quality of life (IIEF ‐ overall satisfaction)" data-id="CD013071-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Testosterone + PDE5I versus PDE5I (short‐term), Outcome 3: Sexual quality of life (IIEF ‐ overall satisfaction) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Testosterone + PDE5I versus PDE5I (short‐term), Outcome 4: Sexual quality of life (AMS total)" data-id="CD013071-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Testosterone + PDE5I versus PDE5I (short‐term), Outcome 4: Sexual quality of life (AMS total) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Testosterone + PDE5I versus PDE5I (short‐term), Outcome 5: Treatment withdrawal due to adverse events" data-id="CD013071-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Testosterone + PDE5I versus PDE5I (short‐term), Outcome 5: Treatment withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Testosterone + PDE5I versus PDE5I (short‐term), Outcome 6: Prostate‐related events" data-id="CD013071-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Testosterone + PDE5I versus PDE5I (short‐term), Outcome 6: Prostate‐related events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013071-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/urn:x-wiley:14651858:media:CD013071:CD013071-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Testosterone + PDE5I versus PDE5I (short‐term), Outcome 7: Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF‐EF)" data-id="CD013071-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_t/tCD013071-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Testosterone + PDE5I versus PDE5I (short‐term), Outcome 7: Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF‐EF) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/media/CDSR/CD013071/image_n/nCD013071-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013071-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Testosterone compared to placebo in men with sexual dysfunction (short‐term: sensitivity analysis)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> men with sexual dysfunction<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> testosterone<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens?</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo (short‐term)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with testosterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erectile function<br/>Assessed with: sexual domain of AMS<br/>Scale from: 5 (best: no impairment) to 25 (worst: severe impairment)<br/>Follow‐up: range 6 months to 12 months </p> <p>MCID: 3.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>792<br/>(3 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean erectile function ranged from 10.66 to 14.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.15 lower<br/>(1.76 lower to 0.54 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Testosterone likely results in little or no difference in erectile function.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erectile function<br/>Assessed with: IIEF‐EF<br/>Scale from: 6 (worst: severe) to 30 (best: normal)<br/>Follow‐up: range 3 months to 12 months </p> <p>MCID: 5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2016<br/>(6 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean erectile function ranged from 7.8 to 10.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.37 higher<br/>(1.67 higher to 3.08 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual quality of life<br/>Assessed with: overall AMS<br/>Scale from: 17 (best: no impairment) to 85 (worst: severe impairment)<br/>Follow‐up: range 4 months to 12 months </p> <p>MCID: 10</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1030<br/>(5 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual quality of life ranged from 33.59 to 39.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.31 lower<br/>(3.63 lower to 1 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Testosterone likely results in little or no difference in sexual quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual quality of life<br/>Assessed with: overall satisfaction domain of IIEF<br/>Scale from: 1 (worst: severe) to 10 (best: normal)<br/>Follow‐up: range 12 weeks to 30 weeks </p> <p>MCID: 1.25</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>786<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual quality of life was 5.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.56 higher<br/>(0.11 lower to 1.23 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality<br/>Follow‐up: range 3 months to 12 months </p> <p>MCID: absolute risk difference of 3%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3525<br/>(10 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.21 to 3.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Testosterone likely results in little or no difference in cardiovascular mortality.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/>(1 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment withdrawal due to adverse events<br/>Follow‐up: range 3 months to 12 months </p> <p>MCID: absolute risk difference of 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2966<br/>(12 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/>(0.56 to 1.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Testosterone likely results in little or no difference in treatment withdrawal due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 fewer per 1000<br/>(16 fewer to 7 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostate‐related events:<br/>Follow‐up: range 3 months to 12 months </p> <p>MCID: absolute risk difference of 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3439<br/>(10 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.65<br/>(1.08 to 2.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Testosterone likely results in little or no difference in prostate‐related events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 more per 1000<br/>(2 more to 29 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower urinary tract symptoms<br/>Assessed with: IPSS<br/>Scale from: 0 (best: not at all) to 35 (worst: almost always)<br/>Follow‐up: range 3 months to 12 months </p> <p>MCID: 3</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1488<br/>(6 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>1,6,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean lower urinary tract symptoms ranged from 5.7 to 10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.37<br/>(1.39 lower to 0.64 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone likely results in little or no difference in lower urinary tract symptoms.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>AMS:</b> Aging Males' Symptoms score; <b>CI:</b> confidence interval; <b>IIEF:</b> International Index of Erectile Function; <b>IPSS:</b> International Prostate Symptom Score; <b>MCID:</b> minimal clinically important difference<i>;</i><b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for indirectness: differences in population (group with mixed age under 40 years old and/or baseline serum testosterone level over 12 nmol/L). </p> <p><sup>2</sup>Minimal clinically important difference: 25% improvement (greater than 3.5 points) from baseline (testosterone: 14.21; placebo: 14.53). </p> <p><sup>3</sup>Minimal clinically important difference: comes from <a href="./references#CD013071-bbs2-0196" title="RosenRC , AllenKR , NiX , AraujoAB . Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. European Urology2011;60(5):1010-6.">Rosen 2011</a>. </p> <p><sup>4</sup>Minimal clinically important difference: 25% improvement (greater than 10.0 points) from baseline (testosterone: 41.88; placebo: 42.74). </p> <p><sup>5</sup>Minimal clinically important difference: 25% improvement (greater than 1.25 points) from baseline (testosterone: 5.35; placebo: 5.28). </p> <p><sup>6</sup>Not downgraded further for inconsistency: moderate heterogeneity, but not clinically important. </p> <p><sup>7</sup>Minimal clinically important difference: comes from <a href="./references#CD013071-bbs2-0131" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker-CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?Journal of Urology1995;154(5):1770-4.">Barry 1995</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Testosterone compared to placebo in men with sexual dysfunction (short‐term: sensitivity analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013071-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Testosterone compared to placebo in men with sexual dysfunction (long‐term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> men with sexual dysfunction<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> testosterone<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens?</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with testosterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erectile function<br/>Assessed with IIEF‐EF<br/>Scale from: 1 (worst: severe) to 30 (best: normal)<br/>Follow‐up: 13 months </p> <p>MCID: 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean erectile function was 10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.2 higher<br/>(2.03 lower to 10.43 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are very uncertain about the effect of testosterone on erectile function.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment withdrawal due to adverse events<br/>Follow‐up: range 13 months to 24 months </p> <p>MCID: absolute risk difference of 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>122<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/>(0.58 to 1.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are very uncertain about the effect of testosterone on treatment withdrawal due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 more per 1000<br/>(133 fewer to 273 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostate‐related events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower urinary tract symptoms</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>IIEF‐EF:</b> International Index of Erectile Function‐Erectile Function; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear or high risk of selection, attrition, and/or reporting bias. </p> <p><sup>2</sup>Downgraded by one level for indirectness: difference in population (inclusion criterion of baseline serum testosterone level below 15 nmol/L in the included study (<a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a>) was higher than that of the diagnostic criteria of late‐onset hypogonadism). </p> <p><sup>3</sup>Downgraded by two levels for imprecision: insufficient information size and/or wide confidence interval crosses the assumed threshold of clinically important difference. </p> <p><sup>4</sup>Minimal clinically important difference: comes from <a href="./references#CD013071-bbs2-0196" title="RosenRC , AllenKR , NiX , AraujoAB . Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. European Urology2011;60(5):1010-6.">Rosen 2011</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Testosterone compared to placebo in men with sexual dysfunction (long‐term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013071-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Testosterone compared to PDE5I in men with sexual dysfunction (short‐term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> men with sexual dysfunction<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> testosterone<br/><b>Comparison:</b> PDE5I </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens?</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PDE5I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with testosterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erectile function<br/>Assessed with IIEF‐5<br/>Scale from: 1 (worst: severe) to 25 (best: normal)<br/>Follow‐up: 6 weeks </p> <p>MCID: 5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean erectile function was 18.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.4 lower<br/>(5.47 lower to 1.33 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are very uncertain about the effect of testosterone on erectile function.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual quality of life<br/>Assessed with AMS<br/>Scale from: 17 (best: no impairment) to 85 (worst: severe impairment)<br/>Follow‐up: 6 weeks </p> <p>MCID: 9.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2,3,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual quality of life was 36.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.82 lower<br/>(6.85 lower to 0.79 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are very uncertain about the effect of testosterone on sexual quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment withdrawal due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostate‐related events<br/>Follow‐up: 6 weeks </p> <p>MCID: absolute risk difference of 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>64<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable <sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are very uncertain about the effect of testosterone on prostate‐related events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower urinary tract symptoms</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>AMS:</b> Aging Males' Symptoms score; <b>CI:</b> confidence interval; <b>IIEF:</b> International Index of Erectile Function; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>PDE5I:</b> phosphodiesterase 5 inhibitor; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear or high risk of selection, performance, detection, and reporting bias. </p> <p><sup>2</sup>Not downgraded further for indirectness: while the included study did not clearly define the age of the study population, the mean age was over 45 years old. </p> <p><sup>3</sup>Downgraded by two levels for imprecision: insufficient information size or confidence interval crosses the assumed threshold of clinically important difference. </p> <p><sup>4</sup>Minimal clinically important difference: comes from <a href="./references#CD013071-bbs2-0205" title="SpalivieroM , StromKH , GuX , ArakiM , CulkinDJ , WongC . Does Greenlight HPS laser photoselective vaporization prostatectomy affect sexual function?Journal of Endourology2010;24(12):2051-7.">Spaliviero 2010</a>. </p> <p><sup>5</sup>Minimal clinically important difference: 25% improvement (greater than 9.5 points) from baseline (testosterone: 38.83; PDE5I: 37.06). </p> <p><sup>6</sup>No events in either group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Testosterone compared to PDE5I in men with sexual dysfunction (short‐term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013071-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Testosterone as an add‐on to PDE5I compared to PDE5I alone in men with sexual dysfunction (short‐term)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> men with sexual dysfunction<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> testosterone as an add‐on to PDE5I vs PDE5I alone<br/><b>Comparison:</b> PDE5I </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens?</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PDE5I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with testosterone + PDE5I</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erectile function (conversion to IIEF‐EF)<br/>Assessed with IIEF‐EF<br/>Scale from: 1 (worst: severe) to 30 (best: normal)<br/>Follow‐up: range 6 weeks to 16 weeks </p> <p>MCID: 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1,2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean erectile function ranged from 14.05 to 20.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.79 higher<br/>(1.25 higher to 4.33 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone as an add‐on to PDEI5I may result in little or no difference in erectile function. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual quality of life assessed with overall satisfaction domain of IIEF<br/>Scale from: 1 (worst: severe) to 10 (best: normal)<br/>Follow‐up: range 14 weeks to 16 weeks </p> <p>MCID: 1.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>282<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>3,5,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean sexual quality of life ranged from 6.10 to 6.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.34 higher<br/>(0.76 lower to 1.45 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone as an add‐on to PDEI5I may result in little or no difference in sexual quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Treatment withdrawal due to adverse events<br/>Follow‐up: range 12 weeks to 16 weeks </p> <p>MCID: absolute risk difference of 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>388<br/>(3 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>1,3,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.26<br/>(0.32 to 4.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Testosterone as an add‐on to PDEI5I may result in little to no difference in treatment withdrawal due to adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 more per 1000<br/>(28 fewer to 163 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Prostate‐related events</p> <p>Follow‐up: range 6 weeks to 16 weeks</p> <p>MCID: absolute risk difference of 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>373<br/>(3 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>8,9,10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.83<br/>(0.84 to 55.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population <sup>11</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are very uncertain about the effect of testosterone as an add‐on to PDEI5I on prostate‐related events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower urinary tract symptoms</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>IIEF‐EF:</b> International Index of Erectile Function‐Erectile Function; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>PDE5I:</b> phosphodiesterase 5 inhibitor; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for study limitations: unclear or high risk of selection, performance, detection, and/or reporting bias among the included studies. </p> <p><sup>2</sup>Not downgraded further for indirectness: while the included studies (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>, <a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a>) did not clearly define the age of the study population, the mean age was over 45 years old. </p> <p><sup>3</sup>Downgraded by one level for imprecision: confidence interval crosses the assumed threshold of clinically important difference. </p> <p><sup>4</sup>Minimal clinically important difference: comes from <a href="./references#CD013071-bbs2-0196" title="RosenRC , AllenKR , NiX , AraujoAB . Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. European Urology2011;60(5):1010-6.">Rosen 2011</a>. </p> <p><sup>5</sup>Downgraded by one level for inconsistency: substantial heterogeneity. </p> <p><sup>6</sup>Minimal clinically important difference: 25% improvement (greater than 1.2 points) from the baseline (testosterone + PDE5I: 4.30; PDE5I: 4.94). </p> <p><sup>7</sup>Not downgraded further for indirectness: while the study includes men aged over 18 years old (<a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a>), the mean age was over 45 years old. </p> <p><sup>8</sup>Not downgraded further for study limitations: while one study was rated unclear or high risk of bias overall (<a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a>), there was no event (no effect on overall effect estimate). </p> <p><sup>9</sup>Downgraded by one level for indirectness: surrogate outcome used (participants with high prostate‐specific antigen over 4 ng/mL). </p> <p><sup>10</sup>Downgraded by two levels for imprecision: insufficient information size or wide confidence interval crosses the assumed threshold of clinically important difference. </p> <p><sup>11</sup>No event in control group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Testosterone as an add‐on to PDE5I compared to PDE5I alone in men with sexual dysfunction (short‐term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013071-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial period (year to year)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting/country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Inclusion criteria</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention and comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Randomized (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Testosterone (nmol/L)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Erectile function<sup>*</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0001" title="Aliaev IuG, VinarovAZ , AkhvledianiND . Choice of treatment of erectile dysfunction associated with hypogonadism. Urologiia2010;4:37-8, 40-2. ">Aliaev 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0023"> <li> <p>IIEF‐5: 8 to 21 points</p> </li> <li> <p>AMS questionnaire: more than 26 points</p> </li> <li> <p>IPSS index: lower than 18 points</p> </li> <li> <p>Plasma content of total testosterone: less than 12 nmol/L</p> </li> <li> <p>PSA: less than 4 ng/mL</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.67 ± 9.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.37 ± 2.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.50 ± 3.87<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE‐5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.85 ± 9.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.24 ± 4.1<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0002" title="AllanCA , ForbesEA , StraussBJ , McLachlanRI . Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. International Journal of Impotence Research2008;20(4):396-401. [DOI: 10.1038/ijir.2008.22]">Allan 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2001 to 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0024"> <li> <p>Age: 55 years and over</p> </li> <li> <p>Serum testosterone level: less than 15 nmol/L</p> </li> <li> <p>Non‐obese (BMI &lt; 30 kg/m² and waist circumference &lt; 102 cm)</p> </li> <li> <p>Non‐smokers in good general health</p> </li> <li> <p>Symptoms consistent with testosterone deficiency</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1 ± 5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.6 ± 2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9 ± 10.2<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.5 ± 7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.5 ± 3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.3 ± 8.5<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0003" title="AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , PezzellaP , et al. Body composition and psychological changes induced by long acting testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:439. [DOI: 10.1111/j.1743-6109.2009.01608-3.x]AversaA , FrancomanoD , BruzzichesR , NataliM , GrecoE , SperaG . Metabolic changes induced by testosterone undecanoate in middle-aged men with hypogonadal-metabolic syndrome: results of 104 weeks placebo-controlled treatment. Journal of Sexual Medicine2009;6:415. [10.1111/j.1743-6109.2009.01608-1.x]">Aversa 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Middle‐aged men with late‐onset hypogonadism and MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0004" title="AversaA , BruzzichesR , FrancomanoD , PiliM , GrecoE , SperaG . Efficacy and safety of different testosterone undecanoate preparations in men with hypogonadism: a single-blind, randomized, placebo-controlled, 12-month follow-up study. Journal of Sexual Medicine2009;6:79. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]AversaA , BruzzichesR , FrancomanoD , SperaG , LenziA . Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. Journal of Endocrinological Investigation2010;33(11):776-83. [DOI: 10.1007/BF03350341]">Aversa 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0025"> <li> <p>Age: between 50 and 65 years</p> </li> <li> <p>History: MS and/or type 2 DM</p> </li> <li> <p>Serum total testosterone level: &lt; 3.20 ng/mL (11 nmol/L) or calculated free testosterone levels: &lt; 250 pmol/L (10 pg/mL) </p> </li> <li> <p>2 symptoms of hypogonadism</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone (IM/oral)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 ± 10/57 ± 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.25 ± 2.1/8.91 ± 2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 ± 2/17 ± 3<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 ± 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.91 ± 2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 ± 2<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0005" title="AversaA , BruzzichesR , FrancomanoD , RosanoG , IsidoriAM , LenziA , et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. Journal of Sexual Medicine2010;7(10):3495-503. [DOI: 10.1111/j.1743-6109.2010.01931.x]">Aversa 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0026"> <li> <p>Age: between 45 and 65 years</p> </li> <li> <p>History: MS and/or type 2 DM</p> </li> <li> <p>Total testosterone serum level below 3.0 ng/mL (11 nmol/L) or calculated free testosterone levels &lt; 250 pmol/L (10 pg/mL) </p> </li> <li> <p>At least 2 symptoms of hypogonadism</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 ± 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.33 ± 2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 ± 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 ± 1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0006" title="AydinS , OdabasO , ErcanM , KaraH , AgargunMY . Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. British Journal of Urology1996;77(2):256-60. [PMID: 8800895]">Aydin 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men of various ages complaining of an inability to create or maintain an erection sufficient for intercourse </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0007" title="BehreHM , TammelaTL , ArverS , TolráJR , BonifacioV , LamcheM , et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male2012;15(4):198-207. [DOI: 10.3109/13685538.2012.699562]">Behre 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0027"> <li> <p>Age: 50 to 80 years</p> </li> <li> <p>Symptoms of testosterone deficiency</p> </li> <li> <p>Serum total testosterone &lt; 15 nmol/L (&lt; 4.3 ng/mL)</p> </li> <li> <p>Bioavailable testosterone &lt; 6.68 nmol/L (&lt; 1.93 ng/mL)</p> </li> <li> <p>AMS rating scale total score &gt; 36</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.9 ± 6.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4 ± 2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.0 ± 3.1<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1± 6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.6 ± 2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.7 ± 3.0<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0008" title="BenkertO , WittW , AdamW , LeitzA . Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Archives of Sexual Behavior1979;8(6):471-9. ">Benkert 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0028"> <li> <p>Sexual impotence with reduced or nonexistent ability to have an erection during intercourse, persistent for at least 1 year, due to unknown etiology, and a prior history of normal penile erection </p> </li> <li> <p>Age: under 60 years old</p> </li> <li> <p>Regular female sexual partner, at least 1 attempt at coitus per week</p> </li> <li> <p>Normal findings in an andrological examination</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1 ± 6.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.2 ± 7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0009" title="BoyanovMA , BonevaZ , ChristovVG . Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male2003;6(1):1-7. [PMID: 12809074]">Boyanov 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Bulgaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0029"> <li> <p>Aged between 45 and 65 years</p> </li> <li> <p>Be married or living in a stable relationship with a female sexual partner for at least 6 months </p> </li> <li> <p>Waist‐hip ratio of at least 0.9</p> </li> <li> <p>Type 2 diabetes mellitus and symptoms of andropause or erectile dysfunction</p> </li> <li> <p>Serum testosterone levels below the normal range for young adults or in the lower third of this range (total testosterone &lt; 15.1 nmol/L) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.56 ± 2.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.25 ± 0.67<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.76 ± 3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.50 ± 0.75<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0010" title="BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo-controlled study. Journal of sexual medicine2016;13(5 Suppl 1):S15-6. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreH , et al. Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Urology2015;193(4 Suppl 1):e412. BrockG , HeiselmanD , MaggiM , KimSW , Rodriguez VallejoJM , BehreHM , et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. Journal of Urology2016;195(3):699-705. [DOI: 10.1016/j.juro.2015.10.083]HeiselmanD , DowsettS . Effect of testosterone solution on total testosterone, sex drive and energy in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S64-5. NCT01816295. A study in men with low testosterone to measure the effects of testosterone solution on testosterone levels, sex drive and energy. clinicaltrials.gov/show/NCT01816295 (first received 19 March 2013). WuF , ZitzmannM , HeiselmanD , DonatucciC , KnorrJ , PatelAB , et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. Journal of Sexual Medicine2016;13(8):1212-9. [DOI: 10.1016/j.jsxm.2016.05.010]">Brock 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men 18 years old or older with 2 total testosterone levels less than 300 ng/dL (11 nmol/L) measured 1 week or more apart and at least 1 symptom of testosterone deficiency </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.7 ± 10.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0 ± 2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.9 ± 11.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0 ± 2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0011" title="BuvatJ , MaggiM , PorstH , ColsonMH , KaipiaA , Martin-MoralesA , et al. What is the threshold level of the PDE5 inhibitors' testosterone-dependence in men? A double blind placebo-controlled trial of testosterone gel addition in men with ED non responding to tadalafil 10 mg once a day alone. European Urology, Supplements2009;8(4):214. BuvatJ , MontorsiF , CuzinB , MeulemanE , YassinA , DeanJ . From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo-controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. Journal of Urology2009;181(4):488. BuvatJ , MontorsiF , MaggiM , PorstH , KaipiaA , ColsonMH , et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Journal of Sexual Medicine2011;8(1):284-93. [DOI: 10.1111/j.1743-6109.2010.01956.x]BuvatJB , MaggiMM , PorstHP , CuzinBC , MoncadaIM , EardleyIE . Addition of testosterone does not improve efficacy of tadalafil 10 mg once-a-day in ED patients non responders to PDE5 inhibitors alone who have only mild testosterone deficiency. Journal of Sexual Medicine2009;6:82. [DOI: 10.1111/j.1743-6109.2008.01125-2.x]NCT00244023. Co-administering testosterone with PDE5 inhibitors in ED patients non responders to PDE5 inhibitors alone. clinicaltrials.gov/show/NCT00244023 (first received 23 October 2005). ">Buvat 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005 to 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0030"> <li> <p>ED complaint ongoing for over 3 months</p> </li> <li> <p>Age: between 45 and 80 years old</p> </li> <li> <p>Stable heterosexual relationship for more than 3 months and anticipates having the same partner for the whole study </p> </li> <li> <p>Not responded adequately to the highest available dosage of tadalafil or other PDE5I</p> </li> <li> <p>Low or low‐to‐normal serum testosterone level</p> </li> <li> <p>Agrees to make at least 4 attempts at sexual intercourse on 4 separate days during the 4‐week run‐in period with daily tadalafil 10 mg </p> </li> <li> <p>At least 50% of attempts during this period must be unsuccessful</p> </li> <li> <p>Agrees not to use any other ED drug or non‐drug treatment during the full course of the study </p> </li> <li> <p>Providing a signed informed consent</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel + PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.3 ± 7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.7 ± 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 ± 4.2<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.9 ± 7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.7 ± 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.8 ± 4.1<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0012" title="O'CarrollR , BancroftJ . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. British Journal of Psychiatry1984;145:146-51. [PMID: 6380630]">Carroll 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1981 to 1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged 19 years old or older presenting with complaint of difficulty in achieving or maintaining a full erection during sexual activity, not secondary to loss of sexual interest or obvious physical or mental illness </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0013" title="ChiangHS , ChoSL , LinYC , HwangTI . Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology2009;73(4):762-6. [DOI: 10.1016/j.urology.2008.10.019]ChiangHS , HwangTI , HsuiYS , LinYC , ChenHE , ChenGC , et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. International Journal of Impotence Research2007;19(4):411-17. [DOI: 10.1038/sj.ijir.3901562]">Chiang 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2002 to 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Taiwan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0031"> <li> <p>Age: between 20 and 75 years</p> </li> <li> <p>Men diagnosed with testosterone deficiency that required testosterone replacement were considered eligible </p> </li> <li> <p>Men had never taken androgen replacement therapy or had withdrawn from testosterone supplements for 6 weeks before the study began </p> </li> <li> <p>Hypogonadal men were eligible if their morning serum testosterone concentrations were &lt; 300 ng/dL (if total testosterone was ≥ 300 ng/dL, free testosterone concentrations were to be &lt; 8.7 pg/mL) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20 to 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4 ± 5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.7 ± 4.9<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1 ± 6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9 ± 6.6<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0014" title="GilbertRN , GrahamCW , ReganJB . Double blind cross-over trial of testosterone enanthate in impotent men with low or low-normal serum testosterone levels. Journal of Urology1992;147(Suppl 4):264. ">Gilbert 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with low testosterone and impotence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0015" title="GiltayEJ , TishovaY , MskhalayaG , GoorenLJG , SaadF , KalinchenkoS . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Endocrine Abstracts2010;22:P524. GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJ , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine2010;7(7):2572-82. [DOI: 10.1111/j.1743-6109.2010.01859.x]GiltayEJ , TishovaYA , MskhalayaGJ , GoorenLJG , SaadF , KalinchenkoSY . Effects of testosterone supplementation on depressive symptoms in hypogonadal men with the metabolic syndrome: the Moscow study. European Psychiatry2010;25:E256. [DOI: 10.1016/S0924-9338(10)70256-X]MskhalayaG , KalinchenkoS , TishovaY , SaadF , GoorenLJG , GiltayEJ . The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count. Endocrine Abstracts2010;22:P523. NCT00696748. The effect of IM testosterone undecanoate on biochemical and anthropometric characteristics of metabolic syndrome in hypogonadal men. clinicaltrials.gov/show/NCT00696748 (first received 11 June 2008). SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects of testosterone supplementation on depressive symptoms, low vitality and sexual dysfunction in hypogonadal men with the metabolic syndrome: the Moscow study. Journal of Andrology2010;31:72. SaadF , KalinchenkoS , TishovaY , MskhalayaG , GoorenL , GiltayE . Effects on sexual, depressive and ageing male symptoms in hypogonadal men treated with testosterone supplementation: results from a randomized, placebo-controlled, double-blind trial. Journal of Sexual Medicine2010;7:164. ">Giltay 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005 to 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged between 35 and 70 years old, with total testosterone levels below 12.0 nmol/L or a calculated free testosterone level below 225 pmol/L, and a diagnosis of MS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.0<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.1<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0016" title="GoorenLJ , BoulouxPM , GiltayEJ , SaadF . The effect of 6 months' treatment with testosterone gel versus placebo on body composition and health-related quality of life in hypogonadal men. Journal of Diabetes2011;3:147. [DOI: 10.1111/j.1753-0407.2011.00122.x]">Gooren 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged 50 to 80 years with total testosterone &lt; 15 nmol/L and AMS rating scale total score &gt; 36 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0017" title="Groti AntoničK , AntoničB , ŽuranI , PfeiferM . Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male2020;23(5):1442-54. [DOI: 10.1080/13685538.2020.1793132]GrotiK , ŽuranI , AntoničB , ForšnaričL , PfeiferM . The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male2018;21(3):158-69. [DOI: 10.1080/13685538.2018]NCT03792321. Study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients (SETH2). clinicaltrials.gov/show/NCT03792321 (first received 27 December 2018). ">Groti 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2014 to 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Slovenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged &gt; 35 years, with confirmed late‐onset hypogonadism, total testosterone level &lt; 11 nmol/L, BMI ≥ 30 kg/m<sup>2</sup>, type 2 DM treated exclusively with non‐insulin antidiabetic medications </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.2 ± 7.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.24 ± 1.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1 ± 5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.96 ± 1.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0018" title="Hackett GI , ColeN , BhartiaM , KennedyD , WilkinsonP , SaghirA . The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Diabetic Medicine2014;31(Suppl 1):3. [DOI: 10.1111/dme.12377_1]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP , et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice2014;68(2):203-15. [DOI: 10.1111/ijcp.12235]HackettG , ColeN , BhartiaM , KennedyD , RajuJ , WilkinsonP . Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Journal of Sexual Medicine2013;10(6):1612-27. [DOI: 10.1111/jsm.12146]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology2017;5(5):905-13. [DOI: 10.1111/andr.12399]HackettG , ColeN , SaghirA , JonesP , StrangeRC , RamachandranS . Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU international2016;118(5):804-13. HackettG . Testosterone therapy: mechanistic relationship between sexual desire and erectile function in men with type 2 diabetes-a 30 week randomized placebo controlled study. Journal of Sexual Medicine2017;14(4 Suppl 1):e147. HackettGI , BhartiaM , ColeN . Metabolic and symptomatic response to testosterone undecanoate in men with type 2 diabetes and hypogonadism takes 12 to 18 months to maximum effect. Journal of Sexual Medicine2012;9(Suppl 4):205. [DOI: 10.1111/j.1743-6109.2012.02863.x]RamachandranS , HackettGI , StrangeRC . Testosterone replacement therapy: pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups. Andrology2020;8(5):1222-32. [DOI: 10.1111/andr.12813]">Hackett 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2008 to 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged 18 to 80 years with symptoms of hypogonadism defined by the AMS together with an initial total testosterone ≤ 12.0 nmol/L or free testosterone ≤ 0.25 nmol/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.2 ± 10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2 ± 3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.24 ± 7.5<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.0 ± 9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9 ± 3.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.64 ± 9.0<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0019" title="HakobyanS . Clinical study of testosterone gel as adjunctive therapy to tadalafil in hypogonadal men with erectile dysfunction. Journal of Sexual Medicine2013;10(Suppl 4):267. [DOI: 10.1111/jsm.12296]">Hakobyan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with arteriogenic ED as evaluated by dynamic color duplex ultrasound studies, normal sexual desire but testosterone and free testosterone in the lower quartile of normal range, not responding to tadalafil treatment on 6 consecutive attempts </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0020" title="HarenM , ChapmanI , CoatesP , MorleyJ , WittertG . Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Ageing2005;34(2):125-30. [DOI: 10.1093/ageing/afi003]">Haren 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0032"> <li> <p>Aged 60 years or older</p> </li> <li> <p>At least 2 symptoms on the Androgen Deficiency in Aging Males questionnaire</p> </li> <li> <p>Free testosterone index between 0.3 and 0.5</p> </li> <li> <p>Total testosterone greater than 8 nmol/L</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0021" title="HisasueSI , IdeH , TsujimuraA , NagayaN , KimuraM , AbdelhamedA , et al. Testosterone gel treatment significantly ameliorates urinary urgency and sleep disturbance: double-blind, placebo-controlled clinical trial. Journal of Urology2015;193(4 Suppl):e772-3. [DOI: 10.1016/j.juro.2015.02.2269]">Hisasue 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men with late‐onset hypogonadism symptoms (total testosterone &lt; 450 ng/dL and total AMS scores ≥ 27) and ≥ 40 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0022" title="HoCC , TongSF , LowWY , NgCJ , KhooEM , LeeVK , et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU International2012;110(2):260-5. [DOI: 10.1111/j.1464-410X.2011.10755.x]HoCCK , TongSF , LowWY , NgCJ , KhooEM , LeeVKM , et al. Assessing quality of life via Aging Male Symptoms (AMS) scale after treatment with intramuscular long-acting testosterone. Journal of Sexual Medicine2011;8(Suppl 5):403. [DOI: 10.1111/j.1743-6109.2010.02546_2.x]TanHM , TongSF , LowWY , NgCJ , KhooEM , ZainuddinZM , et al. The effect of long-acting testosterone treatment on the Aging Male Symptoms (AMS) scale - a randomized double blind placebo control trial. European Urology, Supplements2011;10(2):129. [DOI: 10.1016/S1569-9056(11)60355-2]TanWS , LowWY , NgCJ , TanWK , TongSF , HoC , et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International2013;111(7):1130-40. [DOI: 10.1111/bju.12037]TongSF , NgCJ , LeeBC , LeeVK , KhooEM , LeeEG , et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian Journal of Andrology2012;14(4):604-11. [DOI: 10.1038/aja.2011.178]">Ho 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2008 to 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Malaysia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0033"> <li> <p>Age 40 to 70 years</p> </li> <li> <p>At least 'mild' symptoms for all 3 AMS domains (scores of ≥ 9 in the somatic, ≥ 6 in the psychological, and ≥ 6 in the sexual domain) or total AMS scores ≥ 27 </p> </li> <li> <p>Early morning total testosterone level &lt; 12 nmol/L on 2 occasions</p> </li> <li> <p>PSA level of &lt; 4 ng/mL</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.4 ± 7.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9 ± 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>48 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 ± 8.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1 ± 1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0023" title="KuneliusP , LukkarinenO , HannukselaML , ItkonenO , TapanainenJS . The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism2002;87(4):1467-72. [DOI: 10.1210/jcem.87.4.8138]">Kunelius 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0034"> <li> <p>Rarefaction of nocturnal penile tumescence (once or less per week; frequency of early morning erections together with libido are known to have correlation with serum androgen levels) </p> </li> <li> <p>At least one of the following andropause symptoms: decreased libido, ED, urinary disorders, asthenia, or depressive mood </p> </li> <li> <p>Total testosterone ≤ 15 nmol/L</p> </li> <li> <p>Sex hormone‐binding globulin ≥ 30 nmol/L</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dihydrotestosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.3 ± 4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.26 ± 1.41<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.6 ± 5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.53 ± 1.44<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0024" title="BoulouxPM , LegrosJJ , ElbersJM , GeurtsTB , KaspersMJ , MeehanAG , et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male2013;16(2):38-47. [DOI: 10.3109/13685538.2013.773420]LegrosJJ , MeulemanEJ , ElbersJM , GeurtsTB , KaspersMJ , BoulouxPM . Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology2009;160(5):821-31. [DOI: 10.1530/EJE-08-0634]MeulemanEJ , LegrosJJ , BoulouxPM , Johnson-LevonasAO , KaspersMJ , ElbersJM , et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male2015;18(3):157-63. [DOI: 10.3109/13685538.2015.1032925]NCT00434824. Effects of andriol testocaps in symptomatic late-onset hypogonadism (43203). clinicaltrials.gov/show/NCT00434824 (first received 12 February 2007). ">Legros 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2001 to 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0035"> <li> <p>At least 50 years of age</p> </li> <li> <p>BMI between 18 and 34 kg/m<sup>2</sup> </p> </li> <li> <p>Symptoms of androgen deficiency (as indicated by a positive score on the ADAM questionnaire)</p> </li> <li> <p>Calculated free testosterone &gt; 0.26 nmol/L</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral (80/160/240 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78/82/77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.5 ± 6.5/58.4 ± 5.7/58.6 ± 5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA/NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA/NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.4 ± 5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0025" title="LiGY , LiangJH , MengZB , HuangCC , LiangSK , WeiGQ , et al. Low-dose testosterone undecanoate capsules combined with tadalafil for late-onsethypogonadism accompanied with ED. Zhonghua Nan Ke Xue2013;19(7):630-3. ">Li 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0036"> <li> <p>Married men with living spouse</p> </li> <li> <p>Men with late‐onset hypogonadism symptoms</p> </li> <li> <p>Physical symptoms plus vasomotor symptoms, total score ≥ 5 points; or mental and psychological symptoms ≥ 4 points; or symptoms of sexual dysfunction ≥ 8 points </p> </li> <li> <p>IIEF‐5 score &lt; 21 points and course 3. More than a month</p> </li> <li> <p>Serum total testosterone &lt; 12.0 nmol/L or free testosterone &lt; 0.225 nmol/L</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral + PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.1 ± 1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.7 ± 3.9<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2 ± 1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.6 ± 3.8<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0027" title="LuJ , XiaS , FanJ , ZhuJ , LinGM . The prospective and randomized control study of Viagra combined with Andriol in the treatment of ED in the aging male. Chinese Journal of Andrology 17;3:194-6. ">Lu 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men aged 50 to 70 years who have reliable, fixed sexual partners</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral + PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0028" title="LunglmayrG , StellamorM , SponaJ . Androgen therapy of impotentia coeundi in elderly men. Psychological and endocrinological investigations. Wiener Klinische Wochenschrift 1980;92(7):243-2471980;92(7):243-7. ">Lunglmayr 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA/Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0037"> <li> <p>Men who had suffered from non‐partner‐related erectile impotence for more than 1 year</p> </li> <li> <p>Deterioration of state of mind (in the sense of the so‐called 'climacterium virile')</p> </li> <li> <p>At least 6 of the 32 items from at least 3 different classes were correct and the disorders had only occurred in the last 2 years </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5 ± 5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9 ± 5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0029" title="MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciC . Testosterone solution 2% for erectile, orgasmic and ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(5 Suppl 1):S14. MaggiM , HeiselmanD , KnorrJ , IyengarS , PaduchDA , DonatucciCF . Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. Journal of Sexual Medicine2016;13(8):1220-6. [DOI: 10.1016/j.jsxm.2016.05.012]">Maggi 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0038"> <li> <p>At least 18 years of age</p> </li> <li> <p>Total testosterone level lower than 300 ng/dL (10.4 nmol/L)</p> </li> <li> <p>At least 1 symptom of testosterone deficiency (decreased energy or decreased sexual drive) </p> </li> <li> <p>PSA level lower than 4 ng/mL</p> </li> <li> <p>No use of oral or topical testosterone therapy within 14 days</p> </li> <li> <p>Stable doses of lipid‐lowering medications, insulin, antidepressants, anxiolytics, or therapy for benign prostatic hyperplasia for at least 3 months </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.7 ± 10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.9 ± 11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0030" title="MerzaZ , BlumsohnA , MahPM , MeadsDM , McKennaSP , WylieK , et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. International Journal of Andrology2006;29(3):381-91. [DOI: 10.1111/j.1365-2605.2005.00612.x]">Merza 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA/UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0039"> <li> <p>Men over 40 years presenting to the Sheffield male sexual dysfunction clinic were screened with measurement of serum total testosterone </p> </li> <li> <p>Serum total testosterone &lt; 10 nmol/L and/or a free androgen index &lt; 30%</p> </li> <li> <p>Absence of known prostate or breast cancer, prostatic hypertrophy, raised serum PSA (&gt; 2.5 μg/L), uncontrolled hypertension, diabetes mellitus, uncontrolled cardiac disease, renal failure (creatinine &gt;150 μmol/L), liver disease, polycythemia (hematocrit &gt; 50%), history of aggressive behavior, alcohol or drug abuse, anticoagulant therapy or testosterone replacement </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0031" title="MoralesA , BlackA , EmersonL , BarkinJ , KuzmarovI , DayA . Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male2009;12(4):104-12. [DOI: 10.3109/13685530903294388]NCT00202163. ANDRO 2002: dehydroepiandrosterone (DHEA) or testosterone versus placebo in men with sexual dysfunction. clinicaltrials.gov/show/NCT00202163 (first received 13 September 2005). ">Morales 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006 to 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0040"> <li> <p>Men 45 to 70 years of age with a primary complaint of sexual dysfunction</p> </li> <li> <p>Clinical picture compatible with testosterone deficiency syndrome</p> </li> <li> <p>History of sexual dysfunction for &gt; 3 months with IIEF scores of &lt; 25 on questions 1 to 5 and 15 </p> </li> <li> <p>History of hypoactive sexual desire disorder for &gt; 3 months with scores of &gt; 6 for questions 11 and 12 of the IIEF and serum total testosterone levels &lt; 12 nmol/L and DHEAS of &lt; 3.5 μmol/L </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.0 ± 10.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2 ± 4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.2 ± 9.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0 ± 5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0032" title="NCT01419236. A study of ejaculatory dysfunction in men with low testosterone levels. clinicaltrials.gov/show/NCT01419236 (first received 16 August 2011). PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunction in androgen-deficient men. Journal of Sexual Medicine2015;12(Suppl 2):101-2. PaduchDA , PolzerP , NiX , BasariaS . Effect of testosterone solution 2% for the treatment of ejaculatory dysfunctions in androgen deficient men. Journal of Sexual Medicine2015;12(Suppl 2):182. PaduchDA , PolzerPK , NiX , BasariaS . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2015;100(8):2956-62. [DOI: 10.1210/jc.2014-4434]">Paduch 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011 to 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Canada, Mexico, USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0041"> <li> <p>Community‐dwelling, sexually active men 26 years of age and older</p> </li> <li> <p>Total testosterone levels &lt; 300 ng/dL (10.41 nmol/L) on 2 occasions</p> </li> <li> <p>One or more of the following symptoms: delayed ejaculation, anejaculation, decreased force of ejaculation, or decreased ejaculate volume </p> </li> <li> <p>PSA levels &lt; 4 ng/mL and willingness to masturbate</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.4 ± 9.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4 ± 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 ± 6.4<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.7 ± 9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7 ± 1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 ± 6.3<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0034" title="Reiter WJ , PychaA , SchatzlG , PokornyA , Gruber DM , Huber JC , et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology1999;53(3):590-4; discussion 594-5. [PMID: 10096389]">Reiter 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1996 to 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/Austria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0042"> <li> <p>History of ED for more than 6 months</p> </li> <li> <p>Serum levels of testosterone, prolactin, and PSA within the normal range, and a serum DHEAS level below 1.5 μmol/L </p> </li> <li> <p>IPSS below 7 and a full erection after intracavernosal administration of 10 μg prostaglandin E1 </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0035" title="RothLW , SchwartzRS , MeachamRB . The impact of testosterone supplementation on sexual function in elderly men. Fertility and Sterility2011;96(3 Suppl 1):S1-2. [DOI: 10.1016/j.fertnstert.2011.07.014]">Roth 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Men 60 years old or greater with borderline low testosterone with mild to moderate ED </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel (50 mg/25 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.5/16.1<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.9<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0036" title="SchiaviRC , WhiteD , MandeliJ , LevineAC . Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Archives of Sexual Behavior1997;26(3):231-41. [PMID: 9146812]">Schiavi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1992 to 1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Single center/USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0043"> <li> <p>Age: 45 to 74</p> </li> <li> <p>Married or living with a sexual partner for at least 1 year</p> </li> <li> <p>Possession of a high school diploma</p> </li> <li> <p>English as the primary language</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.30 ± 1.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10 weeks cross‐over (including a washout period of 4 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.69 ± 7.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0037" title="SeftelAD , MackRJ , SecrestAR , SmithTM . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. Journal of Andrology2004;25(6):963-72. [PMID: 15477371]SteidleC , SchwartzS , JacobyK , SebreeT , SmithT , BachandR . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism2003;88(6):2673-81. [DOI: 10.1210/jc.2002-021058]">Seftel 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0044"> <li> <p>Men between 20 and 80 years of age (mean age 58 years)</p> </li> <li> <p>Morning testosterone level ≤ 300 ng/dL (10.4 nmol/L) at screening</p> </li> <li> <p>One or more symptoms of low T (i.e. fatigue, decreased muscle mass, reduced libido, reduced sexual functioning of a non‐mechanical nature) </p> </li> <li> <p>Generally good health</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel (100 mg/50 mg), testosterone patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106/99, 102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.8 ± 10.6/58.1 ± 9.7, 60.5 ± 9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.05 ± 2.15/8.11 ± 1.98, 8.30 ± 2.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.8 ± 10.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.93 ± 2.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0038" title="BurnettAL , Kan-DobroskyN , MillerMG . Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. Journal of Sexual Medicine2013;10(4):1151-61. [DOI: 10.1111/jsm.12059]BurnettAL , MillerM , Kan-DobroskyN . Testosterone replacement and priapism risk: no definite relationship. Journal of Sexual Medicine2012;9:20. [DOI: 10.1111/j.1743-6109.2012.02633.x]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2004;172(2):658-63. [DOI: 10.1097/01.ju.0000132389.97804.d7]ShabsighR , KaufmanJM , SteidleC , Padma-NathanH . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology2008;179(5 Suppl):S97-102. [DOI: 10.1016/j.juro.2008.03.145]">Shabsigh 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2001 to 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0045"> <li> <p>Men 18 to 80 years old</p> </li> <li> <p>ED for 3 months or greater</p> </li> <li> <p>Stable sexual relationship with a female partner for 6 months or greater</p> </li> <li> <p>Morning serum total testosterone level of 400 ng/dL or less</p> </li> <li> <p>Non‐responders to sildenafil monotherapy (defined as a score of 2 or 3 on questions 3 and 4 of IIEF) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel + PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.8 ± 10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.1 ± 8.4<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.1 ± 9.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.4 ± 10.3<sup>f</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0039" title="Abd AlamirM , EllenbergSS , SwerdloffRS , WengerNK , MohlerER , LewisCE , et al. The cardiovascular trial of the testosterone trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coronary Artery Disease2016;27(2):95-103. [DOI: 10.1097/MCA.0000000000000321]BudoffMJ , EllenbergSS , LewisCE , MohlerER , WengerNK , BhasinS , et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317(7):708-16. [DOI: 10.1001/jama.2016.21043]CunninghamGR , Stephens-ShieldsAJ , RosenRC , WangC , BhasinS , MatsumotoAM , et al. Testosterone treatment and sexual function in older men with low testosterone levels. Journal of Clinical Endocrinology &amp; Metabolism2016;101(8):3096-104. [DOI: 10.1210/jc.2016-1645]NCT00799617. The testosterone trials in older men. clinicaltrials.gov/ct2/show/study/NCT00799617 (first received 26 November 2008). SnyderPJ , BhasinS , CunninghamGR , MatsumotoAM , Stephens-ShieldsAJ , CauleyJA , et al. Effects of testosterone treatment in older men. New England Journal of Medicine2016;374(7):611-24. SnyderPJ , EllenbergSS , CunninghamGR , MatsumotoAM , BhasinS , Barrett-ConnorE , et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11(3):362-75. [DOI: 10.1177/1740774514524032]">Snyder 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010 to 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0046"> <li> <p>Age: more than 65 years</p> </li> <li> <p>Total testosterone values: initial testosterone &lt; 275 ng/dL, a second &lt; 300 ng/dL, and an average &lt; 275 ng/dL </p> </li> <li> <p>Derogatis Interview for Sexual Function Sexual Desire Domain: score &lt; 20</p> </li> <li> <p>Heterosexual partner willing to have sexual intercourse at least twice a month</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.1 ± 5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0 ± 2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 ± 8.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.3 ± 5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 ± 2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.8 ± 8.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0040" title="NCT00512707. Effect of testosterone in men with erectile dysfunction. clinicaltrials.gov/show/NCT00512707 (first received 7 August 2007). SpitzerM , BasariaS , TravisonTG , DavdaMN , DeRogatisL , BhasinS . The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology2013;1(3):475-82. [DOI: 10.1111/j.2047-2927.2013.00075.x]SpitzerM , BasariaS , TravisonTG , DavdaMN , PaleyA , CohenB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Annals of Internal Medicine2012;157(10):681-91. [DOI: 10.7326/0003-4819-157-10-201211200-00004]SpitzerMJ , BasariaS , DavdaMN , TravisonTG , PaleyA , KaplanB , et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a randomized, placebo-controlled trial. Endocrine Reviews2012;33(Suppl 1):i726. [DOI: 10.1093/edrv/33.supp.1]">Spitzer 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006 to 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA/USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0047"> <li> <p>ED as defined by a score of 25 or less on the IIEF‐EF</p> </li> <li> <p>Age between 40 and 70 years</p> </li> <li> <p>Serum testosterone &lt; 11.5 nmol/L (330 ng/dL) and/or free testosterone &lt; 173 pmol/L (50 pg/mL) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.1 ± 8.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.61 ± 2.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.6 ± 8.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.81 ± 2.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0041" title="YucelC , KeskinMZ , PeskirciogluCL . The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Current Urology2017;11(1):4-8. [DOI: 10.1159/000447187]">Yucel 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0048"> <li> <p>Men aged between 24 and 76 years</p> </li> <li> <p>AMS scores over 27</p> </li> <li> <p>Total serum testosterone level below 350 ng/dL (12.1 nmol/L) who presented to the urology clinic with complaints of lower urinary tract symptoms and ED </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.6 ± 15.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6 ± 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.0 ± 5.0<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.7 ± 11.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.3 ± 1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.7 ± 4.6<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0042" title="ZhangE , ZhangB , ChenJ , ZangZ , QiT . Sildenafil plus undecanoate and sildenafil alone in the treatment of type 2 diabetic patients with erectile dysfunction. Heart2012;98:E154-5. [DOI: 10.1136/heartjnl-2012-302920g.2]">Zhang 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Type 2 diabetic men with ED</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.8 ± 1.9<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3 ± 2.1<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013071-bbs2-0043" title="ZhongJ , LiangG , LiP , DaiJ , XuD , PingP , LiZ . A multicenter research of sildenafil combined with testosterone undecanoate for treatment of erectile dysfunction with diabetes. Chinese Journal of Andrology2013;27(4):26-9. ">Zhong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2009 to 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicenter/China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD013071-list-0049"> <li> <p>Typical diabetes symptoms associated with blood glucose &gt; 11.1 mmol/L or fasting plasma glucose &gt; 7.0 mmol/L </p> </li> <li> <p>IIEF‐5 score &lt; 21</p> </li> <li> <p>Disease duration: more than 3 months</p> </li> <li> <p>Fixed sexual partner and regular sexual life, normal genital development</p> </li> <li> <p>Low total testosterone levels</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone oral + PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.0 ± 2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.0 ± 3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>AMS: Aging Males' Symptoms; BMI: body mass index; DHEAS: dehydroepiandrosterone sulfate; DM: diabetes mellitus; ED: erectile dysfunction; IIEF‐EF: International Index of Erectile Function‐Erectile Function; IM: intramuscular; IPSS: International Prostate Symptom Score; MS: metabolic syndrome; NA: not available; PDE5I: phosphodiesterase 5 inhibitor; PSA: prostate specific antigen </p> <p><sup>*</sup>Erectile function measured by: <sup>a</sup>IIEF‐5/<sup>b</sup>IIEF‐EF/<sup>c</sup>Sexual domain of AMS/<sup>d</sup>Partial Androgen Deficiency of the Aging Male/<sup>e</sup>Ability to maintain erection during intercourse (1, always; 2, in 75% of intercourse; 3, in 50%; 4, in less than 25%; 5, in less than 10%; 6, never)/<sup>f</sup>Overall IIEF </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/full#CD013071-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013071-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Testosterone versus placebo (short‐term)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Erectile function (AMS sexual) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.15 [‐1.76, ‐0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Erectile function (IIEF) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 IIEF‐EF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.73 [‐1.68, 13.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 IIEF‐5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.94 [1.14, 6.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Erectile function (conversion to IIEF‐EF) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.69 [‐0.02, 11.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Sexual quality of life (AMS total) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.09 [‐9.45, ‐0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Sexual quality of life (IIEF‐overall satisfaction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [‐1.23, 5.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.21, 3.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Treatment withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.52, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Prostate‐related events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.08, 2.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Lower urinary tract symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐1.51, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Erectile function (subgroup: age and testosterone level, conversion to IIEF‐EF) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.69 [‐0.02, 11.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 All ages over 18 years/testosterone ≤ 12 nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [‐0.38, 12.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Age ≥ 65 years/testosterone &lt; 8 nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>470</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [0.93, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Cardiovascular mortality (subgroup: age and testosterone level) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.21, 3.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 All ages over 18 years/testosterone ≤ 12 nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.23, 4.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Age ≥ 65 years/testosterone &lt; 8 nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF‐EF) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.69 [‐0.02, 11.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 MS: participants with MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.14 [1.16, 5.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 MS: participants without MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.06 [6.42, 25.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.3 MS: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [1.56, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Sexual quality of life (subgroup: metabolic syndrome (MS), AMS total) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.09 [‐9.45, ‐0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 MS: participants with MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐3.52, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 MS: participants without MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐22.60 [‐28.30, ‐16.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 MS: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>844</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.71 [‐4.14, ‐1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Sexual quality of life (subgroup: metabolic syndrome (MS), IIEF ‐ overall satisfaction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [‐1.23, 5.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 MS: participants with MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.77, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 MS: participants without MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.88 [6.33, 7.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 MS: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.78, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Cardiovascular mortality (subgroup: metabolic syndrome (MS)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.21, 3.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 MS: participants with MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 5.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 MS: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.25, 5.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Erectile function (conversion to IIEF‐EF; sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [1.67, 3.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Sexual quality of life (AMS total; sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.31 [‐3.63, ‐1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Sexual quality of life (IIEF‐overall satisfaction; sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [‐0.11, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Treatment withdrawal due to adverse events (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.56, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Prostate‐related events (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.08, 2.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Lower urinary tract symptoms (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐1.39, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Testosterone versus placebo (short‐term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013071-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Testosterone versus placebo (long‐term)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Erectile function (IIEF‐EF) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.20 [‐2.03, 10.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Treatment withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.58, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Testosterone versus placebo (long‐term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013071-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Testosterone versus PDE5I (short‐term)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Erectile function (IIEF‐5) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.40 [‐5.47, ‐1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Sexual quality of life (AMS total) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.82 [‐6.85, ‐0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Prostate‐related events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Testosterone versus PDE5I (short‐term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013071-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Testosterone + PDE5I versus PDE5I (short‐term)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Erectile function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 IIEF‐EF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [0.65, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 IIEF‐5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [‐0.30, 5.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Erectile function (conversion to IIEF‐EF) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.79 [1.25, 4.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Sexual quality of life (IIEF ‐ overall satisfaction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [‐0.76, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Sexual quality of life (AMS total) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.32 [‐8.48, ‐2.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Treatment withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.32, 4.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Prostate‐related events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.83 [0.84, 55.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF‐EF) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.79 [1.25, 4.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 MS: participants with DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.80 [2.20, 9.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 MS: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [0.69, 3.75]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Testosterone + PDE5I versus PDE5I (short‐term)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013071.pub2/references#CD013071-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013071.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD013071-note-0011">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD013071-note-0021">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013071-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013071-note-0020">Français</a> </li> <li class="section-language"> <a class="" href="id#CD013071-note-0019">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD013071-note-0017">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD013071-note-0013">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013071-note-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD013071-note-0015">Português</a> </li> <li class="section-language"> <a class="" href="th#CD013071-note-0014">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013071-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013071\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013071\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013071\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013071\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013071\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013071.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013071.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013071.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013071.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013071.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714610547"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013071.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714610551"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013071.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d72ddba1c937f',t:'MTc0MDcxNDYxMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 